0001213900-16-018520.txt : 20161114 0001213900-16-018520.hdr.sgml : 20161111 20161114172423 ACCESSION NUMBER: 0001213900-16-018520 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 72 CONFORMED PERIOD OF REPORT: 20160930 FILED AS OF DATE: 20161114 DATE AS OF CHANGE: 20161114 FILER: COMPANY DATA: COMPANY CONFORMED NAME: DanDrit Biotech USA, Inc. CENTRAL INDEX KEY: 0001527728 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 452259340 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-54478 FILM NUMBER: 161995997 BUSINESS ADDRESS: STREET 1: DANDRIT BIOTECH A/S STREET 2: FRUEBJERGVEJ 3 BOX 62 CITY: 2100 COPENHAGEN STATE: G7 ZIP: 0 BUSINESS PHONE: 45 39179840 MAIL ADDRESS: STREET 1: DANDRIT BIOTECH A/S STREET 2: FRUEBJERGVEJ 3 BOX 62 CITY: 2100 COPENHAGEN STATE: G7 ZIP: 0 FORMER COMPANY: FORMER CONFORMED NAME: Putnam Hills Corp. DATE OF NAME CHANGE: 20110810 10-Q 1 f10q0916_dandritbiotech.htm QUARTERLY REPORT

U.S. SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2016

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ________ to ________

Commission file number 000-54478

DanDrit Biotech USA, Inc.

(Exact name of registrant as specified in its charter)

Delaware		45-2259340
(State or other jurisdiction of		(I.R.S. Employer
incorporation or organization)		Identification Number)

DanDrit Biotech A/S

Fruebjergvej 3 Box 62

2100 Copenhagen, Denmark

(Address of principal executive offices)

+45 39179840

(Registrant’s telephone number, including area code)

DanDrit Biotech USA, Inc.

Fruebjergvej 3

2100 Copenhagen, Denmark

+45 30127206

(Name, address, including zip code, and telephone number, including area code, of agent for service)

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐.

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐.

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated file. See definition of accelerated filer and large accelerated filer in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☐	Smaller reporting company	☒
(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒.

APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY PROCEEDINGS DURING THE PRECEDING FIVE YEARS:

Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. Yes ☐ No ☐.

APPLICABLE ONLY TO CORPORATE ISSUERS

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 9,533,290 shares of common stock, par value $0.0001 per share (including 185,053 shares of common stock reserved for issuance to the Non-Consenting Shareholders (as defined below) and deemed issued and outstanding for accounting purposes), outstanding as of November 14, 2016.

DANDRIT BIOTECH USA, INC. AND SUBSIDIARY

- INDEX -

		Page
PART I – FINANCIAL INFORMATION:

Item 1.	Financial Statements (Unaudited):	1

	Consolidated Balance Sheets as of September 30, 2016 (Unaudited) and June 30, 2016	2

	Consolidated Statements of Operations (Unaudited) for the Three Months Ended September 30, 2016 and 2015	3

	Consolidated Statements of Comprehensive Loss (Unaudited) for the Three Months Ended September 30, 2016 and 2015	4

	Consolidated Statements of Cash Flows (Unaudited) for the Three Months Ended September 30, 2016 and 2015	5

	Notes to the Financial Statements	6

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	19

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	24

Item 4.	Controls and Procedures	24

PART II – OTHER INFORMATION:

Item 1.	Legal Proceedings	25

Item 1A.	Risk Factors	25

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	25

Item 3.	Defaults Upon Senior Securities	25

Item 4.	Mine Safety Disclosures	25

Item 5.	Other Information	25

Item 6.	Exhibits	26

Signatures		27

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements.

The accompanying financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and in accordance with the instructions for Form 10-Q. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.

In the opinion of management, the financial statements contain all material adjustments, consisting only of normal recurring adjustments necessary to present fairly the financial condition, results of operations, and cash flows of the Company for the interim periods presented.

The results for the period ended September 30, 2016 are not necessarily indicative of the results of operations for the full year. These financial statements and related footnotes should be read in conjunction with the financial statements and footnotes thereto included in the Company’s Form 10-K for the fiscal year ended June 30, 2016 filed with the Securities and Exchange Commission on September 28, 2016.

DANDRIT BIOTECH USA, INC. AND SUBSIDIARY

CONSOLIDATED BALANCE SHEETS

	September 30,			June 30,
	2016			2016
	(Unaudited)
ASSETS
CURRENT ASSETS:
Cash	$	31,675		$	23,368
Other Receivables		746,452			695,418
Prepaid Expenses		6,435			13,693

Total Current Assets		784,562			732,479

PROPERTY AND EQUIPMENT, Net accumulated Depreciation		-			-

OTHER ASSETS
Definite Life Intangible Assets		132,503			135,743
Deferred stock offering costs		25,000			-
Deposits		2,619			2,609

Total Other Assets		160,122			138,352

TOTAL ASSETS	$	944,684		$	870,831

LIABILITIES AND STOCKHOLDER'S EQUITY

CURRENT LIABILITIES:
Notes Payable - Related Party	$	103,474		$	102,882
Accounts Payable		979,029			1,087,758
Accounts Payable - Related Party		97,718			97,357
Accrued Expenses		229,838			220,232

Total Current Liabilities		1,410,059			1,508,229
Convertible Notes Payable, Current Portion (Net of discounts of $10,931 and $0, respectively)		229,669			-
Convertible Notes Payable – Related Party, (Net of discounts of $17,359 and $0, respectively)		102,941			-
Total Long Term Liabilities		332,610			-

Total Liabilities		1,742,669			1,508,229

STOCKHOLDER’S EQUITY(Deficit):
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding		-			-
Common stock, par value $0.0001, 100,000,000 shares authorized, 9,533,290, and 9,533,290 issued and outstanding at September 30, 2016 and June 30, 2016, respectively		953			953
Additional paid-in capital		25,756,232			25,098,050
Accumulated Deficit		(27,093,875	)		(26,300,694	)
Other comprehensive income, net		538,705			564,293
Total Stockholder’s Equity (Deficit)		(797,985	)		(637,398	)

TOTAL LIABILITIES AND STOCKHOLDER’S EQUITY	$	944,684			870,831

See accompanying notes to the unaudited financial statements.

DANDRIT BIOTECH USA, INC. AND SUBSIDIARY

CONSOLIDATED STATEMENT OF OPERATIONS

	For the Three Months Ended
	September 30,
	2016			2015

Revenues	$	-		$	-

Cost of Goods Sold		-			-

Gross profit (Loss)		-			-

Operating Expenses
General and Administrative Expenses		204,951			204,851
Non-cash compensation expenses		626,487			-
Research and Development Expenses		17,104			101,759
Depreciation and Amortization		3,749			3,937
Consulting Expenses		-			30,848
Total Operating Expense		852,291			341,395

(LOSS) FROM OPERATIONS		(852,291	)		(341,395	)

Other Income (Expense)
Interest (expense)		(1,017	)		-
Interest (expense) – Related Party		(3,464	)		(592	)
Gain (Loss) on Currency Transactions		23,084			(32,228	)
Interest and Other Income		-			-
Total Other Income (Expense)		18,603			(32,820	)

(Loss) Before Income Taxes		(833,688	)		(374,215	)

Income Tax Expense (Benefit)		(40,507	)		(23,913	)

NET (LOSS)	$	(793,181	)	$	(350,302	)

BASIC AND DILUTED LOSS PER SHARE	$	(0.08	)	$	(0.04	)

WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - BASIC AND DILUTED		9,533,290			9,533,290

See accompanying notes to the unaudited financial statements.

DANDRIT BIOTECH USA, INC. AND SUBSIDIARY

STATEMENTS OF OTHER COMPREHENSIVE LOSS

	For the Three Months
	Ended September 30,
	2016			2015
	(Unaudited)

Net Loss	$	(793,181	)	$	(350,302	)
Currency Translation, Net of Taxes		(25,588	)		(9,816	)

Other Comprehensive Loss	$	(818,769	)	$	(360,118	)

See accompanying notes to the unaudited financial statements.

DANDRIT BIOTECH USA, INC. AND SUBSIDIARY

CONSOLIDATED STATEMENT OF CASH FLOWS

	For the Three Months Ended September 30,
	2016			2015
	(Unaudited)

NET (LOSS)	$	(793,181	)	$	(350,302	)

ADJUSTMENT TO RECONCILE NET LOSS TO NET CASH USED IN OPERATING ACTIVITIES:
Depreciation and Amortization		3,749			3,937
Non-cash compensation		626,487			-
Accrued Interest on Notes Payable - Related Party		592			592
Accretion of discount on notes payable		3,404			-
CHANGES IN ASSETS AND LIABILITIES:
(Increase) Decrease in Other Receivables		(51,034	)		(28,134	)
(Increase) Decrease in Prepaid Expenses/Deposits		7,248			(59,800	)
Increase (Decrease) in Accounts Payable		(133,728	)		4,761
Increase (Decrease) in Accounts Payable – Related Party		361			9,667
Increase (Decrease) in Accrued Expenses		9,606			3,243
Total Adjustments		466,685			(65,734	)

NET CASH USED IN OPERATING ACTIVITIES		(326,496	)		(416,036	)

CASH FLOWS FROM INVESTING ACTIVITIES:
Net (Increase) Decrease in Cash Held in Escrow		-			1,052,989

NET CASH USED BY INVESTING ACTIVITIES		-			1,052,989

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from Notes Payable – Related Party		138,070			-
Proceeds from Notes Payables		222,830			-

NET CASH PROVIDED BY (USED BY) FINANCING ACTIVITIES		360,900			-

Gain (Loss) on Currency Translation		(26,097	)		(9,978	)

NET INCREASE (DECREASE) IN CASH		8,307			626,975

CASH, BEGINNING OF PERIOD		23,368			421,145

CASH, END OF PERIOD	$	31,675		$	1,048,120

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Cash paid during the periods for:
Interest	$	-		$	-
Income Taxes	$	-		$	-

SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES
Imputed interest on Non-interest bearing Convertible Notes Payable	$	14,402		$	-
Beneficial Conversion Feature of Convertible Notes Payable		17,293			-
Compensation for the issuance of stock options to the Board		626,487			-

See accompanying notes to the unaudited financial statements.

DANDRIT BIOTECH USA, INC. AND SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The accompanying financial statements are unaudited. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows at September 30, 2016 and 2015 and for the periods then ended have been made. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. It is suggested that these condensed financial statements be read in conjunction with the financial statements and notes thereto included in the Company’s June 30, 2016 audited financial statements. The results of operations for the periods ended September 30, 2016 and 2015 are not necessarily indicative of the operating results for the full year.

Business and Basis of Presentation — DanDrit Biotech USA, Inc. (“DanDrit USA”, the “Company”, “we”, “us”, “our”) was originally incorporated in the state of Delaware on January 18, 2011 as a vehicle to pursue a business combination through the acquisition of, or merger with, an operating business.

DanDrit BioTech A/S, a Danish Corporation was incorporated on April 1, 2001 (“DanDrit Denmark”) and is treated as a wholly owned subsidiary of the Company. On February 12, 2014, pursuant to the terms and conditions of a Share Exchange Agreement (the "Share Exchange Agreement"), DanDrit USA (the “Parent”) acquired approximately 100% of the issued and outstanding capital stock of DanDrit BioTech A/S, a Danish corporation (“DanDrit Denmark”) and as a result became the parent of DanDrit Denmark (the “Share Exchange”). Prior to the Share Exchange there were 5,000,000 shares of the common stock, par value $0.0001 per share (the “Common Stock”) of DanDrit Denmark’s parent company (the “Parent”) outstanding. The Parent and a shareholder agreed to cancel 4,400,000 shares of its common stock and issued 1,440,000 shares of common stock for legal and consulting services related to the Share Exchange and a future financing. At the time of the Share Exchange, the outstanding shares of the common stock of DanDrit Denmark were exchanged for 1.498842 shares of Parent’s common stock, for a total of 6,000,000 shares of common stock (including 185,053 shares of common stock reserved for issuance in accordance with Section 70 of the Danish Companies Act and the Articles of Association of DanDrit Denmark to the Non-Consenting Shareholders, deemed issued and outstanding for accounting purposes). Following the closing of the Share Exchange, DanDrit Biotech USA, Inc., the wholly owned subsidiary of the Company, merged with and into the Company, thereby changing the Company’s name to “DanDrit Biotech USA, Inc.” DanDrit Denmark engages in the research and development, manufacturing and clinical trials of pharmaceutical and biological products for the human treatment of cancer using the dendritic cell technology.

Fiscal Year End - In June 2015, DanDrit’s board of directors approved a change to DanDrit’s fiscal year end from December 31 to June 30.

Reverse Acquisition — On February 12, 2014, pursuant to the Share Exchange Agreement (the "Share Exchange Agreement"), DanDrit USA completed the acquisition of 100% of the issued and outstanding capital stock of DanDrit Denmark (the “Share Exchange”) and as a result became DanDrit Denmark’s parent company (the “Parent”). Prior to the Share Exchange there were 5,000,000 shares of the common stock, par value $.0001 per share (the “Common Stock”) of Parent outstanding. Parent and an existing shareholder agreed to cancel 4,400,000 shares of its Common Stock and issued 1,440,000 shares of Common Stock for legal and consulting services related to the Share Exchange and a future public offering. At the time of the Share Exchange each outstanding share of common stock of DanDrit Denmark was exchanged for 1.498842 shares of Parent’s Common Stock, for a total of 6,000,000 shares, resulting in 8,040,000 shares of the Parent’s Common Stock outstanding immediately following the Share Exchange, including 185,053 shares of Common Stock reserved for issuance in accordance with Section 70 of the Danish Companies Act and the Articles of Association of DanDrit Denmark to the DanDrit Denmark shareholders who have not consented to the Share Exchange (the “Non-Consenting Shareholders”), and deemed issued and outstanding for accounting purposes.

Consolidation — For the three months ended September 30, 2016 and 2015, the consolidated financial statements include the accounts and operations of DanDrit Denmark, and the accounts and operations of DanDrit USA. All material inter-company transactions and accounts have been eliminated in the consolidation.

DANDRIT BIOTECH USA, INC. AND SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Functional Currency / Foreign currency translation — The functional currency of DanDrit USA is the U.S. Dollar. The functional currency of DanDrit Denmark is the Danish Kroner (“DKK”). The Company’s reporting currency is the U.S. Dollar for the purpose of these financial statements. The Company’s balance sheet accounts are translated into U.S. dollars at the period-end exchange rates and all revenue and expenses are translated into U.S. dollars at the average exchange rates prevailing during the periods ending September 30, 2016 and 2015. Translation gains and losses are deferred and accumulated as a component of other comprehensive income in stockholders’ equity. Transaction gains and losses that arise from exchange rate fluctuations from transactions denominated in a currency other than the functional currency are included in the statement of operations as incurred.

Cash and Cash Equivalents — The Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents. At September 30, 2016 and 2015 the Company had balances held in financial institutions in Denmark of $31,675 and $23,368, respectively.

Property and Equipment — Property and equipment are stated at cost. Expenditures for major renewals and betterments that extend the useful lives of property and equipment are capitalized, upon being placed in service. Expenditures for maintenance and repairs are charged to expense as incurred. Depreciation is computed for financial statement purposes on a straight-line basis over the estimated useful lives of the assets which range from four to nine years (See Note 3).

Intangible Assets — Definite life intangible assets include patents. The Company accounts for definite life intangible assets in accordance with Financial Accounting Standards Board, (“FASB”) Accounting Standards Codification, (“ASC”) Topic 350, “Goodwill and Other Intangible Assets” and amortized the patents on a straight line basis over the estimated useful life of twenty years. Costs incurred in relation to patent applications are capitalized cost and amortized over the estimated useful life of the patent. If it is determined that a patent will not be issued, the related remaining patent application costs are charged to expense.

Impairment of Long-Lived Assets — Long-lived assets, such as property, plant, and equipment and patents are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Circumstances which could trigger a review include, but are not limited to: significant decreases in the market price of the asset; significant adverse changes in the business climate or legal factors; current period cash flow or operating losses combined with a history of losses or a forecast of continuing losses associated with the use of the asset; and current expectation that the asset will more likely than not be sold or disposed of significantly before the end of its estimated useful life.

Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset. Assets to be disposed of would be separately presented in the balance sheet and reported at the lower of the carrying amount or fair value less costs to sell, and would no longer be depreciated. The depreciable basis of assets that are impaired and continue in use is their respective fair values.

Revenue Recognition and Sales — The Company’s sales of its MelCancerVac® (“MCV”) colorectal cancer vaccine have been limited to a compassionate use basis in Singapore after stage IIA trials and is not approved for current sale for any other use or location. The Company's accounts for revenue recognition in accordance with the Securities and Exchange Commission Staff Accounting Bulletin No. 101, “Revenue Recognition in Financial Statements” (SAB 101), and FASB ASC 605 Revenue Recognition. The Company recognizes revenue when rights and risk of ownership have passed to the customer, when there is persuasive evidence of an arrangement, product has been shipped or delivered to the customer, the price and terms are finalized, and collections of resulting receivable is reasonably assured. Products are primarily shipped FOB shipping point at which time title passes to the customer.

Value Added Tax — In Denmark, Value Added Tax (“VAT”) of 25% of the invoice amount is collected in respect of the sales of goods on behalf of tax authorities. The VAT collected is not revenue of the Company; instead, the amount is recorded as a liability on the balance sheet until such VAT is paid to the authorities. VAT of 25% is also paid to Danish and EU vendors on invoices these amounts are refundable from the respective governmental authority and recorded as other receivables in the accompanying financial statements.

Research and Development Expenses — The Company expenses research and development costs incurred in formulating, improving, validating and creating alternative or modified processes related to and expanding the use of our MAGE –A dendrite cell cancer therapy. Research and development expenses were included in operating expenses for the three months ended September 30, 2016 and 2015, totaled $17,104 and $101,759, respectively.

Our research and development expenses may fluctuate substantially from quarter to quarter depending on the clinical studies and the timing of samples supporting the clinical studies.

DANDRIT BIOTECH USA, INC. AND SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Income Taxes — The Company accounts for income taxes in accordance with FASB ASC Topic 740 Accounting for Income Taxes. This statement requires an asset and liability approach for accounting for income taxes.

Loss Per Share — The Company calculates earnings /(loss) per share in accordance with FASB ASC 260 Earnings Per Share. Basic earnings per common share (EPS) are based on the weighted average number of shares of common stock outstanding during each period. Diluted earnings per common share are based on shares outstanding (computed as under basic EPS) and potentially dilutive common shares. Potential shares of common stock included in the diluted earnings per share calculation include in-the-money stock options that have been granted but have not been exercised.

Fair Value of Financial Instruments — The Company accounts for fair value measurements for financial assets and financial liabilities in accordance with FASB ASC Topic 820, “Fair Value Measurements”. The authoritative guidance, which, among other things, defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as the exit price, representing the amount that would either be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:

●

Level 1. Observable inputs such as quoted prices in active markets for identical assets or liabilities;

●

Level 2. Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and

●

Level 3. Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

Unless otherwise disclosed, the fair value of the Company’s financial instruments including cash, accounts receivable, prepaid expenses, investments, accounts payable, accrued expenses, capital lease obligations and notes payable approximates their recorded values due to their short-term maturities.

Accounting Estimates — The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimated.

Recent Accounting Pronouncements - In May 2014, the Financial Accounting Standards Board (FASB) issued a new standard to achieve a consistent application of revenue recognition within the U.S., resulting in a single revenue model to be applied by reporting companies under U.S. generally accepted accounting principles. Under the new model, recognition of revenue occurs when a customer obtains control of promised goods or services in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In addition, the new standard requires that reporting companies disclose the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. On July 9, 2015, the FASB agreed to delay the effective date by one year; accordingly, the new standard is effective for us beginning in the first quarter of 2018 and we expect to adopt it at that time. The new standard is required to be applied retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying it recognized at the date of initial application. We have not yet selected a transition method, nor have we determined the impact of the new standard on our consolidated financial statements.

DANDRIT BIOTECH USA, INC. AND SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

In 2015, the FASB issued an amended standard requiring that we classify all deferred tax assets and liabilities as non-current on the balance sheet instead of separating deferred taxes into current and non-current. The amended standard is effective for us beginning in the first quarter of 2017; early adoption is permitted and we are evaluating whether we will early adopt. The amended standard may be adopted on either a prospective or retrospective basis. We do not expect that the adoption of this standard will have a significant impact on our financial position or results of operations.

In February 2016, the FASB issued changes to the accounting for leases that primarily affect presentation and disclosure requirements. The new standard will require the recognition of a right to use asset and underlying lease liability for operating leases with an initial life in excess of one year. This standard is effective for us beginning in the first quarter of 2019. We have not yet determined the impact of the new standard on our consolidated financial statements.

Other recent accounting pronouncements issued by the FASB did not or are not believed by management to have a material impact on the Company's present or future financial statements.

Reclassification — The financial statement for the period ended September 30, 2015 and June 30, 2016 have been reclassified to conform to the headings and classifications used in the September 30, 2016 financial statements.

NOTE 2 — GOING CONCERN

The accompanying unaudited consolidated financial statements have been prepared in conformity with generally accepted accounting principles of the United States of America, which contemplate continuation of the Company as a going concern. However, the Company has incurred significant losses, has not yet been successful in establishing profitable operations and has short-term obligations in excess of anticipated cash. These factors raise substantial doubt about the ability of the Company to continue as a going concern. In this regard, management plans to mitigate this doubt by raising additional funds through debt and/or equity offerings. The Company is attempting to raise $15,000,000 or more through a private placement offering and close the acquisition of OncoSynergy, Inc. The closing of the private placement is contingent on the closing of the acquisition of the assets of OncoSynergy, Inc. There is no assurance that the Company will be successful in raising additional funds through the debt or equity or achieving profitable operations. The consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties.

NOTE 3 — PROPERTY AND EQUIPMENT

Property and equipment consisted of the following at September 30, 2016 and June 30, 2016:

	Useful Life	September 30, 2016			June 30, 2016
Lab equipment and instruments	4-6	$	164,565		$	163,959
Computer equipment	4-6		56,363			56,155
			220,928			220,114
Less Accumulated Depreciation			(220,928	)		(220,114	)
Net Property and Equipment		$	-		$	-

Depreciation expense amounted to $0 and $0 for the three month period ended September 30, 2016 and 2015, respectively.

NOTE 4 — DEFINITE-LIFE INTANGIBLE ASSETS

At September 30, 2016 and June 30, 2016, definite-life intangible assets, net of accumulated amortization, consist of patents on the Company’s products and processes of $132,503 and $135,743, respectively. The patents are recorded at cost and amortized over twenty years from the date of application. Amortization expense for the three months ended September 30, 2016 and 2015 was $3,749 and $3,937, respectively. Expected future amortization expense for the years ended are as follows:

Year ending June 30,
2017	$	11,106
2018		14,849
2019		14,849
2020		14,890
2021		14,849
Thereafter		61,960
	$	132,503

DANDRIT BIOTECH USA, INC. AND SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 5 — NOTES PAYABLE – RELATED PARTY

Notes payable to related parties consists of the following as of September 30, 2016 and June 30, 2016:

	September 30, 2016			June 30, 2016
Non-Interest Bearing Loan Payable Sunrise Financial Group Inc.	$	38,235		$	38,235
Note Payable ML Group		17,478			17,414
6% Promissory Note payable to NLBDIT 2010 Enterprises, LLC		47,825			47,233
Total Notes Payable – Related Party		103,538			102,882
Less Current Maturities		(103,538	)		(102,882	)
Note Payables – Related Party Long Term	$	-		$	-

The following represents the future maturities of long-term debt as of September 30, 2016:

Year ending June 30,
2017			103,538
2018			-
2019			-
2020			-
2021			-
Thereafter			-
			103,538

As of September 30, 2016, the outstanding balance of $38,235 for professional fees paid by a related party and amounts advanced to the Parent are reported as loan payable - related party. The $38,235 loan payable was acquired in the reverse acquisition. The amount is unsecured, non-interest bearing and has no stipulated repayment terms.

A 6% Promissory Note payable (the “Note”) to NLBDIT 2010 Enterprises, LLC, an entity controlled by a shareholder of the Company, was acquired by the Company in the reverse acquisition, payable on February 12, 2014 upon the completion date of the Share Exchange. As of September 30, 2016, the outstanding balance on the Note, including accrued interest, was $47,825. During the three months ended September 30, 2016 and 2015, the Company recorded related party interest on the Note of $592 and $592 respectively.

DANDRIT BIOTECH USA, INC. AND SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 6 — CONVERTIBLE NOTES PAYABLE – RELATED PARTY

Convertible Notes payable to related parties consists of the following as of September 30, 2016 and June 30, 2016:

	September 30, 2016			June 30, 2016
Non-Interest Bearing Notes Payable Paseco ApS	$	120,300		$	-
Less Discount		(17,359	)		-
Total Convertible Notes Payable – Related Party		102,941		$	-
Less Current Maturities		-			-
Net Convertible Note Payables – Related Party Long Term	$	102,941			-

The following represents the future maturities of long-term debt as of September 30, 2016:

Year ending June 30,
2017			-
2018			120,300
2019			-
2020			-
2021			-
Thereafter			-
			120,300

On July 1, 2016, the Company entered into a non-interest bearing convertible notes for $60,150, with a shareholder of the Company. The note matures December 31, 2017. The note is convertible into shares of common stock at $2.00 per share. As the Company’s stock was trading at $2.50 on July 1, 2016, the Company bifurcated the intrinsic value of the beneficial conversion feature and recorded a discount of $15,038. As the note is non-interest bearing the Company imputed the interest at 3% and further recorded a discount of $2,639. The interest is being amortized to expense using the effective interest method through the December 31, 2017 maturity. For the three months ended September 30, 2016, interest expense of $2,527 was recorded for the amortization of the discount.

On July 19, 2016, the Company entered into a non-interest bearing convertible notes for $60,150, with a shareholder of the Company. The note matures December 31, 2017. The note is convertible into shares of common stock at $2.00 per share. As the note is non-interest bearing the Company imputed the interest at 3% and further recorded a discount of $2,555. The interest will be amortized to expense using the effective interest method through the December 31, 2017 maturity. For the three months ended September 30, 2016, interest expense of $346 was recorded for the amortization of the discount.

DANDRIT BIOTECH USA, INC. AND SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 7 — CONVERTIBLE NOTES PAYABLE

Convertible Notes payable to consists of the following as of September 30, 2016 and June 30, 2016:

	September 30, 2016			June 30, 2016
Non-Interest Bearing Notes Payable Equine Invest Aps	$	240,600		$	-
Less Discounts		(10,931	)		-
Total Convertible Notes Payable		229,669
Less Current Maturities		-			-
Net Convertible Note Payables – Long Term	$	229,669		$	-

The following represents the future maturities of long-term debt as of September 30, 2016:

Year ending June 30,
2017			-
2018			240,600
2019			-
2020			-
2021			-
Thereafter			-
			240,600

On August 24, 2016, the Company entered into a non-interest bearing convertible notes $90,225. The note matures December 31, 2017. The note is convertible into shares of common stock at $2.00 per share. As the Company’s common stock was trading at $2.05 on July 1, 2016, the Company bifurcated the intrinsic value of the beneficial conversion feature and recorded a discount of $2,256. As the note is non-interest bearing the Company imputed the interest at 3% and further recorded a discount of $3,577. The interest will be amortized to expense using the effective interest method through the December 31, 2017 maturity. For the three months ended September 30, 2016, interest expense of $425 was recorded for the amortization of the discount.

On September 21, 2016 the Company entered into a non-interest bearing convertible notes for $150,375. The note matures December 31, 2017. The note is convertible into shares of common stock at $2.00 per share. As the note is non-interest bearing the Company imputed the interest at 3% and further recorded a discount of $5,630. The interest will be amortized to expense using the effective interest method through the December 31, 2017 maturity. For the three months ended September 30, 2016, interest expense of $107 was recorded for the amortization of the discount.

NOTE 8 — LEASES

Operating Leases — The Company leases laboratory and production space under operating lease agreements which can be cancelled with 3-months notice. The lease calls for monthly payments of DKK 6,300 (approximately $945 at September 30, 2016).

On March 25, 2015, the Company entered into an agreement for use of virtual office space at a rate of $375/month on a month-to-month basis, which can be terminated by either party on one month’s notice.

Lease expense charged to operations was $3,960 and $3,940 for the three ended September 30, 2016 and 2015, respectively.

DANDRIT BIOTECH USA, INC. AND SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 9 — INCOME TAXES

The Company accounts for income taxes in accordance with FASB ASC Topic 740, Accounting for Income Taxes; which requires the Company to provide a net deferred tax asset or liability equal to the expected future tax benefit or expense of temporary reporting differences between book and tax accounting and any available operating loss or tax credit carry forwards. The amount of and ultimate realization of the benefits from the deferred tax assets for income tax purposes is dependent, in part, upon the tax laws in effect, the Company’s future earnings, and other future events, the effects of which cannot be determined.

As of September 30, 2016, the Company had net operating loss carry-forwards of approximately $10,379,545 at an estimated effective tax rate of 22% or approximately $2,283,500 for Danish tax purposes which do not expire and net operating loss carry-forwards of approximately $1,048,174 at an estimated effective tax rate of 34% or approximately $356,379 for U.S. Federal Tax purposes which expire through 2034, a portion of which shall be limited due to the change in control of the Parent.

The Company files U.S. and Danish income tax returns, and they are generally no longer subject to tax examinations for years prior to 2012 and 2008, respectively.

The temporary differences, tax credits and carry forwards gave rise to the following deferred tax asset (liabilities) at September 30, 2016 and June 30, 2016:

	September 30, 2016			June 30, 2016
Excess of Tax over book depreciation Fixed assets	$	7,660		$	7,660
Excess of Tax over book depreciation Patents		870			870
Net Operating Loss Carry forward		2,639,879			2,558,080
Valuation Allowance		(2,648,409	)		(2,566,610	)
Total Deferred Tax Asset (Liabilities)	$	-		$	-

In accordance with prevailing accounting guidance, the Company is required to recognize and disclose any income tax uncertainties. The guidance provides a two-step approach to recognize and disclose any income tax uncertainties. The guidance provides a two-step approach to recognizing and measuring tax benefits and liabilities when realization of the tax position is uncertain. The first step is to determine whether the tax position meet the more-likely-than-not condition for recognition and the second step is to determine the amount to be recognized based on the cumulative probability that exceeds 50%. The amount of and ultimate realization of the benefits from the deferred tax assets for income tax purposes is dependent, in part, upon the tax laws in effect, the Company’s future earnings, and other future events, the effects of which can be difficult to determine and can only be estimated. Management estimates that it is more likely than not that the Company will not generate adequate net profits to use the deferred tax assets; and consequently, a valuation allowance was recorded for all deferred tax assets.

A reconciliation of income tax expense at the federal statutory rate to income tax expense at the Company’s effective rate is as follows at September 30, 2016 and 2015:

	September 30, 2016			September 30, 2015
Computed Tax at Expected Statutory Rate	$	(283,454	)	$	(127,233	)
Non-US Income Taxed at Different Rates		14,465			41,760
Non-Deductible expenses		214,163			-
Valuation allowance		14,319			61,560
Income Tax Expense	$	(40,507	)	$	(23,913	)

DANDRIT BIOTECH USA, INC. AND SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 9 — INCOME TAXES (Continued)

The components of income tax expense (benefit) from continuing operations for the three months ended September, 2016 and 2015 consisted of the following:

	2016			2015
Current Tax Expense
Danish Income Tax	$	(40,507	)	$	(23,913	)
Total Current Tax Expense		(40,507	)		(23,913	)
Deferred Income Tax Expense (Benefit)
Excess of Tax over Book Depreciation Fixed Assets		-			-
Excess of Tax over Book Depreciation Patents		-			-
Net Operating Loss Carry forwards		(81,798	)		(52,647	)
Change in the Valuation allowance		81,798			52,647
Total Deferred Tax Expense	$	-		$	-

Deferred income tax expense / (benefit) results primarily from the reversal of temporary timing differences between tax and financial statement income.

NOTE 10 — LOSS PER SHARE

The following data shows the amounts used in computing loss per share and the effect on income and the weighted average number of shares of potential dilutive common stock for the three month periods ended September 30, 2016, and 2015:

	For the 3 Months Ended
	September 30,
	2016			2015
Net (Loss)		(793,181	)		(350,302	)
Weighted average number of common shares used in basic earnings per share		9,533,290			9,533,290
Effect of dilutive securities, stock options and warrants		-			-
Weighted average number of common shares and potential dilutive common shares outstanding used in dilutive earnings per share		9,533,290			9,533,290

At September 30, 2016, the Company had convertible notes payable totaling $360,900 convertible into 180,450 shares of common stock that were not included in the calculation of weighted average shares of common stock and potential dilutive common shares as their effect is anti-dilutive.

At September 30, 2015, the Company had no common stock equivalents.

DANDRIT BIOTECH USA, INC. AND SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 11 — STOCKHOLDERS’ EQUITY

Common Stock — The Company has 100,000,000 authorized shares of Common stock $0.0001. As of September 30, 2016 and June 30, 2016 there were 9,533,290 shares issued and outstanding.

Common Stock Offering – On September 15, 2016, the Company filed a Form D disclosing that the Company is seeking to raise up to $16,500,000 additional equity capital though a private placement offering exempt under Rule 506(b).

Share Exchange Agreement/Reverse Acquisition - On February 12, 2014, in accordance with the terms and conditions of a Share Exchange Agreement (the "Share Exchange Agreement"), we completed the acquisition of approximately 100% of the issued and outstanding capital stock of DanDrit Denmark (the “Share Exchange”) and as a result became DanDrit Denmark’s parent company (the “Parent”). In connection with the Share Exchange, each outstanding share of common stock of DanDrit Denmark was exchanged for 1.498842 shares of DanDrit USA’s common stock, par value $.0001 per share (the “Common Stock”) for an aggregate of 6,000,000 shares, including 185,053 shares of Common Stock reserved for issuance, in accordance with Section 70 of the Danish Companies Act and the Articles of Association of DanDrit Denmark, to the DanDrit Denmark shareholders who did not consent to the Share Exchange and deemed issued and outstanding for accounting purposes. In addition, in connection with the Share Exchange (1) the sole shareholder prior to the Share Exchange agreed to cancel 4,400,000 shares of outstanding Common Stock owned by it and (2) the board of directors and executive management of DanDrit Denmark was appointed to serve as the Board of Directors and executive management of DanDrit USA effective upon the resignation of the sole officer and director of DanDrit USA prior to the closing of the Share Exchange.

Voting — Holders of the Company’s common stock are entitled to one vote for each share held of record on each matter submitted to a vote of stockholders, including the election of directors, and do not have any right to cumulate votes in the election of directors.

Dividends — Holders of the Company’s common stock are entitled to receive ratably such dividends as our Board of Directors from time to time may declare out of funds legally available.

Liquidation Rights — In the event of any liquidation, dissolution or winding-up of affairs of the Company, after payment of all of our debts and liabilities, the holders of the Company’s common stock will be entitled to share ratably in the distribution of any of our remaining assets.

Stock Options — On September 15, 2016, Parent’s Board of Directors approved the grant stock options to employees, officers, and directors of the Company. The Board granted 300,000 options at a strike price of $2.00 per share to each of Eric Leire, APE Invest A/S for Aldo Petersen and N.E. Nielson, in consideration of their service to the Company, for an aggregate of 900,000 options. The options were granted pursuant to written agreements with each optionee. The options vested upon grant, contain certain anti-dilution provisions and expire December 31, 2019.

DANDRIT BIOTECH USA, INC. AND SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 11 — STOCKHOLDERS’ EQUITY (Continued)

The Company recognizes compensation costs for stock option awards to employees based on their grant-date fair value. The value of each stock option is estimated on the date of grant using the Black-Scholes option-pricing model. The weighted-average assumptions used to estimate the fair values of the stock options granted using the Black-Scholes option-pricing model are as follows:

	DanDrit Biotech USA, Inc.
Expected term (in years)		3.29
Volatility		189.65	%
Risk free interest rate		0.87	%
Dividend yield		0	%

The Company recognized stock based compensation expense related to the options of $626,487 and $0 for the three months ended September 30, 2016 and 2015, respectively. At September 30, 2016 the Company had approximately $0 of unrecognized compensation cost related to non-vested options.

A summary of the status of the options outstanding at September 30, 2016 is presented below:

			Options Outstanding						Options Exercisable
	Exercise Prices		Number Outstanding		Weighted Average Remaining Contractual Life (years)		Weighted Average Exercise Price		Number Exercisable		Weighted Average Exercise Price
	$	2.00		900,000		3.25	$	2.00		900,000	$	2.00
Total				900,000		3.25	$	2.00		900,000	$	2.00

A summary of the status of the options at September 30, 2016, and changes during the period are presented below:

	September 30, 2016
	Shares		Weighted Average Exercise Price		Average Remaining Life		Weighted Average Intrinsic Value

Outstanding at beginning of period		0	$	-		-	$	-
Granted		900,000		2.00		3.25		675,000
Exercised		-		-		-		-
Forfeited		-		-		-		-
Expired		-		-		-		-
Outstanding at end of period		900,000	$	2.00		3.25	$	675,000
Vested and expected to vest		900,000	$	2.00		3.25	$	675,000
Exercisable end of period		900,000	$	2.00		3.25	$	675,000

At September 30, 2016, all options issued are exercisable. The total intrinsic value of options at September 30, 2016 was $675,000. Intrinsic value is measured using the fair market value at the date of exercise (for shares exercised) or at September 30, 2016 (for outstanding options), less the applicable exercise price.

DANDRIT BIOTECH USA, INC. AND SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 12 — COMMITMENTS AND CONTINGENCIES

Shares held for non-consenting shareholders – In connection with the Share Exchange agreement certain shareholders of Dandrit Denmark had not been identified or did not consent to the exchange of shares. In accordance with Section 70 of the Danish Companies Act and the Articles of Association of DanDrit Denmark, the Non-Consenting Shareholders that did not exchange the DanDrit Denmark equity interests owned by such Non-Consenting Shareholders for shares of the Company, will be entitled to receive up to 185,053 shares of common stock of the Company that each such Non-Consenting Shareholder would have been entitled to receive if such shareholder had consented to the Share Exchange. The 185,053 shares have been reflected as issued and outstanding in the accompanying financial statements.

Clinical Trial Agreements – The Company’s subsidiary, DanDrit Biotech A/S signed a contract of collaboration with the University Hospital IRCCS “San Martino” - IST – National Institute for Cancer Research, known as the San Martino Hospital of Genoa. Dr. Alberto Sobrero, the Head of the Medical Oncology Unit at the San Martino Hospital, is principal investigator of the randomized multicenter study. The collaboration relates to a Phase III adjuvant study of DanDrit’s vaccine in patients with no evident disease (“NED”) stage IV colorectal cancer (“CRC”). The primary goal of the study is to evaluate the efficacy of DanDrit’sMelCancerVac® (“MCV”) in stage IV CRC patients rendered disease free after the completion of standard treatments in accordance with local practices.

On April 28, 2015 the Company entered into a service agreement with Fondazione Giscad per la Ricerca sui Tumori to support Dandrit in a clinical trial to be conducted in Italy.

Patient Name Use Program Agreements - On December 16, 2013, DanDrit Denmark entered into an agreement with a Dutch company (the “MCV Partner”) regarding a Patient Name Use Program (PNU) for the Company’s MCV. This program will allow DanDrit Denmark to sell MCV for a year of treatment (10 vaccines) to cancer patients through the MCV Partner. The MCV Partner offers a worldwide online platform providing access to non-registered medicines for patients with life threatening diseases. The MCV Partner is a turnkey solution and will be in charge of regulatory, recruitment, logistics, and pharmaco vigilance. The Company will pay the MCV Partner a royalty on a country to country basis for 20 years on MCV sales sold under the agreement. Either party may terminate the agreement with 180 day written notice.

On April 23, 2015, the Company entered into a collaboration agreement with Riyadh Pharma in Saudi Arabia to promote cooperation in the manufacturing and marketing of DanDrit's dendritic cell cancer vaccine.

Manufacturing Agreements - On January 28, 2014, the Company entered into an agreement with Cellin Technologies for the manufacture of the MCV Cancer vaccine.

On August 8, 2014, the Company entered into an agreement with Cellin Technologies for the manufacture of the Melanoma Cell Lysate.

Food and Drug Administration (FDA) - The FDA has extensive regulatory authority over biopharmaceutical products (drugs and biological products), manufacturing protocols and procedures and the facilities in which they will be manufactured. Any new bio product intended for use in humans is subject to rigorous testing requirements imposed by the FDA with respect to product efficacy and safety, possible toxicity and side effects. FDA approval for the use of new bio products (which can never be assured) requires several rounds of extensive preclinical testing and clinical investigations conducted by the sponsoring pharmaceutical company prior to sale and use of the product. At each stage, the approvals granted by the FDA include the manufacturing process utilized to produce the product. Accordingly, the Company’s cell systems used for the production of therapeutic or bio therapeutic products are subject to significant regulation by the FDA under the Federal Food, Drug and Cosmetic Act, as amended.

Product liability - The contract production services for therapeutic products offered exposes an inherent risk of liability as bio therapeutic substances manufactured, at the request and to the specifications of customers, could foreseeably cause adverse effects. The Company seeks to obtain agreements from contract production customers indemnifying and defending the Company from any potential liability arising from such risk. There can be no assurance, however, that the Company will be successful in obtaining such agreements in the future or that such indemnification agreements will adequately protect the Company against potential claims relating to such contract production services. The Company may also be exposed to potential product liability claims by users of its products. A successful partial or completely uninsured claim against the Company could have a material adverse effect on the Company’s operations.

Employment Agreements - The Company and its Subsidiary have an employment agreement with an officer of the Company.

Contingencies - The Company is from time to time involved in routine legal and administrative proceedings and claims of various types. While any proceedings or claim contains an element of uncertainty, management does not expect a material impact on our results of operations or financial position.

DANDRIT BIOTECH USA, INC. AND SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 13 — RELATED PARTY TRANSACTIONS

At September 30, 2016 and 2015, the Company had various notes payable with shareholders of the Company (See Note 5 and 6).

During the three months ended September 30, 2016 and 2015 the Company paid $0 and $22,345 respectively, for medical consultancy services to JARO Holding ApS. JARO Holding ApS is an entity owned by a director of the Company.

In July, 2015 the Company paid DKK50.000 ($7,448) to Paseco ApS, an entity owned by a shareholder of the Company, for consultancy services provided in July 2015.

During the three months ended September 30, 2016 and 2015, a law firm partially owned by the Company’s Chairman of the Board of Directors provided legal services of $0 and $8,193, respectively, to the Company. At September 30, 2016, and June 30, 2016, the Company had a payable to the firm in the amount of $97,718 and $97,358.

On July 1, 2016, the Company entered into a non-interest bearing convertible notes $60,150, with a shareholder of the Company. The note matures December 31, 2017. The note is convertible into shares of common stock at $2.00 per share. As the Company’s stock was trading at $2.50 on July 1, 2016, the Company bifurcated the intrinsic value of the beneficial conversion feature and recorded a discount of $15,038. As the note is non-interest bearing the Company imputed the interest at 3% and further recorded a discount of $2,639. The interest is being amortized to expense using the effective interest method through the December 31, 2017 maturity. For the three months ended September 30, 2016, interest expense of $2,527 was recorded for the amortization of the discount.

On July 1, 2016, the Company entered into a financial service agreement with APE Invest AS (an entity owned by a director of the Company) for consultancy services related to the Company raising additional equity financing in the US and Danish Capital Markets. The agreement calls for monthly payment of $20,000 with a $100,000 retainer payment due November 1, 2016. The agreement can be terminated with 12 month notice.

On September 15, 2016, the Company recorded $626,487 in non-cash compensation for the grant of 900,000 stock options to employees, officers, and directors of the Company, which shall be fully vested upon grant, to purchase shares of common stock of the Company at $2.00 per share, and expire December 31, 2019. The options contain certain anti-dilution provisions.

NOTE 14 — ASSET PURCHASE AGREEMENT

During April 2016 the Company entered into an Asset Purchase Agreement (the “Purchase Agreement”) wherein the Company will acquire OncoSynergy, Inc. (“OncoSynergy”). The purchase price for the acquisition consists of (i) a number of shares of Common Stock of the Company equal to the number of shares of Series A Common Stock and Common Stock outstanding of the OncoSynergy, immediately prior to the closing of the Transaction, and (ii) derivative securities (including any option, right, warrant, call, convertible security, right to subscribe, conversion right or other agreement or commitment immediately outstanding prior to the closing, if any), of like tenor, except as to timing of exercisability and maturity, exercisable or convertible into a like number of shares of Common Stock, and having rights, preferences, terms and conditions consistent in all other respects with such outstanding derivative security. Immediately following the closing it is estimated OncoSynergy, Inc. will hold between 33% and 40% of the capital stock of the Company on a fully diluted basis, assuming the exercise or conversion in full of all outstanding derivative securities of the Dandrit BioTech USA, Inc.

On October 31, 2016, the Company and OncoSynergy entered into the First Amendment to the Asset Purchase Agreement, pursuant to which the date to close the acquisition was amended from October 31, 2016 to December 31, 2016. On November 8, 2016, the Company and OncoSynergy entered into the First Amendment to the Asset Purchase Agreement, pursuant to which certain conditions to closing the transactions described in the Purchase Agreement have been waived, including the requirements that the Company (i) obtain votes from its stockholders in order to consummate the transactions contemplated thereby, (ii) demonstrate that it satisfies the listing requirements to be uplisted to a national stock exchange, including by effecting a reverse stock split, and (iii) change its name to “OncoSynergy, Inc.” upon closing the acquisition.

NOTE 15 — SUBSEQUENT EVENTS

The Company’s management reviewed material events through November 14, 2016.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Forward Looking Statement Notice

Certain statements made in this Quarterly Report on Form 10-Q are “forward-looking statements” (within the meaning of the Private Securities Litigation Reform Act of 1995) regarding the plans and objectives of management for future operations. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of DanDrit Biotech USA, Inc. (“we”, “DanDrit USA”, “us”, “our”, the “Parent” or the “Company”) to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. The forward-looking statements included herein are based on current expectations that involve numerous risks and uncertainties. The Company's plans and objectives are based, in part, on assumptions involving the continued expansion of business. Assumptions relating to the foregoing involve judgments with respect to, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the control of the Company. Although the Company believes its assumptions underlying the forward-looking statements are reasonable, any of the assumptions could prove inaccurate and, therefore, there can be no assurance the forward-looking statements included in this Quarterly Report will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by the Company or any other person that the objectives and plans of the Company will be achieved.

Description of Business

We are a biopharmaceutical company developing and commercializing targeted oncology vaccines that address major medical needs to advance cancer care. We are developing a polytopic (mainly MAGE-A family) dendritic cell vaccine cancer immuno therapy, which address patient populations of cancer survivors to prevent recurrence. Our lead product candidate, MCV, is a dendritic cell vaccine that could strengthen the immune response in colorectal cancer patients. In December 2013, DanDrit Denmark entered into an agreement with a Dutch company that provides access to non-registered medicines for patients with life threatening diseases, regarding a Patient Name Use Program (PNU) for MCV. This program will allow us to sell to the Dutch company MCV for one year of treatment (10 vaccines) to cancer patients.

The Company was originally incorporated in Delaware on January 18, 2011 under the name “Putnam Hills Corp.” as a vehicle to pursue a business combination through the acquisition of, or merger with, an operating business. We filed a Registration Statement on Form 10 with the U.S. Securities and Exchange Commission (the “SEC”) on August 12, 2011.

On February 12, 2014, pursuant to the terms and conditions of a Share Exchange Agreement (the "Share Exchange Agreement"), DanDrit USA (the “Parent”) acquired approximately 100% of the issued and outstanding capital stock of DanDrit BioTech A/S, a Danish corporation (“DanDrit Denmark”) and as a result became the parent of DanDrit Denmark (the “Share Exchange”). Prior to the Share Exchange there were 5,000,000 shares of the common stock, par value $.0001 per share (the “Common Stock”) of the Parent outstanding. The Parent and a shareholder agreed to cancel 4,400,000 shares of its common stock and issued 1,440,000 shares of common stock for legal and consulting services related to the Share Exchange and a future financing. At the time of the Share Exchange, the outstanding shares of the common stock of DanDrit Denmark were exchanged for 1.498842 shares of Parent’s common stock, for a total of 6,000,000 shares of common stock (including 185,053 shares of common stock reserved for issuance in accordance with Section 70 of the Danish Companies Act and the Articles of Association of DanDrit Denmark to the Non-Consenting Shareholders, deemed issued and outstanding for accounting purposes). Following the closing of the Share Exchange, DanDrit Biotech USA, Inc., the wholly owned subsidiary of the Company, merged with and into the Company, thereby changing the Company’s name to “DanDrit Biotech USA, Inc.”

On February 14, 2014, the Company filed a registration statement on Form S-1 (the “Registration Statement”) to register 2,400,000 shares of common stock at a purchase price of $5.00 per share in an initial public offering of up to an aggregate of $12,000,000 in gross proceeds. The Registration Statement was declared effective by the SEC on August 14, 2014 (the “Offering”). In connection with the Offering, the Company issued and sold an aggregate 1,493,290 shares of common stock for gross proceeds of $5,466,450 and total aggregate gross proceeds of $5,310,089 raised in the Offerings.

On December 31, 2014, the Company received $2,000,000 in connection with a private offering of 400,000 shares of common stock at an offering price of $5.00 per share.

On September 24, 2014, DanDrit Denmark signed a contract of collaboration with the University Hospital IRCCS “San Martino” - IST – National Institute for Cancer Research, known as the San Martino Hospital of Genoa. Dr. Alberto Sobrero, the Head of the Medical Oncology Unit at the San Martino Hospital, is principal investigator of the randomized multicenter study. The collaboration relates to a Phase III adjuvant study of DanDrit’s vaccine in patients with no evident disease stage IV colorectal cancer. The primary goal of the study is to evaluate the efficacy of DanDrit’s MelCancerVac® (“MCV”) in stage IV CRC patients rendered disease free after the completion of standard treatments in accordance with local practices.

The Company is an “emerging growth company”, as defined in the Jumpstart Our Business Startups Act of 2012 (“JOBS Act”), and may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not “emerging growth companies” including, but not limited to, not being required to comply with the auditor attestation requirements of section 404(b) of the Sarbanes-Oxley Act, and exemptions from the requirements of Sections 14A(a) and (b) of the Securities Exchange Act of 1934 to hold a nonbinding advisory vote of shareholders on executive compensation and any golden parachute payments not previously approved.

The Company has also elected to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(1) of the JOBS Act. This election allows us to delay the adoption of new or revised accounting standards that have different effective dates for public and private companies until those standards apply to private companies. As a result of this election, our financial statements may not be comparable to companies that comply with public company effective dates.

We will remain an “emerging growth company” until the earliest of (1) the last day of the fiscal year during which our revenues exceed $1 billion, (2) the date on which we issue more than $1 billion in non-convertible debt in a three year period, (3) the last day of the fiscal year following the fifth anniversary of the date of the first sale of our common equity securities pursuant to an effective registration statement filed pursuant to the Securities Act of 1933, as amended, or (4) when the market value of our common stock that is held by non-affiliates exceeds $700 million as of the last business day of our most recently completed second fiscal quarter. To the extent that we continue to qualify as a “smaller reporting company”, as such term is defined in Rule 12b-2 under the Securities Exchange Act of 1934, after we cease to qualify as an emerging growth company, certain of the exemptions available to us as an emerging growth company may continue to be available to us as a smaller reporting company, including: (1) not being required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes Oxley Act; (2) scaled executive compensation disclosures; and (3) the requirement to provide only two years of audited financial statements, instead of three years.

Liquidity and Capital Resources

We have historically satisfied our capital and liquidity requirements through funding from our largest shareholders, the issuance of convertible notes (which over time have been converted into shares of our common stock) and the sale of common stock.

As of September 30, 2016, the Company had $31,675 in cash and working deficit of $(625,497) as compared to June 30, 2016, when the Company had $23,368 in cash and working deficit of $(775,750). The increase in cash and working capital is primarily due to the Company’s efforts to secure financings through equity offering and expenses for research and development attributable to the Company engaging an entity to perform Phase III clinical trial of MelCancerVac™.

Following is a summary of the company’s cash flows provided by (used in) operating, investing, and financing activities:

	Three Months Ended September 30, 2015			Three Months Ended September 30, 2014
Net Cash (Used by) Operating Activities	$	(326,496	)	$	(416,036	)
Net Cash (Used by) Investing Activities		-			1,052,989
Net Cash Provided by Financing Activities	$	360,900		$	-
(Gain) Loss on Currency Translation		(26,096	)		(9,978	)
Net Increase (Decrease) in Cash and Cash Equivalents	$	8,307		$	626,975

The accompanying unaudited consolidated financial statements have been prepared in conformity with generally accepted accounting principles of the United States of America, which contemplate continuation of the Company as a going concern. However, the Company has incurred significant losses, has not yet been successful in establishing profitable operations and has short-term obligations in excess of anticipated cash. These factors raise substantial doubt about the ability of the Company to continue as a going concern. In this regard, management plans to mitigate this doubt by raising additional funds through debt and/or equity offerings. The Company is attempting to raise $15,000,000 or more through a private placement offering and close the acquisition of the assets of OncoSynergy, Inc. The closing of the private placement is contingent on the closing of the acquisition of the assets of OncoSynergy, Inc.There is no assurance that the Company will be successful in raising additional funds through the debt or equity or achieving profitable operations. The consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties.

We may also need additional funds for possible future strategic acquisitions of businesses, products or technologies complementary to our business. If additional funds are required, we may raise such funds from time to time through public or private sales of equity or debt securities. Financing may not be available on acceptable terms, or at all, and our failure to raise capital when needed could materially adversely impact our growth plans and our financial condition and results of operations.

A 6% Promissory Note payable (the “Note”) to NLBDIT 2010 Enterprises, LLC, an entity controlled by a shareholder of the Company, was acquired by the Company in the reverse acquisition, payable on February 12, 2014 upon the completion date of the Share Exchange. As of September 30, 2016, and 2015, the outstanding balance on the Note, including accrued interest, was $47,825 and $45,471, respectively. During the three months ended September 30, 2016 and 2015 the Company recorded related party interest on the Note of $592, and $592, respectively.

On August 24, 2016, the Company entered into a non-interest bearing convertible notes for $90,225. The note matures December 31, 2017. The note is convertible into shares of common stock at $2.00 per share. As the Company’s stock was trading at $2.05 on July 1, 2016, the Company bifurcated the intrinsic value of the beneficial conversion feature and recorded a discount of $2,256. As the note is non-interest bearing the Company imputed the interest at 3% and further recorded a discount of $3,577. The interest will be amortized to expense using the effective interest method through the December 31, 2017 maturity. For the three months ended September 30, 2016, interest expense of $425 was recorded for the amortization of the discount.

Results of Operations

The Company’s sole source of operations is through its wholly owned Danish subsidiary, DanDrit Biotech A/S (“DanDrit Denmark”). There can be no assurance that DanDrit Denmark will be successful in obtaining US Food and Drug Administration approval of its colorectal vaccine, MCV, nor produce sufficient revenues from MCV to sustain operations. It is management's assertion that these circumstances may hinder the Company's ability to continue as a going concern. The Company’s plan of operation for the next twelve months shall be to continue its efforts to raise capital and revenues associated with its MCV product.

Three months ended September 30, 2016 compared to the three months ended September 30, 2015

The following table sets forth our revenues, expenses and net income for the three months ended September 30, 2016 and 2015. The financial information below is derived from our unaudited condensed consolidated financial statements.

	For the Three Months Ended
	September 30,
	2016			2015

Revenues	$	-		$	-

Cost of Goods Sold		-			-

Gross profit (Loss)		-			-

Operating Expenses
General and Administrative Expenses		204,951			204,851
Non-cash compensation expenses		626,487			-
Research and Development Expenses		17,104			101,759
Depreciation and Amortization		3,749			3,937
Consulting Expenses		-			30,848
Total Operating Expense		852,291			341,395

(LOSS) FROM OPERATIONS		(852,291	)		(341,395	)

Other Income (Expense)
Interest (expense)		(1,017	)		-
Interest (expense) – Related Party		(3,464	)		(592	)
Gain (Loss) on Currency Transactions		23,084			(32,228	)
Interest and Other Income		-			-
Total Other Income (Expense)		18,603			(32,820	)

(Loss) Before Income Taxes		(833,688	)		(374,215	)

Income Tax Expense (Benefit)		(40,507	)		(23,913	)

NET (LOSS)	$	(793,181	)	$	(350,302	)

BASIC AND DILUTED LOSS PER SHARE	$	(0.08	)	$	(0.04	)

WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - BASIC AND DILUTED		9,533,290			9,533,290

Revenues

Revenues from operations for the three months ended September 30, 2016, and 2015 were $0 and $0, respectively. There were no sales of lysate under a compassionate use program by DanDrit Denmark during the three months ended September 30, 2016 and 2015.

Cost of Goods Sold

Our cost of goods sold was $0 and $0 during the three months ended September 30, 2016, and 2015, respectively.

Gross profit (Loss)

Gross profit for the three months ended September 30, 2016, and 2015 was $0 and $0, respectively.

Expenses

Our operating expense for the three months ended September 30, 2016 totaled $852,291, representing an increase of $510,896, or approximately 150% compared to $341,395 for the three months ended September 30, 2015. The largest contributors to the increase in operating expenses was the $626,487 in non-cash compensation expenses for stock options granted.

General and administrative expenses for the three months ended September 30, 2016 totaled $204,951, representing an increase of $100, compared to $204,851 for the three months ended September 30, 2015. General and administrative expenses include audit and legal fees, office rental, insurance, patent fees, salaries and travel expenses.

Research and Development expenses for the three months ended September 30, 2016 and 2015 were $17,104 and $101,759 respectively, representing a decrease of $84,655 or 83%. The research and development expenses are attributable to the Company performing Phase III clinical trial of MelCancerVac™.

Depreciation and amortization expenses for the three months ended September 30, 2016 and 2015 were $3,749 and $3,937, respectively, related to the amortization of patents.

Consulting expenses for the three months ended September 30, 2016 and 2015 were $0 and $30,848, respectively, representing a decrease of $30,848 or 100%. The expenses in 2015 were primarily to medical consultancy services.

Other income (expense) net for the three months ended September 30, 2016 and 2015 were $18,604 and $(32,820), respectively. Other expense is associated with interest on related party loans and Gain/(losses) on currency transactions.

Net Loss

Net loss for the three months ended September 30, 2016 was $(793,181) or $(0.08) per share compared to a net loss of $(350,302) or $(0.04) per share for the three months ended September 30, 2015 representing an increase of $(442,879) or 126%. The net increase was primarily due to the increase in the non-cash compensation expenses and a decrease in Research and Development expenses and consulting expenses.

Cash Flows

Cash used by operating activities for the three months ended September 30, 2016 was $326,496, representing a decrease of $89,540, or approximately 21% compared to cash used by operating activities of $416,036 for the three months ended September 30, 2015. The net cash used by operating activities was primarily due to fund raising efforts of the Company and the operations of DanDrit Denmark.

Assets

Total assets as of September 30, 2016 were $944,684 compared to $870,831 as of June 30, 2016. Total current liabilities decreased to $1,410,059 as of September 30, 2016 compared to $1,508,229 as of June 30, 2016. The increases in total assets and decrease in total current liabilities were mainly due to a continued loss from operations for research and development, additional borrowing and expenditures to raise additional capital funding.

Off-Balance Sheet Arrangements

The Company does not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on the Company’s financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

Emerging Growth Company

As an “emerging growth company” under the JOBS Act, the Company has elected to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(1) of the JOBS Act. This election allows us to delay the adoption of new or revised accounting standards that have different effective dates for public and private companies until those standards apply to private companies. As a result of this election, our financial statements may not be comparable to companies that comply with public company effective dates.

Significant Accounting Policies and Critical Accounting Estimates

The methods, estimates, and judgments that we use in applying our accounting policies have a significant impact on the results that we report in our financial statements. Some of our accounting policies require us to make difficult and subjective judgments, often as a result of the need to make estimates regarding matters that are inherently uncertain. In addition, Section 107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We are not choosing to “opt out” of this provision. Section 107 of the JOBS Act provides that our decision to opt out of the extended transition period for complying with new or revised accounting standards is irrevocable. As a result of our election, not to “opt out” of Section 107, DanDrit’s financial statements may not be comparable to companies that comply with public company effective dates.

For a full explanation of our accounting policies, see Note 1 to the financial statements.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

As a “smaller reporting company” as defined by Rule 12b-2 of the Securities Exchange Act of 1934, the Company is not required to provide the information required by this Item.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

Our Chief Executive Officer (the “Certifying Officer”) is responsible for establishing and maintaining disclosure controls and procedures for the Company. The Certifying Officer has designed such disclosure controls and procedures to ensure that material information is made known to him, particularly during the period in which this Report was prepared.

The Certifying Officer is responsible for establishing and maintaining adequate internal control over financial reporting for the Company used the “Internal Control over Financial Reporting Integrated Framework” issued by Committee of Sponsoring Organizations (“COSO”) to conduct an extensive review of the Company’s “disclosure controls and procedures” (as defined in the Exchange Act, Rules 13a-15(e) and 15-d-15(e)) as of the end of each of the periods covered by this Report (the “Evaluation Date”). Based upon that evaluation, the Certifying Officer concluded that, as of September 30, 2016, our disclosure controls and procedures were not effective in ensuring that the information we were required to disclose in reports that we file or submit under the Securities and Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission (“SEC”) rules and forms. The deficiencies are attributed to the fact that the Company does not have adequate resources to address complex accounting issues, as well as an inadequate number of persons to whom it can segregate accounting tasks within the Company so as to ensure the segregation of duties between those persons who approve and issue payment from those persons who are responsible to record and reconcile such transactions within the Company’s accounting system. These control deficiencies will be monitored and attention will be given to the matter as we continue to accelerate through our current growth stage.

The Certifying Officer based his conclusion on the fact that the Company has identified material weaknesses in controls over financial reporting, detailed below. In order to reduce the impact of these weaknesses to an acceptable level, the Company has contracted with consultants with expertise in U.S. GAAP and SEC financial reporting standards to review and compile all financial information prior to filing that information with the SEC. However, even with the added expertise of these consultants, we still expect to be deficient in our internal controls over disclosure and procedures until sufficient capital is available to hire the appropriate internal accounting staff and individuals with requisite GAAP and SEC financial reporting knowledge. There have been no significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of their evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.

Changes in Internal Controls

There have been no changes in our internal controls over financial reporting during the quarter ended September 30, 2016 that have materially affected or are reasonably likely to materially affect our internal controls.

PART II — OTHER INFORMATION

Item 1. Legal Proceedings.

There are presently no material pending legal proceedings to which the Company or any of its subsidiaries, is a party or as to which any of its property is subject, and no such proceedings are known to the Company to be threatened or contemplated against it.

Item 1A. Risk Factors.

As a “smaller reporting company” as defined by Rule 12b-2 of the Securities Exchange Act of 1934, the Company is not required to provide the information required by this Item.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

None.

Item 6. Exhibits.

(a) Exhibits required by Item 601 of Regulation S-K.

Exhibit No.		Description

2.1		Share Exchange Agreement dated February 12, 2014. (2)

3.1		Certificate of Incorporation, as filed with the Delaware Secretary of State on January 18, 2011.(2)

3.2		By-laws. (3)

3.3		Articles of Association of DanDrit Denmark, as amended, dated February 26, 2004. (2)

3.4		Certificate of Ownership and Merger, dated February 12, 2014. (2)

31.1		Certification of the Company’s Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, with respect to the registrant’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2016.*

32.1		Certification of the Company’s Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*

10.1		Asset Purchase Agreement by and between OncoSynergy Inc. and DanDrit Biotech USA, Inc., dated April 4, 2016 (4)

101.INS		XBRL Instance Document*

101.SCH		XBRL Taxonomy Extension Schema*

101.CAL		XBRL Taxonomy Extension Calculation Linkbase*

101.DEF		XBRL Taxonomy Extension Definition Linkbase*

101.LAB		XBRL Taxonomy Extension Label Linkbase*

101.PRE		XBRL Taxonomy Extension Presentation Linkbase*

(1)	Filed as an exhibit to the Company’s Form 8-K filed with the SEC on August 12, 2014 and incorporated herein by reference.
(2)	Filed as an exhibit to the Company’s Form S-1 filed with the SEC on February 14, 2014 and incorporated herein by reference.
(3)	Filed as an exhibit to the Company's Registration Statement on Form 10, as filed with the SEC on August 12, 2011, and incorporated herein by this reference.
(4)	Filed as an exhibit to the Company’s Form 8-K filed with the SEC on April 5, 2016 and incorporated herein by reference.
*	Filed herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	DanDrit Biotech USA, Inc.

Dated: November 14, 2016	By:	/s/ Eric J. Leire
		Eric J. Leire
		Chief Executive Officer and Principal Financial Officer (Principal Executive Officer)

EX-31.1 2 f10q0916ex31i_dandritbiotech.htm CERTIFICATION

Exhibit 31.1

CERTIFICATION

I, Eric J. Leire, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q for the three months ended September 30, 2016 of DanDrit Biotech USA, Inc. (the “registrant”);

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a–15(e) and 15d–15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a–15(f) and 15d–15(f)) for the registrant and have:

(a)

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	(b)	designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	(c)	evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 14, 2016

/s/ Eric J. Leire

Eric J. Leire

Chief Executive Officer and
Principal Financial Officer

(Principal Executive Officer)

EX-32.1 3 f10q0916ex32i_dandritbiotech.htm CERTIFICATION

Exhibit 32.1

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of DanDrit Biotech USA, Inc. (the “Company”) on Form 10-Q for the three months ended September 30, 2016, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, in the capacities and on the date indicated below, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:

(1)

the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: November 14, 2016	/s/ Eric J. Leire
	Eric J. Leire
	Chief Executive Officer and Principal Financial Officer
	(Principal Executive Officer)

The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. § 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

EX-101.INS 4 ddrt-20160930.xml XBRL INSTANCE FILE 0001527728 2013-12-13 2013-12-16 0001527728 us-gaap:CommonStockMember 2014-02-12 0001527728 2014-02-01 2014-02-12 0001527728 us-gaap:CommonStockMember 2014-02-01 2014-02-12 0001527728 ddrt:VirtualOfficeMember 2015-03-01 2015-03-25 0001527728 2015-06-30 0001527728 ddrt:PasecoApsMember 2015-06-01 2015-06-30 0001527728 2015-07-01 2015-09-30 0001527728 2015-09-30 0001527728 ddrt:OncosynergyIncMember 2016-04-01 2016-04-30 0001527728 2016-06-28 0001527728 us-gaap:EmployeeStockOptionMember 2016-06-28 0001527728 2016-06-30 0001527728 ddrt:NotePayableMlGroupMember 2016-06-30 0001527728 ddrt:LabEquipmentAndInstrumentsMember 2016-06-30 0001527728 us-gaap:ComputerEquipmentMember 2016-06-30 0001527728 ddrt:NonInterestBearingLoanPayableSunriseFinancialGroupIncMember 2016-06-30 0001527728 ddrt:SixPercentPromissoryNotePayableToNlbditTwoZeroOneZeroEnterprisesLlcMember 2016-06-30 0001527728 ddrt:NotesPayableRelatedPartiesMember 2016-06-30 0001527728 ddrt:ConvertibleNotesPayableRelatedPartiesMember 2016-06-30 0001527728 ddrt:ConvertibleNotesPayableRelatedPartiesMember 2016-06-25 2016-06-30 0001527728 ddrt:ApeInvestAsMember 2016-07-02 0001527728 ddrt:ConvertibleNotesPayableRelatedPartiesMember 2016-07-19 0001527728 ddrt:ConvertibleNotesPayableRelatedPartiesMember 2016-07-11 2016-07-19 0001527728 us-gaap:ConvertibleNotesPayableMember 2016-08-24 0001527728 us-gaap:ConvertibleNotesPayableMember 2016-08-21 2016-08-24 0001527728 us-gaap:EmployeeStockOptionMember 2016-09-15 0001527728 us-gaap:BoardOfDirectorsChairmanMember 2016-09-15 0001527728 us-gaap:EmployeeStockOptionMember 2016-09-01 2016-09-15 0001527728 us-gaap:BoardOfDirectorsChairmanMember 2016-09-01 2016-09-15 0001527728 us-gaap:ConvertibleNotesPayableMember 2016-09-21 0001527728 us-gaap:ConvertibleNotesPayableMember 2016-09-16 2016-09-21 0001527728 2016-06-29 2016-09-30 0001527728 us-gaap:EmployeeStockOptionMember 2016-06-29 2016-09-30 0001527728 ddrt:SixPercentPromissoryNotePayableToNlbditTwoZeroOneZeroEnterprisesLlcMember 2016-06-29 2016-09-30 0001527728 ddrt:ConvertibleNotesPayableRelatedPartiesMember 2016-06-29 2016-09-30 0001527728 ddrt:ApeInvestAsMember 2016-06-29 2016-09-30 0001527728 us-gaap:ConvertibleNotesPayableMember 2016-06-29 2016-09-30 0001527728 ddrt:JaroHoldingApsMember 2016-06-29 2016-09-30 0001527728 ddrt:UnitedStatesFederalTaxMember 2016-06-29 2016-09-30 0001527728 ddrt:DanishTaxMember 2016-06-29 2016-09-30 0001527728 ddrt:LeasedLaboratorySpaceMember 2016-06-29 2016-09-30 0001527728 ddrt:LabEquipmentAndInstrumentsMember us-gaap:MaximumMember 2016-06-29 2016-09-30 0001527728 ddrt:LabEquipmentAndInstrumentsMember us-gaap:MinimumMember 2016-06-29 2016-09-30 0001527728 us-gaap:ComputerEquipmentMember us-gaap:MaximumMember 2016-06-29 2016-09-30 0001527728 us-gaap:ComputerEquipmentMember us-gaap:MinimumMember 2016-06-29 2016-09-30 0001527728 us-gaap:EmployeeStockOptionMember ddrt:ExercisePriceRangeMember 2016-06-29 2016-09-30 0001527728 2016-09-30 0001527728 us-gaap:EmployeeStockOptionMember 2016-09-30 0001527728 ddrt:NotePayableMlGroupMember 2016-09-30 0001527728 ddrt:LabEquipmentAndInstrumentsMember 2016-09-30 0001527728 us-gaap:ComputerEquipmentMember 2016-09-30 0001527728 ddrt:NonInterestBearingLoanPayableSunriseFinancialGroupIncMember 2016-09-30 0001527728 ddrt:SixPercentPromissoryNotePayableToNlbditTwoZeroOneZeroEnterprisesLlcMember 2016-09-30 0001527728 ddrt:ConvertibleNotesPayableRelatedPartiesMember 2016-09-30 0001527728 us-gaap:ConvertibleNotesPayableMember 2016-09-30 0001527728 ddrt:DanishTaxMember 2016-09-30 0001527728 us-gaap:EmployeeStockOptionMember ddrt:ExercisePriceRangeMember 2016-09-30 0001527728 2016-11-14 xbrli:shares iso4217:USD iso4217:USDxbrli:shares xbrli:pure iso4217:DKK DanDrit Biotech USA, Inc. 0001527728 false --06-30 10-Q 2016-09-30 2017 Q1 Smaller Reporting Company 9533290

421145

1048120

23368

31675

695418

746452

13693

6435

732479

784562

135743

132503

25000

2609

2619

138352

160122

870831

944684

102882

103474

1087758

979029

97357

97718

220232

229838

1508229

1410059

229669

102941

332610

1508229

1742669

953

25098050

25756232

-26300694

-27093875

564293

538705

-637398

-797985

870831

944684

0 10931 0 17359

0.0001

10000000

0.0001

100000000

9533290

204851

204951

626487

101759

17104

3937

3749

30848

341395

852291

-341395

-852291

1017

592

3464

-32228

23084

-32820

18603

-374215

-833688

-23913

-40507

-350302

-793181

-0.04

-0.08

9533290

9816

25588

-360118

-818769

3937

3749

626487

592

3404

28134

51034

59800 -7248

4761

-133728

9667

361

3243

9606

-65734

466685

-416036

-326496

1052989

138070

222830

360900

-9978

-26097

626975

8307

14402

17293 626487

<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify;">NOTE 1 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;">The accompanying financial statements are unaudited. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows at September 30, 2016 and 2015 and for the periods then ended have been made. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. It is suggested that these condensed financial statements be read in conjunction with the financial statements and notes thereto included in the Company’s June 30, 2016 audited financial statements. The results of operations for the periods ended September 30, 2016 and 2015 are not necessarily indicative of the operating results for the full year.<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;">Business and Basis of Presentation — DanDrit Biotech USA, Inc. (“DanDrit USA”, the “Company”, “we”, “us”, “our”) was originally incorporated in the state of Delaware on January 18, 2011 as a vehicle to pursue a business combination through the acquisition of, or merger with, an operating business. <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;">DanDrit BioTech A/S, a Danish Corporation was incorporated on April 1, 2001 (“DanDrit Denmark”) and is treated as a wholly owned subsidiary of the Company. On February 12, 2014, pursuant to the terms and conditions of a Share Exchange Agreement (the "Share Exchange Agreement"), DanDrit USA (the “Parent”) acquired approximately 100% of the issued and outstanding capital stock of DanDrit BioTech A/S, a Danish corporation (“DanDrit Denmark”) and as a result became the parent of DanDrit Denmark (the “Share Exchange”). Prior to the Share Exchange there were 5,000,000 shares of the common stock, par value $0.0001 per share (the “Common Stock”) of DanDrit Denmark’s parent company (the “Parent”) outstanding. The Parent and a shareholder agreed to cancel 4,400,000 shares of its common stock and issued 1,440,000 shares of common stock for legal and consulting services related to the Share Exchange and a future financing. At the time of the Share Exchange, the outstanding shares of the common stock of DanDrit Denmark were exchanged for 1.498842 shares of Parent’s common stock, for a total of 6,000,000 shares of common stock (including 185,053 shares of common stock reserved for issuance in accordance with Section 70 of the Danish Companies Act and the Articles of Association of DanDrit Denmark to the Non-Consenting Shareholders, deemed issued and outstanding for accounting purposes). Following the closing of the Share Exchange, DanDrit Biotech USA, Inc., the wholly owned subsidiary of the Company, merged with and into the Company, thereby changing the Company’s name to “DanDrit Biotech USA, Inc.” DanDrit Denmark engages in the research and development, manufacturing and clinical trials of pharmaceutical and biological products for the human treatment of cancer using the dendritic cell technology.<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;">Fiscal Year End - In June 2015, DanDrit’s board of directors approved a change to DanDrit’s fiscal year end from December 31 to June 30. <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;">Reverse Acquisition — On February 12, 2014, pursuant to the Share Exchange Agreement (the "Share Exchange Agreement"), DanDrit USA completed the acquisition of 100% of the issued and outstanding capital stock of DanDrit Denmark (the “Share Exchange”) and as a result became DanDrit Denmark’s parent company (the “Parent”). Prior to the Share Exchange there were 5,000,000 shares of the common stock, par value $.0001 per share (the “Common Stock”) of Parent outstanding. Parent and an existing shareholder agreed to cancel 4,400,000 shares of its Common Stock and issued 1,440,000 shares of Common Stock for legal and consulting services related to the Share Exchange and a future public offering. At the time of the Share Exchange each outstanding share of common stock of DanDrit Denmark was exchanged for 1.498842 shares of Parent’s Common Stock, for a total of 6,000,000 shares, resulting in 8,040,000 shares of the Parent’s Common Stock outstanding immediately following the Share Exchange, including 185,053 shares of Common Stock reserved for issuance in accordance with Section 70 of the Danish Companies Act and the Articles of Association of DanDrit Denmark to the DanDrit Denmark shareholders who have not consented to the Share Exchange (the “Non-Consenting Shareholders”), and deemed issued and outstanding for accounting purposes.<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;">Consolidation — For the three months ended September 30, 2016 and 2015, the consolidated financial statements include the accounts and operations of DanDrit Denmark, and the accounts and operations of DanDrit USA. All material inter-company transactions and accounts have been eliminated in the consolidation.<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;">Functional Currency / Foreign currency translation — The functional currency of DanDrit USA is the U.S. Dollar. The functional currency of DanDrit Denmark is the Danish Kroner (“DKK”). The Company’s reporting currency is the U.S. Dollar for the purpose of these financial statements. The Company’s balance sheet accounts are translated into U.S. dollars at the period-end exchange rates and all revenue and expenses are translated into U.S. dollars at the average exchange rates prevailing during the periods ending September 30, 2016 and 2015. Translation gains and losses are deferred and accumulated as a component of other comprehensive income in stockholders’ equity. Transaction gains and losses that arise from exchange rate fluctuations from transactions denominated in a currency other than the functional currency are included in the statement of operations as incurred.<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;">Cash and Cash Equivalents — The Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents. At September 30, 2016 and 2015 the Company had balances held in financial institutions in Denmark of $31,675 and $23,368, respectively.<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;">Property and Equipment — Property and equipment are stated at cost. Expenditures for major renewals and betterments that extend the useful lives of property and equipment are capitalized, upon being placed in service. Expenditures for maintenance and repairs are charged to expense as incurred. Depreciation is computed for financial statement purposes on a straight-line basis over the estimated useful lives of the assets which range from four to nine years (See Note 3).<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;">Intangible Assets — Definite life intangible assets include patents. The Company accounts for definite life intangible assets in accordance with Financial Accounting Standards Board, (“FASB”) Accounting Standards Codification, (“ASC”) Topic 350, “Goodwill and Other Intangible Assets” and amortized the patents on a straight line basis over the estimated useful life of twenty years. Costs incurred in relation to patent applications are capitalized cost and amortized over the estimated useful life of the patent. If it is determined that a patent will not be issued, the related remaining patent application costs are charged to expense.<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;">Impairment of Long-Lived Assets — Long-lived assets, such as property, plant, and equipment and patents are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Circumstances which could trigger a review include, but are not limited to: significant decreases in the market price of the asset; significant adverse changes in the business climate or legal factors; current period cash flow or operating losses combined with a history of losses or a forecast of continuing losses associated with the use of the asset; and current expectation that the asset will more likely than not be sold or disposed of significantly before the end of its estimated useful life.<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;">Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset. Assets to be disposed of would be separately presented in the balance sheet and reported at the lower of the carrying amount or fair value less costs to sell, and would no longer be depreciated. The depreciable basis of assets that are impaired and continue in use is their respective fair values.<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;">Revenue Recognition and Sales — The Company’s sales of its MelCancerVac® (“MCV”) colorectal cancer vaccine have been limited to a compassionate use basis in Singapore after stage IIA trials and is not approved for current sale for any other use or location. The Company's accounts for revenue recognition in accordance with the Securities and Exchange Commission Staff Accounting Bulletin No. 101, “Revenue Recognition in Financial Statements” (SAB 101), and FASB ASC 605 Revenue Recognition. The Company recognizes revenue when rights and risk of ownership have passed to the customer, when there is persuasive evidence of an arrangement, product has been shipped or delivered to the customer, the price and terms are finalized, and collections of resulting receivable is reasonably assured. Products are primarily shipped FOB shipping point at which time title passes to the customer.<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;">Value Added Tax — In Denmark, Value Added Tax (“VAT”) of 25% of the invoice amount is collected in respect of the sales of goods on behalf of tax authorities. The VAT collected is not revenue of the Company; instead, the amount is recorded as a liability on the balance sheet until such VAT is paid to the authorities. VAT of 25% is also paid to Danish and EU vendors on invoices these amounts are refundable from the respective governmental authority and recorded as other receivables in the accompanying financial statements.<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;">Research and Development Expenses — The Company expenses research and development costs incurred in formulating, improving, validating and creating alternative or modified processes related to and expanding the use of our MAGE –A dendrite cell cancer therapy. Research and development expenses were included in operating expenses for the three months ended September 30, 2016 and 2015, totaled $17,104 and $101,759, respectively.<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;">Our research and development expenses may fluctuate substantially from quarter to quarter depending on the clinical studies and the timing of samples supporting the clinical studies.<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;">Income Taxes — The Company accounts for income taxes in accordance with FASB ASC Topic 740 Accounting for Income Taxes. This statement requires an asset and liability approach for accounting for income taxes.<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;">Loss Per Share — The Company calculates earnings /(loss) per share in accordance with FASB ASC 260 Earnings Per Share. Basic earnings per common share (EPS) are based on the weighted average number of shares of common stock outstanding during each period. Diluted earnings per common share are based on shares outstanding (computed as under basic EPS) and potentially dilutive common shares. Potential shares of common stock included in the diluted earnings per share calculation include in-the-money stock options that have been granted but have not been exercised.<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;">  <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;">Fair Value of Financial Instruments — The Company accounts for fair value measurements for financial assets and financial liabilities in accordance with FASB ASC Topic 820, “Fair Value Measurements”. The authoritative guidance, which, among other things, defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as the exit price, representing the amount that would either be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"> <table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><td style="width: 48px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: justify;"> </td><td style="width: 24px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: justify;">●</td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: justify;">Level 1. Observable inputs such as quoted prices in active markets for identical assets or liabilities;</td></tr></table><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"> <table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><td style="width: 48px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: justify;"> </td><td style="width: 24px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: justify;">●</td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: justify;">Level 2. Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and</td></tr></table><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"> <table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><td style="width: 48px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: justify;"> </td><td style="width: 24px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: justify;">●</td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: justify;">Level 3. Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</td></tr></table><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;">Unless otherwise disclosed, the fair value of the Company’s financial instruments including cash, accounts receivable, prepaid expenses, investments, accounts payable, accrued expenses, capital lease obligations and notes payable approximates their recorded values due to their short-term maturities.<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;">Accounting Estimates — The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimated.<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;">Recent Accounting Pronouncements - In May 2014, the Financial Accounting Standards Board (FASB) issued a new standard to achieve a consistent application of revenue recognition within the U.S., resulting in a single revenue model to be applied by reporting companies under U.S. generally accepted accounting principles. Under the new model, recognition of revenue occurs when a customer obtains control of promised goods or services in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In addition, the new standard requires that reporting companies disclose the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. On July 9, 2015, the FASB agreed to delay the effective date by one year; accordingly, the new standard is effective for us beginning in the first quarter of 2018 and we expect to adopt it at that time. The new standard is required to be applied retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying it recognized at the date of initial application. We have not yet selected a transition method, nor have we determined the impact of the new standard on our consolidated financial statements.<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;">In 2015, the FASB issued an amended standard requiring that we classify all deferred tax assets and liabilities as non-current on the balance sheet instead of separating deferred taxes into current and non-current. The amended standard is effective for us beginning in the first quarter of 2017; early adoption is permitted and we are evaluating whether we will early adopt. The amended standard may be adopted on either a prospective or retrospective basis. We do not expect that the adoption of this standard will have a significant impact on our financial position or results of operations.<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;">In February 2016, the FASB issued changes to the accounting for leases that primarily affect presentation and disclosure requirements. The new standard will require the recognition of a right to use asset and underlying lease liability for operating leases with an initial life in excess of one year. This standard is effective for us beginning in the first quarter of 2019. We have not yet determined the impact of the new standard on our consolidated financial statements. <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;">Other recent accounting pronouncements issued by the FASB did not or are not believed by management to have a material impact on the Company's present or future financial statements.<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;">Reclassification — The financial statement for the period ended September 30, 2015 and June 30, 2016 have been reclassified to conform to the headings and classifications used in the September 30, 2016 financial statements.<div> </div>

<p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; font-family: 'times new roman', serif; margin: 0px; text-align: justify;">NOTE 7 — CONVERTIBLE NOTES PAYABLE<p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; font-family: 'times new roman', serif; margin: 0px; text-align: justify; text-indent: 36pt;"> <p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; font-family: 'times new roman', serif; margin: 0px; text-align: justify; text-indent: 36pt;">Convertible Notes payable to consists of the following as of September 30, 2016 and June 30, 2016:<p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; font-family: 'times new roman', serif; margin: 0px; text-align: justify; text-indent: 36pt;"> <table style="font: 10pt/normal calibri, helvetica, sans-serif; width: 1422.72px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td> </td><td style="font-family: 'times new roman', times, serif; font-weight: bold; padding-bottom: 1.5pt;"> </td><td style="font-family: 'times new roman', times, serif; font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">September 30, 2016</td><td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif; font-weight: bold;"> </td><td style="font-family: 'times new roman', times, serif; font-weight: bold; padding-bottom: 1.5pt;"> </td><td style="font-family: 'times new roman', times, serif; font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">June 30, 2016</td><td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif; font-weight: bold;"> </td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1081.81811523438px; font-family: 'times new roman', times, serif; text-align: left;">Non-Interest Bearing Notes Payable Equine Invest Aps</td><td style="width: 14.5454540252686px; font-family: 'times new roman', times, serif;"> </td><td style="width: 14.5454540252686px; font-family: 'times new roman', times, serif; text-align: left;">$</td><td style="width: 128.18180847168px; font-family: 'times new roman', times, serif; text-align: right;">240,600</td><td style="width: 14.5454540252686px; font-family: 'times new roman', times, serif; text-align: left;"> </td><td style="width: 14.5454540252686px; font-family: 'times new roman', times, serif;"> </td><td style="width: 13.63636302948px; font-family: 'times new roman', times, serif; text-align: left;">$</td><td style="width: 127.272727966309px; font-family: 'times new roman', times, serif; text-align: right;">         -</td><td style="width: 13.63636302948px; font-family: 'times new roman', times, serif; text-align: left;"> </td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-family: 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt;">Less Discounts</td><td style="font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"> </td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-family: 'times new roman', times, serif; text-align: left;"> </td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-family: 'times new roman', times, serif; text-align: right;">(10,931</td><td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif; text-align: left;">)</td><td style="font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"> </td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-family: 'times new roman', times, serif; text-align: left;"> </td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-family: 'times new roman', times, serif; text-align: right;">-</td><td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif; text-align: left;"> </td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font-family: 'times new roman', times, serif; text-align: left;">Total Convertible Notes Payable</td><td style="font-family: 'times new roman', times, serif;"> </td><td style="font-family: 'times new roman', times, serif; text-align: left;"> </td><td style="font-family: 'times new roman', times, serif; text-align: right;">229,669</td><td style="font-family: 'times new roman', times, serif; text-align: left;"> </td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;"> </td><td style="text-align: left;"> </td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-family: 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt;">Less Current Maturities</td><td style="font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"> </td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-family: 'times new roman', times, serif; text-align: left;"> </td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-family: 'times new roman', times, serif; text-align: right;">-</td><td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif; text-align: left;"> </td><td style="font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"> </td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-family: 'times new roman', times, serif; text-align: left;"> </td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-family: 'times new roman', times, serif; text-align: right;">-</td><td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif; text-align: left;"> </td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font-family: 'times new roman', times, serif; text-align: left; padding-bottom: 4pt;">Net Convertible Note Payables – Long Term</td><td style="font-family: 'times new roman', times, serif; padding-bottom: 4pt;"> </td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-family: 'times new roman', times, serif; text-align: left;">$</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-family: 'times new roman', times, serif; text-align: right;">229,669</td><td style="padding-bottom: 4pt; font-family: 'times new roman', times, serif; text-align: left;"> </td><td style="font-family: 'times new roman', times, serif; padding-bottom: 4pt;"> </td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-family: 'times new roman', times, serif; text-align: left;">$</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-family: 'times new roman', times, serif; text-align: right;">-</td><td style="padding-bottom: 4pt; font-family: 'times new roman', times, serif; text-align: left;"> </td></tr></table><p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; font-family: 'times new roman', serif; margin: 0px; text-align: justify; text-indent: 36pt;"> <p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; font-family: 'times new roman', serif; margin: 0px; text-align: justify; text-indent: 36pt;">The following represents the future maturities of long-term debt as of September 30, 2016:<p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; font-family: 'times new roman', serif; margin: 0px; text-align: justify; text-indent: 36pt;"> <table style="font: 10pt/normal calibri, helvetica, sans-serif; width: 1422.72px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="font-family: 'times new roman', times, serif; font-weight: bold; text-align: left;">Year ending June 30,</td><td> </td><td style="text-align: right;" colspan="2"> </td><td> </td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font-family: 'times new roman', times, serif; text-align: left;">2017</td><td style="font-family: 'times new roman', times, serif;"> </td><td style="font-family: 'times new roman', times, serif; text-align: left;"> </td><td style="font-family: 'times new roman', times, serif; text-align: right;">-</td><td style="font-family: 'times new roman', times, serif; text-align: left;"> </td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="width: 1252.72729492188px; font-family: 'times new roman', times, serif; text-align: left;">2018</td><td style="width: 14.5454540252686px; font-family: 'times new roman', times, serif;"> </td><td style="width: 14.5454540252686px; font-family: 'times new roman', times, serif; text-align: left;"> </td><td style="width: 127.272727966309px; font-family: 'times new roman', times, serif; text-align: right;">240,600</td><td style="width: 13.63636302948px; font-family: 'times new roman', times, serif; text-align: left;"> </td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font-family: 'times new roman', times, serif; text-align: left;">2019</td><td style="font-family: 'times new roman', times, serif;"> </td><td style="font-family: 'times new roman', times, serif; text-align: left;"> </td><td style="font-family: 'times new roman', times, serif; text-align: right;">-</td><td style="font-family: 'times new roman', times, serif; text-align: left;"> </td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-family: 'times new roman', times, serif; text-align: left;">2020</td><td style="font-family: 'times new roman', times, serif;"> </td><td style="font-family: 'times new roman', times, serif; text-align: left;"> </td><td style="font-family: 'times new roman', times, serif; text-align: right;">-</td><td style="font-family: 'times new roman', times, serif; text-align: left;"> </td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font-family: 'times new roman', times, serif; text-align: left;">2021</td><td style="font-family: 'times new roman', times, serif;"> </td><td style="font-family: 'times new roman', times, serif; text-align: left;"> </td><td style="font-family: 'times new roman', times, serif; text-align: right;">-</td><td style="font-family: 'times new roman', times, serif; text-align: left;"> </td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-family: 'times new roman', times, serif; padding-bottom: 1.5pt; text-align: left;">Thereafter</td><td style="font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"> </td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-family: 'times new roman', times, serif; text-align: left;"> </td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-family: 'times new roman', times, serif; text-align: right;">-</td><td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif; text-align: left;"> </td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding-bottom: 4pt; text-align: left;"> </td><td style="font-family: 'times new roman', times, serif; padding-bottom: 4pt;"> </td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-family: 'times new roman', times, serif; text-align: left;"> </td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-family: 'times new roman', times, serif; text-align: right;">240,600</td><td style="padding-bottom: 4pt; font-family: 'times new roman', times, serif; text-align: left;"> </td></tr></table><p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; font-family: 'times new roman', serif; margin: 0px; text-align: justify; text-indent: 36pt;"> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;">On August 24, 2016, the Company entered into a non interest bearing convertible notes $90,225. The note matures December 31, 2017. The note is convertible into common shares at $2.00 per share. As the Company’s stock was trading at $2.05 on July 1, 2016, the Company bifurcated the intrinsic value of the beneficial conversion feature and recorded a discount of $2,256. As the note is non-interest bearing the Company imputed the interest at 3% and further recorded a discount of $3,577. The interest will be amortized to expense using the effective interest method through the December 31, 2017 maturity. For the three months ended September 30, 2016, recorded interest expense of $425 for the amortization of the discount.<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify;"> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"> On September 21, 2016 the Company entered into a non interest bearing convertible notes for $150,375. The note matures December 31, 2017. The note is convertible into common shares at $2.00 per share. As the note is non-interest bearing the Company imputed the interest at 3% and further recorded a discount of $5,630. The interest will be amortized to expense using the effective interest method through the December 31, 2017 maturity. For the three months ended September 30, 2016, recorded interest expense of $107 for the amortization of the discount.

<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify;">NOTE 11 — STOCKHOLDERS’ EQUITY<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;">Common Stock — The Company has 100,000,000 authorized shares of Common stock $0.0001. As of September 30, 2016 and June 30, 2016 there were 9,533,290 shares issued and outstanding.<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;">Common Stock Offering – On September 15, 2016, the Company filed a Form D disclosing that the Company is seeking to raise up to $16,500,000 additional equity capital though a private placement offering exempt under Rule 506(b).  <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;">Share Exchange Agreement/Reverse Acquisition - On February 12, 2014, in accordance with the terms and conditions of a Share Exchange Agreement (the "Share Exchange Agreement"), we completed the acquisition of approximately 100% of the issued and outstanding capital stock of DanDrit Denmark (the “Share Exchange”) and as a result became DanDrit Denmark’s parent company (the “Parent”). In connection with the Share Exchange, each outstanding share of common stock of DanDrit Denmark was exchanged for 1.498842 shares of DanDrit USA’s common stock, par value $.0001 per share (the “Common Stock”) for an aggregate of 6,000,000 shares, including 185,053 shares of Common Stock reserved for issuance, in accordance with Section 70 of the Danish Companies Act and the Articles of Association of DanDrit Denmark, to the DanDrit Denmark shareholders who did not consent to the Share Exchange and deemed issued and outstanding for accounting purposes. In addition, in connection with the Share Exchange (1) the sole shareholder prior to the Share Exchange agreed to cancel 4,400,000 shares of outstanding Common Stock owned by it and (2) the board of directors and executive management of DanDrit Denmark was appointed to serve as the Board of Directors and executive management of DanDrit USA effective upon the resignation of the sole officer and director of DanDrit USA prior to the closing of the Share Exchange.<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;">Voting — Holders of the Company’s common stock are entitled to one vote for each share held of record on each matter submitted to a vote of stockholders, including the election of directors, and do not have any right to cumulate votes in the election of directors.<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;">Dividends — Holders of the Company’s common stock are entitled to receive ratably such dividends as our Board of Directors from time to time may declare out of funds legally available.<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;">Liquidation Rights — In the event of any liquidation, dissolution or winding-up of affairs of the Company, after payment of all of our debts and liabilities, the holders of the Company’s common stock will be entitled to share ratably in the distribution of any of our remaining assets.<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;">Stock Options — On September 15, 2016, Parent’s Board of Directors approved the grant stock options to employees, officers, and directors of the Company. The Board granted 300,000 options at a strike price of $2.00 per share to each of Eric Leire, APE Invest A/S for Aldo Petersen and N.E. Nielson, in consideration of their service to the Company, for an aggregate of 900,000 options. The options were granted pursuant to written agreements with each optionee. The options vested upon grant, contain certain anti-dilution provisions and expire December 31, 2019.<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;">The Company recognizes compensation costs for stock option awards to employees based on their grant-date fair value. The value of each stock option is estimated on the date of grant using the Black-Scholes option-pricing model. The weighted-average assumptions used to estimate the fair values of the stock options granted using the Black-Scholes option-pricing model are as follows:<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"><table style="font: 10pt/normal calibri, helvetica, sans-serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td> </td><td style="font-family: 'times new roman', serif; font-weight: bold; padding-bottom: 1.5pt;"> </td><td style="font-family: 'times new roman', serif; font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">DanDrit Biotech USA, Inc.</td><td style="padding-bottom: 1.5pt; font-family: 'times new roman', serif; font-weight: bold;"> </td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1379px; font-family: 'times new roman', serif; text-align: left;">Expected term (in years)</td><td style="width: 16px; font-family: 'times new roman', serif;"> </td><td style="width: 16px; font-family: 'times new roman', serif; text-align: left;"> </td><td style="width: 141px; font-family: 'times new roman', serif; text-align: right;">3.29</td><td style="width: 15px; font-family: 'times new roman', serif; text-align: left;"> </td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-family: 'times new roman', serif;">Volatility</td><td style="font-family: 'times new roman', serif;"> </td><td style="font-family: 'times new roman', serif; text-align: left;"> </td><td style="font-family: 'times new roman', serif; text-align: right;">189.65</td><td style="font-family: 'times new roman', serif; text-align: left;">%</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font-family: 'times new roman', serif; text-align: left;">Risk free interest rate</td><td style="font-family: 'times new roman', serif;"> </td><td style="font-family: 'times new roman', serif; text-align: left;"> </td><td style="font-family: 'times new roman', serif; text-align: right;">0.87</td><td style="font-family: 'times new roman', serif; text-align: left;">%</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-family: 'times new roman', serif; text-align: left;">Dividend yield</td><td style="font-family: 'times new roman', serif;"> </td><td style="font-family: 'times new roman', serif; text-align: left;"> </td><td style="font-family: 'times new roman', serif; text-align: right;">0</td><td style="font-family: 'times new roman', serif; text-align: left;">%</td></tr></table><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt; text-align: justify;"> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;">The Company recognized stock based compensation expense related to the options of $626,487 and $0 for the three months ended September 30, 2016 and 2015, respectively. At September 30, 2016 the Company had approximately $0 of unrecognized compensation cost related to non-vested options.<p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0pt; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 15.3333320617676px; font-family: 'times new roman', serif; margin: 0pt;"> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;">A summary of the status of the options outstanding at September 30, 2016 is presented below: <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"> <table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"> </td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"> </td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;" colspan="2"> </td><td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"> </td><td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"> </td><td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: center;" colspan="10">Options Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: center;"> </td><td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt; text-align: center;"> </td><td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: center;" colspan="6">Options Exercisable</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"> </td></tr><tr style="vertical-align: bottom; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"> </td><td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"> </td><td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: center;" colspan="2">Exercise Prices</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: center;"> </td><td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt; text-align: center;"> </td><td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: center;" colspan="2">Number Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: center;"> </td><td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt; text-align: center;"> </td><td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: center;" colspan="2">Weighted Average Remaining Contractual Life (years)</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: center;"> </td><td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt; text-align: center;"> </td><td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: center;" colspan="2">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: center;"> </td><td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt; text-align: center;"> </td><td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: center;" colspan="2">Number Exercisable</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: center;"> </td><td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt; text-align: center;"> </td><td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: center;" colspan="2">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"> </td></tr><tr style="vertical-align: bottom; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; background-color: #cceeff;"><td style="width: 439px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"></td><td style="width: 16px; padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"> </td><td style="width: 16px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">$</td><td style="width: 142px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">2.00</td><td style="width: 16px; padding-bottom: 1.5pt; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"> </td><td style="width: 16px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"> </td><td style="width: 16px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"> </td><td style="width: 142px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">900,000</td><td style="width: 16px; padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"> </td><td style="width: 16px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"> </td><td style="width: 16px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"> </td><td style="width: 142px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">3.25</td><td style="width: 16px; padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"> </td><td style="width: 15px; padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"> </td><td style="width: 15px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">$</td><td style="width: 141px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">2.00</td><td style="width: 15px; padding-bottom: 1.5pt; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"> </td><td style="width: 15px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"> </td><td style="width: 15px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"> </td><td style="width: 141px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">900,000</td><td style="width: 15px; padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"> </td><td style="width: 15px; padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"> </td><td style="width: 15px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">$</td><td style="width: 141px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">2.00</td><td style="width: 15px; padding-bottom: 1.5pt; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"> </td></tr><tr style="vertical-align: bottom; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; background-color: white;"><td style="padding-bottom: 4pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">Total</td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 4pt;"> </td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"> </td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"> </td><td style="padding-bottom: 4pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"> </td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 4pt;"> </td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"> </td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">900,000</td><td style="padding-bottom: 4pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"> </td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 4pt;"> </td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"> </td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">3.25</td><td style="padding-bottom: 4pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"> </td><td style="padding-bottom: 4pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"> </td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">$</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">2.00</td><td style="padding-bottom: 4pt; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"> </td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 4pt;"> </td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"> </td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">900,000</td><td style="padding-bottom: 4pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"> </td><td style="padding-bottom: 4pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"> </td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">$</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">2.00</td><td style="padding-bottom: 4pt; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"> </td></tr></table><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;"> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;"><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;">A summary of the status of the options at September 30, 2016, and changes during the period are presented below:<p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"> <table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td> </td><td style="font-weight: bold; padding-bottom: 1.5pt;"> </td><td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="14">September 30, 2016</td><td style="padding-bottom: 1.5pt; font-weight: bold;"> </td></tr><tr style="vertical-align: bottom;"><td> </td><td style="font-weight: bold; padding-bottom: 1.5pt;"> </td><td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold;"> </td><td style="padding-bottom: 1.5pt;"> </td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: 15.3333320617676px; font-family: 'times new roman', serif; margin: 0pt 0px; text-align: center; text-indent: 0pt;">Weighted<p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: 15.3333320617676px; font-family: 'times new roman', serif; margin: 0pt 0px; text-align: center; text-indent: 0pt;">Average<p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: 15.3333320617676px; font-family: 'times new roman', serif; margin: 0pt 0px; text-align: center; text-indent: 0pt;">Exercise<p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: 15.3333320617676px; font-family: 'times new roman', serif; margin: 0pt 0px; text-align: center; text-indent: 0pt;">Price</td><td style="padding-bottom: 1.5pt;"> </td><td style="padding-bottom: 1.5pt;"> </td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: 15.3333320617676px; font-family: 'times new roman', serif; margin: 0pt 0px; text-align: center; text-indent: 0pt;">Average<p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: 15.3333320617676px; font-family: 'times new roman', serif; margin: 0pt 0px; text-align: center; text-indent: 0pt;">Remaining<p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: 15.3333320617676px; font-family: 'times new roman', serif; margin: 0pt 0px; text-align: center; text-indent: 0pt;">Life</td><td style="padding-bottom: 1.5pt;"> </td><td style="padding-bottom: 1.5pt;"> </td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: 15.3333320617676px; font-family: 'times new roman', serif; margin: 0pt 0px; text-align: center; text-indent: 0pt;">Weighted<p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: 15.3333320617676px; font-family: 'times new roman', serif; margin: 0pt 0px; text-align: center; text-indent: 0pt;">Average<p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: 15.3333320617676px; font-family: 'times new roman', serif; margin: 0pt 0px; text-align: center; text-indent: 0pt;">Intrinsic<p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: 15.3333320617676px; font-family: 'times new roman', serif; margin: 0pt 0px; text-align: center; text-indent: 0pt;">Value</td><td style="padding-bottom: 1.5pt;"> </td></tr><tr style="vertical-align: bottom;"><td> </td><td> </td><td colspan="2"> </td><td> </td><td> </td><td colspan="2"> </td><td> </td><td> </td><td colspan="2"> </td><td> </td><td> </td><td colspan="2"> </td><td> </td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 815px;">Outstanding at beginning of period</td><td style="width: 16px;"> </td><td style="width: 16px; text-align: left;"> </td><td style="width: 142px; text-align: right;">0</td><td style="width: 16px; text-align: left;"> </td><td style="width: 16px;"> </td><td style="width: 16px; text-align: left;">$</td><td style="width: 142px; text-align: right;">-</td><td style="width: 16px; text-align: left;"> </td><td style="width: 15px;"> </td><td style="width: 15px; text-align: left;"> </td><td style="width: 141px; text-align: right;">-</td><td style="width: 15px; text-align: left;"> </td><td style="width: 15px;"> </td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">-</td><td style="width: 15px; text-align: left;"> </td></tr><tr style="vertical-align: bottom; background-color: white;"><td>Granted</td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">900,000</td><td style="text-align: left;"> </td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">2.00</td><td style="text-align: left;"> </td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">3.25</td><td style="text-align: left;"> </td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">675,000</td><td style="text-align: left;"> </td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td>Exercised</td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">-</td><td style="text-align: left;"> </td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">-</td><td style="text-align: left;"> </td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">-</td><td style="text-align: left;"> </td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">-</td><td style="text-align: left;"> </td></tr><tr style="vertical-align: bottom; background-color: white;"><td>Forfeited</td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">-</td><td style="text-align: left;"> </td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">-</td><td style="text-align: left;"> </td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">-</td><td style="text-align: left;"> </td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">-</td><td style="text-align: left;"> </td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding-bottom: 1.5pt;">Expired</td><td style="padding-bottom: 1.5pt;"> </td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"> </td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;">-</td><td style="padding-bottom: 1.5pt; text-align: left;"> </td><td style="padding-bottom: 1.5pt;"> </td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"> </td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;">-</td><td style="padding-bottom: 1.5pt; text-align: left;"> </td><td style="padding-bottom: 1.5pt;"> </td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"> </td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;">-</td><td style="padding-bottom: 1.5pt; text-align: left;"> </td><td style="padding-bottom: 1.5pt;"> </td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"> </td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;">-</td><td style="padding-bottom: 1.5pt; text-align: left;"> </td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 1.5pt;">Outstanding at end of period</td><td style="padding-bottom: 1.5pt;"> </td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"> </td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;">900,000</td><td style="padding-bottom: 1.5pt; text-align: left;"> </td><td style="padding-bottom: 1.5pt;"> </td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;">$</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;">2.00</td><td style="padding-bottom: 1.5pt; text-align: left;"> </td><td style="padding-bottom: 1.5pt;"> </td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"> </td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;">3.25</td><td style="padding-bottom: 1.5pt; text-align: left;"> </td><td style="padding-bottom: 1.5pt;"> </td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;">$</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;">675,000</td><td style="padding-bottom: 1.5pt; text-align: left;"> </td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 1.5pt;">Vested and expected to vest</td><td style="padding-bottom: 1.5pt;"> </td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"> </td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;">900,000</td><td style="padding-bottom: 1.5pt; text-align: left;"> </td><td style="padding-bottom: 1.5pt;"> </td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;">$</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;">2.00</td><td style="padding-bottom: 1.5pt; text-align: left;"> </td><td style="padding-bottom: 1.5pt;"> </td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"> </td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;">3.25</td><td style="padding-bottom: 1.5pt; text-align: left;"> </td><td style="padding-bottom: 1.5pt;"> </td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;">$</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;">675,000</td><td style="padding-bottom: 1.5pt; text-align: left;"> </td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 4pt;">Exercisable end of period</td><td style="padding-bottom: 4pt;"> </td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;"> </td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;">900,000</td><td style="padding-bottom: 4pt; text-align: left;"> </td><td style="padding-bottom: 4pt;"> </td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;">$</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;">2.00</td><td style="padding-bottom: 4pt; text-align: left;"> </td><td style="padding-bottom: 4pt;"> </td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;"> </td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;">3.25</td><td style="padding-bottom: 4pt; text-align: left;"> </td><td style="padding-bottom: 4pt;"> </td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;">$</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;">675,000</td><td style="padding-bottom: 4pt; text-align: left;"> </td></tr></table><p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0pt; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: 15.3333320617676px; font-family: 'times new roman', serif; margin: 0pt 0px;"> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;">At September 30, 2016, all options issued are exercisable. The total intrinsic value of options at September 30, 2016 was $675,000. Intrinsic value is measured using the fair market value at the date of exercise (for shares exercised) or at September 30, 2016 (for outstanding options), less the applicable exercise price.

<div> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">NOTE 12 — COMMITMENTS AND CONTINGENCIES <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Shares held for non-consenting shareholders – In connection with the Share Exchange agreement certain shareholders of Dandrit Denmark had not been identified or did not consent to the exchange of shares. In accordance with Section 70 of the Danish Companies Act and the Articles of Association of DanDrit Denmark, the Non-Consenting Shareholders that did not exchange the DanDrit Denmark equity interests owned by such Non-Consenting Shareholders for shares of the Company, will be entitled to receive up to 185,053 shares of common stock of the Company that each such Non-Consenting Shareholder would have been entitled to receive if such shareholder had consented to the Share Exchange. The 185,053 shares have been reflected as issued and outstanding in the accompanying financial statements. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Clinical Trial Agreements – The Company’s subsidiary, DanDrit Biotech A/S signed a contract of collaboration with the University Hospital IRCCS “San Martino” - IST – National Institute for Cancer Research, known as the San Martino Hospital of Genoa. Dr. Alberto Sobrero, the Head of the Medical Oncology Unit at the San Martino Hospital, is principal investigator of the randomized multicenter study. The collaboration relates to a Phase III adjuvant study of DanDrit’s vaccine in patients with no evident disease (“NED”) stage IV colorectal cancer (“CRC”). The primary goal of the study is to evaluate the efficacy of DanDrit’sMelCancerVac® (“MCV”) in stage IV CRC patients rendered disease free after the completion of standard treatments in accordance with local practices. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">On April 28, 2015 the Company entered into a service agreement with Fondazione Giscad per la Ricerca sui Tumori to support Dandrit in a clinical trial to be conducted in Italy. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Patient Name Use Program Agreements - On December 16, 2013, DanDrit Denmark entered into an agreement with a Dutch company (the “MCV Partner”) regarding a Patient Name Use Program (PNU) for the Company’s MCV.  This program will allow DanDrit Denmark to sell MCV for a year of treatment (10 vaccines) to cancer patients through the MCV Partner.  The MCV Partner offers a worldwide online platform providing access to non-registered medicines for patients with life threatening diseases. The MCV Partner is a turnkey solution and will be in charge of regulatory, recruitment, logistics, and pharmaco vigilance.   The Company will pay the MCV Partner a royalty on a country to country basis for 20 years on MCV sales sold under the agreement. Either party may terminate the agreement with 180 day written notice. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">On April 23, 2015, the Company entered into a collaboration agreement with Riyadh Pharma in Saudi Arabia to promote cooperation in the manufacturing and marketing of DanDrit's dendritic cell cancer vaccine. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Manufacturing Agreements - On January 28, 2014, the Company entered into an agreement with Cellin Technologies for the manufacture of the MCV Cancer vaccine. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">On August 8, 2014, the Company entered into an agreement with Cellin Technologies for the manufacture of the Melanoma Cell Lysate. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Food and Drug Administration (FDA) - The FDA has extensive regulatory authority over biopharmaceutical products (drugs and biological products), manufacturing protocols and procedures and the facilities in which they will be manufactured. Any new bio product intended for use in humans is subject to rigorous testing requirements imposed by the FDA with respect to product efficacy and safety, possible toxicity and side effects. FDA approval for the use of new bio products (which can never be assured) requires several rounds of extensive preclinical testing and clinical investigations conducted by the sponsoring pharmaceutical company prior to sale and use of the product. At each stage, the approvals granted by the FDA include the manufacturing process utilized to produce the product. Accordingly, the Company’s cell systems used for the production of therapeutic or bio therapeutic products are subject to significant regulation by the FDA under the Federal Food, Drug and Cosmetic Act, as amended. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Product liability - The contract production services for therapeutic products offered exposes an inherent risk of liability as bio therapeutic substances manufactured, at the request and to the specifications of customers, could foreseeably cause adverse effects. The Company seeks to obtain agreements from contract production customers indemnifying and defending the Company from any potential liability arising from such risk. There can be no assurance, however, that the Company will be successful in obtaining such agreements in the future or that such indemnification agreements will adequately protect the Company against potential claims relating to such contract production services. The Company may also be exposed to potential product liability claims by users of its products. A successful partial or completely uninsured claim against the Company could have a material adverse effect on the Company’s operations. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Employment Agreements - The Company and its Subsidiary have an employment agreement with an officer of the Company. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Contingencies - The Company is from time to time involved in routine legal and administrative proceedings and claims of various types. While any proceedings or claim contains an element of uncertainty, management does not expect a material impact on our results of operations or financial position. </div>

<div><b style="color: #000000; font-family: 'times new roman', times, serif; font-size: 13.3333330154419px; font-style: normal; font-variant: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px;">Cash and Cash Equivalents — The Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents. At September 30, 2016 and 2015 the Company had balances held in financial institutions in Denmark of $31,675 and $23,368, respectively.</div>

<div><b style="color: #000000; font-family: 'times new roman', times, serif; font-size: 13.3333330154419px; font-style: normal; font-variant: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px;">Research and Development Expenses — The Company expenses research and development costs incurred in formulating, improving, validating and creating alternative or modified processes related to and expanding the use of our MAGE –A dendrite cell cancer therapy. Research and development expenses were included in operating expenses for the three months ended September 30, 2016 and 2015, totaled $17,104 and $101,759, respectively.</div>

<div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Fair Value of Financial Instruments — The Company accounts for fair value measurements for financial assets and financial liabilities in accordance with FASB ASC Topic 820, “Fair Value Measurements”. The authoritative guidance, which, among other things, defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as the exit price, representing the amount that would either be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"> <table style="font: 10pt/normal 'times new roman', times, serif; width: 1250.4px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 48px; text-align: justify; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 24px; text-align: justify; font-stretch: normal;">●</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;">Level 1. Observable inputs such as quoted prices in active markets for identical assets or liabilities;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"> <table style="font: 10pt/normal 'times new roman', times, serif; width: 1250.4px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 48px; text-align: justify; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 24px; text-align: justify; font-stretch: normal;">●</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;">Level 2. Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"> <table style="font: 10pt/normal 'times new roman', times, serif; width: 1250.4px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 48px; text-align: justify; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 24px; text-align: justify; font-stretch: normal;">●</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;">Level 3. Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Unless otherwise disclosed, the fair value of the Company’s financial instruments including cash, accounts receivable, prepaid expenses, investments, accounts payable, accrued expenses, capital lease obligations and notes payable approximates their recorded values due to their short-term maturities.</div>

<div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Recent Accounting Pronouncements - In May 2014, the Financial Accounting Standards Board (FASB) issued a new standard to achieve a consistent application of revenue recognition within the U.S., resulting in a single revenue model to be applied by reporting companies under U.S. generally accepted accounting principles. Under the new model, recognition of revenue occurs when a customer obtains control of promised goods or services in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In addition, the new standard requires that reporting companies disclose the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. On July 9, 2015, the FASB agreed to delay the effective date by one year; accordingly, the new standard is effective for us beginning in the first quarter of 2018 and we expect to adopt it at that time. The new standard is required to be applied retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying it recognized at the date of initial application. We have not yet selected a transition method, nor have we determined the impact of the new standard on our consolidated financial statements.<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">In 2015, the FASB issued an amended standard requiring that we classify all deferred tax assets and liabilities as non-current on the balance sheet instead of separating deferred taxes into current and non-current. The amended standard is effective for us beginning in the first quarter of 2017; early adoption is permitted and we are evaluating whether we will early adopt. The amended standard may be adopted on either a prospective or retrospective basis. We do not expect that the adoption of this standard will have a significant impact on our financial position or results of operations.<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">In February 2016, the FASB issued changes to the accounting for leases that primarily affect presentation and disclosure requirements. The new standard will require the recognition of a right to use asset and underlying lease liability for operating leases with an initial life in excess of one year. This standard is effective for us beginning in the first quarter of 2019. We have not yet determined the impact of the new standard on our consolidated financial statements. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Other recent accounting pronouncements issued by the FASB did not or are not believed by management to have a material impact on the Company's present or future financial statements.</div>

<table align="center" style="width: 1422.72px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="font-size: 10pt;"> </td><td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"> </td><td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">September 30, 2016</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"> </td><td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"> </td><td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">September 30, 2015</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"> </td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1081.81811523438px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">Computed Tax at Expected Statutory Rate</td><td style="width: 14.5454540252686px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"> </td><td style="width: 14.5454540252686px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">$</td><td style="width: 128.18180847168px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">(283,454</td><td style="width: 14.5454540252686px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">)</td><td style="width: 14.5454540252686px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"> </td><td style="width: 13.63636302948px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">$</td><td style="width: 127.272727966309px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">(127,233</td><td style="width: 13.63636302948px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">Non-US Income Taxed at Different Rates</td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"> </td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"> </td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">14,465</td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"> </td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"> </td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"> </td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">41,760</td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"> </td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">Non-Deductible expenses</td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"> </td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"> </td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">214,163</td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"> </td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"> </td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"> </td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">-</td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"> </td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt;">Valuation allowance</td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"> </td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"> </td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">14,319</td><td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"> </td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"> </td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"> </td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">61,560</td><td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"> </td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; padding-left: 10pt;">Income Tax Expense</td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 4pt;"> </td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">$</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">(40,507</td><td style="padding-bottom: 4pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">)</td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 4pt;"> </td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">$</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">(23,913</td><td style="padding-bottom: 4pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">)</td></tr></table><div> </div>

<table align="center" style="font: 10pt/normal 'times new roman', times, serif; width: 1422.72px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="padding-left: 10pt; text-indent: -10pt;"> </td><td style="font-weight: bold;"> </td><td style="font-weight: bold; text-align: center;" colspan="6">For the 3 Months Ended</td><td style="font-weight: bold;"> </td></tr><tr style="vertical-align: bottom;"><td style="padding-left: 10pt; text-indent: -10pt;"> </td><td style="font-weight: bold; padding-bottom: 1.5pt;"> </td><td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6">September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold;"> </td></tr><tr style="vertical-align: bottom;"><td style="padding-left: 10pt; text-indent: -10pt;"> </td><td style="font-weight: bold; padding-bottom: 1.5pt;"> </td><td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2016</td><td style="padding-bottom: 1.5pt; font-weight: bold;"> </td><td style="font-weight: bold; padding-bottom: 1.5pt;"> </td><td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2015</td><td style="padding-bottom: 1.5pt; font-weight: bold;"> </td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1068.49426269531px; text-align: left; padding-left: 10pt; text-indent: -10pt;">Net (Loss)</td><td style="width: 14.5454540252686px;"> </td><td style="width: 14.5454540252686px; text-align: left;"> </td><td style="width: 128.18180847168px; text-align: right;">    (793,181</td><td style="width: 14.5454540252686px; text-align: left;">)</td><td style="width: 14.5454540252686px;"> </td><td style="width: 13.63636302948px; text-align: left;"> </td><td style="width: 127.272727966309px; text-align: right;">(350,302</td><td style="width: 13.63636302948px; text-align: left;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: justify; padding-left: 10pt; text-indent: -10pt;">Weighted average number of common shares used in basic earnings per share</td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">9,533,290</td><td style="text-align: left;"> </td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">9,533,290</td><td style="text-align: left;"> </td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt; text-indent: -10pt;">Effect of dilutive securities, stock options and warrants</td><td style="padding-bottom: 1.5pt;"> </td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"> </td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;">-</td><td style="padding-bottom: 1.5pt; text-align: left;"> </td><td style="padding-bottom: 1.5pt;"> </td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"> </td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;">-</td><td style="padding-bottom: 1.5pt; text-align: left;"> </td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt; text-indent: -10pt;">Weighted average number of common shares and potential dilutive common shares outstanding used in dilutive earnings per share</td><td style="padding-bottom: 1.5pt;"> </td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"> </td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;">9,533,290</td><td style="padding-bottom: 1.5pt; text-align: left;"> </td><td style="padding-bottom: 1.5pt;"> </td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"> </td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;">9,533,290</td><td style="padding-bottom: 1.5pt; text-align: left;"> </td></tr></table><div> </div>

<table style="font: 10pt/normal 'times new roman', times, serif; width: 1422.72px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"> </td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"> </td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;" colspan="2"> </td><td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"> </td><td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"> </td><td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: center;" colspan="10">Options Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: center;"> </td><td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt; text-align: center;"> </td><td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: center;" colspan="6">Options Exercisable</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"> </td></tr><tr style="vertical-align: bottom; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"> </td><td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"> </td><td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: center;" colspan="2">Exercise Prices</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: center;"> </td><td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt; text-align: center;"> </td><td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: center;" colspan="2">Number Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: center;"> </td><td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt; text-align: center;"> </td><td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: center;" colspan="2">Weighted Average Remaining Contractual Life (years)</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: center;"> </td><td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt; text-align: center;"> </td><td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: center;" colspan="2">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: center;"> </td><td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt; text-align: center;"> </td><td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: center;" colspan="2">Number Exercisable</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: center;"> </td><td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt; text-align: center;"> </td><td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: center;" colspan="2">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"> </td></tr><tr style="vertical-align: bottom; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; background-color: #cceeff;"><td style="width: 399.090911865234px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"></td><td style="width: 14.5454540252686px; padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"> </td><td style="width: 14.5454540252686px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">$</td><td style="width: 128.18180847168px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">2.00</td><td style="width: 14.5454540252686px; padding-bottom: 1.5pt; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"> </td><td style="width: 14.5454540252686px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"> </td><td style="width: 14.5454540252686px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"> </td><td style="width: 128.18180847168px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">900,000</td><td style="width: 14.5454540252686px; padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"> </td><td style="width: 14.5454540252686px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"> </td><td style="width: 14.5454540252686px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"> </td><td style="width: 128.18180847168px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">3.25</td><td style="width: 14.5454540252686px; padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"> </td><td style="width: 14.5454540252686px; padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"> </td><td style="width: 14.5454540252686px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">$</td><td style="width: 128.18180847168px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">2.00</td><td style="width: 14.5454540252686px; padding-bottom: 1.5pt; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"> </td><td style="width: 13.63636302948px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"> </td><td style="width: 13.63636302948px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"> </td><td style="width: 127.272727966309px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">900,000</td><td style="width: 13.63636302948px; padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"> </td><td style="width: 13.63636302948px; padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"> </td><td style="width: 13.63636302948px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">$</td><td style="width: 127.272727966309px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">2.00</td><td style="width: 13.63636302948px; padding-bottom: 1.5pt; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"> </td></tr><tr style="vertical-align: bottom; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; background-color: white;"><td style="padding-bottom: 4pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">Total</td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 4pt;"> </td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"> </td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"> </td><td style="padding-bottom: 4pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"> </td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 4pt;"> </td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"> </td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">900,000</td><td style="padding-bottom: 4pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"> </td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 4pt;"> </td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"> </td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">3.25</td><td style="padding-bottom: 4pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"> </td><td style="padding-bottom: 4pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"> </td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">$</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">2.00</td><td style="padding-bottom: 4pt; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"> </td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 4pt;"> </td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"> </td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">900,000</td><td style="padding-bottom: 4pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"> </td><td style="padding-bottom: 4pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"> </td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">$</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">2.00</td><td style="padding-bottom: 4pt; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"> </td></tr></table><div> </div>

8040000

Straight line basis over the estimated useful life of twenty years.

Depreciation is computed for financial statement purposes on a straight-line basis over the estimated useful lives of the assets which range from four to nine years

185053

0.25 0.25 5000000 1.00 1.498842 6000000 6000000 4400000 1440000

15000000

P6Y

P4Y

P6Y

P4Y

220114

163959

56155

220928

164565

56363

220114

220928

11106

14849

14890

14849

61960

3937

3749

102882

17414

38235

47233

103538

17478

38235

47825

-102882

-103538

103538

120300

240600

103538

120300

240600

38235

47825

120300 102941

60150

90225

150375

0.03

2.00

2017-12-31

2019-12-31

2.50 2.05

2639

2555

3577

5630

15038 2256

2527

346

240600

229669

0.03

425

107

375

3940

3960

945

6300

7660 7660 870 870

2558080

2639879

2566610

2648409

-127233

-283454

41760

14465

214163

61560

14319

-23913

-40507

-23913

-40507

-52647 -81798 -52647 -81798

10379545

1048174

2034-09-30

0.34

0.22

356379

2283500

9533290

360900

180450

P3Y3M15D

1.8965

0.0087

0.00

2.00

900000

P3Y3M

2.00

900000

2.00

900000

2.00

P3Y3M

675000

300000

2.00

16500000

1.498842 P180D P20Y 50.000 7448 8193 0

1052989

100000

9533290

900000

9533290

2019-12-31

The agreement calls for monthly payment of $20,000 with a $100,000 retainer payment due November 1, 2016. The agreement can be terminated with 12 month notice. (i) a number of shares of Common Stock of the Company equal to the number of shares of Series A Common Stock and Common Stock outstanding of the OncoSynergy, Inc. immediately prior to the closing of the Transaction, and (ii) derivative securities (including any option, right, warrant, call, convertible security, right to subscribe, conversion right or other agreement or commitment immediately outstanding prior to the closing, if any), of like tenor, except as to timing of exercisability and maturity, exercisable or convertible into a like number of shares of Common Stock, and having rights, preferences, terms and conditions consistent in all other respects with such outstanding derivative security. Immediately following the closing it is estimated OncoSynergy, Inc. will hold between 33% and 40% of the capital stock of the Company on a fully diluted basis, assuming the exercise or conversion in full of all outstanding derivative securities of the Dandrit BioTech USA, Inc.

EX-101.SCH 5 ddrt-20160930.xsd XBRL SCHEMA FILE 001 - Document - Document and Entity Information link:presentationLink link:definitionLink link:calculationLink 002 - Statement - Consolidated Balance Sheets link:presentationLink link:definitionLink link:calculationLink 003 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 004 - Statement - Consolidated Statement of Operations link:presentationLink link:definitionLink link:calculationLink 005 - Statement - Statements of Other Comprehensive Loss link:presentationLink link:definitionLink link:calculationLink 006 - Statement - Consolidated Statement of Cash Flows link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - Going Concern link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - Property and Equipment link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - Definite-Life Intangible Assets link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - Notes Payable - Related Party link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - Convertible Notes Payable - Related Party link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - Convertible Notes Payable link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - Leases link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - Income Taxes link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - Loss Per Share link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - Stockholders' Equity link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - Related Party Transactions link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - Asset Purchase Agreement link:presentationLink link:definitionLink link:calculationLink 021 - Disclosure - Subsequent Event link:presentationLink link:definitionLink link:calculationLink 022 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:definitionLink link:calculationLink 023 - Disclosure - Property and Equipment (Tables) link:presentationLink link:definitionLink link:calculationLink 024 - Disclosure - Definite-Life Intangible Assets (Tables) link:presentationLink link:definitionLink link:calculationLink 025 - Disclosure - Notes Payable - Related Party (Tables) link:presentationLink link:definitionLink link:calculationLink 026 - Disclosure - Convertible Notes Payable - Related Party (Tables) link:presentationLink link:definitionLink link:calculationLink 027 - Disclosure - Convertible Notes Payable (Tables) link:presentationLink link:definitionLink link:calculationLink 028 - Disclosure - Income Taxes (Tables) link:presentationLink link:definitionLink link:calculationLink 029 - Disclosure - Loss Per Share (Tables) link:presentationLink link:definitionLink link:calculationLink 030 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:definitionLink link:calculationLink 031 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:definitionLink link:calculationLink 032 - Disclosure - Going Concern (Details) link:presentationLink link:definitionLink link:calculationLink 033 - Disclosure - Property and Equipment (Details) link:presentationLink link:definitionLink link:calculationLink 034 - Disclosure - Property and Equipment (Details Textual) link:presentationLink link:definitionLink link:calculationLink 035 - Disclosure - Definite-Life Intangible Assets (Details) link:presentationLink link:definitionLink link:calculationLink 036 - Disclosure - Definite-Life Intangible Assets (Details Textual) link:presentationLink link:definitionLink link:calculationLink 037 - Disclosure - Notes Payable - Related Party (Details) link:presentationLink link:definitionLink link:calculationLink 038 - Disclosure - Notes Payable - Related Party (Details 1) link:presentationLink link:definitionLink link:calculationLink 039 - Disclosure - Notes Payable - Related Party (Details Textual) link:presentationLink link:definitionLink link:calculationLink 040 - Disclosure - Convertible Notes Payable - Related Party (Details) link:presentationLink link:definitionLink link:calculationLink 041 - Disclosure - Convertible Notes Payable - Related Party (Details 1) link:presentationLink link:definitionLink link:calculationLink 042 - Disclosure - Convertible Notes Payable - Related Party (Details Textual) link:presentationLink link:definitionLink link:calculationLink 043 - Disclosure - Convertible Notes Payable (Details) link:presentationLink link:definitionLink link:calculationLink 044 - Disclosure - Convertible Notes Payable (Details 1) link:presentationLink link:definitionLink link:calculationLink 045 - Disclosure - Convertible Notes Payable (Details Textual) link:presentationLink link:definitionLink link:calculationLink 046 - Disclosure - Leases (Details) link:presentationLink link:definitionLink link:calculationLink 047 - Disclosure - Income Taxes (Details) link:presentationLink link:definitionLink link:calculationLink 048 - Disclosure - Income Taxes (Details 1) link:presentationLink link:definitionLink link:calculationLink 049 - Disclosure - Income Taxes (Details 2) link:presentationLink link:definitionLink link:calculationLink 050 - Disclosure - Income Taxes (Details Textual) link:presentationLink link:definitionLink link:calculationLink 051 - Disclosure - Loss Per Share (Details) link:presentationLink link:definitionLink link:calculationLink 052 - Disclosure - Stockholders' Equity (Details) link:presentationLink link:definitionLink link:calculationLink 053 - Disclosure - Stockholders' Equity (Details 1) link:presentationLink link:definitionLink link:calculationLink 054 - Disclosure - Stockholders' Equity (Details 2) link:presentationLink link:definitionLink link:calculationLink 055 - Disclosure - Stockholders' Equity (Details Textual) link:presentationLink link:definitionLink link:calculationLink 056 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:definitionLink link:calculationLink 057 - Disclosure - Related Party Transactions (Details) link:presentationLink link:definitionLink link:calculationLink 058 - Disclosure - Asset Purchase Agreement (Details) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 6 ddrt-20160930_cal.xml XBRL CALCULATION FILE EX-101.DEF 7 ddrt-20160930_def.xml XBRL DEFINITION FILE EX-101.LAB 8 ddrt-20160930_lab.xml XBRL LABEL FILE Document and Entity Information [Abstract] Document - Document and Entity Information [Abstract] Document - Document and Entity Information [Abstract] Document and Entity Information. Entity Registrant Name Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Entity Central Index Key Amendment Flag Amendment Flag Amendment Flag Current Fiscal Year End Date Current Fiscal Year End Date Current Fiscal Year End Date Document Type Document Type Document Type Document Period End Date Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Document Fiscal Period Focus Entity Filer Category Entity Filer Category Entity Filer Category Entity Common Stock Shares Outstanding Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Balance Sheet [Abstract] Assets [Abstract] ASSETS Assets Current [Abstract] CURRENT ASSETS: CURRENT ASSETS: Cash and Cash Equivalents, at Carrying Value Cash held in escow balance Cash CASH, BEGINNING OF PERIOD CASH, END OF PERIOD Cash held in escrow balance Other Receivables, Net, Current Other Receivables Prepaid Expense, Current Prepaid Expenses Assets Current Total Current Assets Total Current Assets Property, Plant and Equipment, Net Net Property and Equipment Property and Equipment, net accumulated depreciation Net Property and Equipment PROPERTY AND EQUIPMENT, Net accumulated Depreciation Assets, Noncurrent [Abstract] OTHER ASSETS Finite-Lived Intangible Assets, Net Definite-life intangible assets Definite Life Intangible Assets Finite-Lived Intangible Assets, Net Deferred Offering Costs Deferred stock offering costs Deposits Assets, Noncurrent Deposits Assets, Noncurrent Total Other Assets Assets TOTAL ASSETS TOTAL ASSETS Liabilities and Stockholders Equity [Abstract] Liabilities and Shareholder's Equity LIABILITIES AND STOCKHOLDER'S EQUITY Liabilities Current [Abstract] CURRENT LIABILITIES: CURRENT LIABILITIES: Notes Payable, Related Parties, Current Notes Payable - Related Party Less Current Maturities Total Notes Payable - Related Party Notes Payable - Related Party Less Current Maturities Accounts Payable, Current Accounts Payable Accounts Payable, Related Parties, Current Accounts payable - Related party Accounts Payable - Related Party Accrued Liabilities, Current Accrued Expenses Liabilities Current Total Current Liabilities Total Current Liabilities Convertible Notes Payable, Noncurrent Net Convertible Note Payables - Long Term Convertible Notes Payable, Current Portion (Net of discounts of $10,931 and $0, respectively) Net Convertible Note Payables - Long Term Convertible Notes Payable Related Party Convertible Notes Payable - Related Party, (Net of discounts of $17,359 and $0, respectively) Convertible Notes Payable - Related Party, (Net of discounts of $20,232 and $0, respectively) Net Convertible Note Payables - Related Party Long Term Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder. Liabilities, Noncurrent Total Long Term Liabilities Total Long Term Liabilities Liabilities Total Liabilities Total Liabilities Stockholders Equity [Abstract] STOCKHOLDER'S EQUITY(Deficit): STOCKHOLDER'S DEFICIENCY: Preferred Stock, Value, Issued Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding Common Stock Value Common stock, par value $0.0001, 100,000,000 shares authorized, 9,533,290, and 9,533,290 issued and outstanding at March 31, 2016 and June 30, 2015, respectively Common stock; par value 0.0001, 100,000,000 shares authorized, 9,533,290 issued and outstanding at June 30, 2015, 9,533,290 issued and outstanding at December 31, 2014, and 6,000,000 shares issued and outstanding at December 31, 2013 Common stock, par value $0.0001, 100,000,000 shares authorized, 9,533,290, and 9,533,290 issued and outstanding at September 30, 2016 and June 30, 2016, respectively Common stock, par value $0.0001, 100,000,000 shares authorized, 9,533,290, and 9,533,290 issued and outstanding at March 31, 2016 and June 30, 2015, respectively Additional Paid In Capital Additional paid-in capital Additional paid-in capital Retained Earnings (Accumulated Deficit) Accumulated Deficit Accumulated Deficit Accumulated Other Comprehensive Income (Loss), Net of Tax Other comprehensive income, net Stockholders' Equity Attributable to Parent Total Stockholder's Deficiency Total Stockholder's Equity (Deficit) Beginning Balance Ending Balance Liabilities and Stockholders Equity TOTAL LIABILITIES AND STOCKHOLDER'S EQUITY TOTAL LIABILITIES AND STOCKHOLDER'S EQUITY Convertible Notes Payable Debt Discount Less Discounts Convertible Notes Payable Current Portion Net of discounts It represents convertible notes payable debt discount current. Less Discounts Convertible Notes Payable Related Party Debt Discount Convertible Notes Payable - Related Party Net of discounts It represents convertible notes payable related party debt discount current. Less Discount Preferred Stock, Par or Stated Value Per Share Preferred stock, par value Preferred Stock, Shares Authorized Preferred stock, shares authorized Preferred Stock, Shares Issued Preferred stock, shares issued Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Common Stock, Par or Stated Value Per Share Common stock, par value Common stock, par value Common Stock, Shares Authorized Common stock, shares authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding Statement of Operations [Abstract] Income Statement [Abstract] Income Statement [Abstract] Revenues Revenues Cost of Goods Sold Cost of Goods Sold Cost of Goods Sold Gross Profit Gross Income (Loss) Gross profit (Loss) Operating Expenses [Abstract] Operating Expenses General and Administrative Expense GENERAL AND ADMINISTRATIVE EXPENSES General and Administrative Expenses Noncash Compensation Expenses Non-cash compensation expenses Amount of expense or loss included in net income. Research and Development Expense Research and development expense Research and Development Expenses Depreciation, Depletion and Amortization Depreciation and Amortization Consulting Expenses Consulting Expenses Consulting expenses The expense in the period incurred with respect to consulting. Operating Expenses Total Operating Expense Total Operating Expense Operating Income (Loss) Loss from Operations (LOSS) FROM OPERATIONS Nonoperating Income (Expense) [Abstract] Other Income (Expense) Interest Expense Interest (expense) Interest (expense) Interest Expense, Related Party Interest (expense) - Related Party Related party interest on note Interest (expense) - Related Party Foreign Currency Transaction Gain (Loss), Realized Gain (Loss) on Currency Transactions Gain (loss) on currency transactions Gain (Loss) on Currency Transactions Interest Income, Other Interest and Other Income Nonoperating Income (Expense) Total Other Income (Expense) Total Other Income (Expense) Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest Loss Before Income Taxes (LOSS) BEFORE BENEFIT FROM INCOME TAXES (Loss) Before Income Taxes (LOSS) BEFORE BENEFIT FROM INCOME TAXES Income Tax Expense (Benefit) Income Tax Expense (Benefit) Income Tax Expense Income Tax Expense (Benefit) Net Income (Loss) Attributable to Parent Net Loss Net Loss NET (LOSS) Net Income (Loss) Net (Loss) (Net Loss) Earnings Per Share Basic and Diluted BASIC AND DILUTED LOSS PER SHARE BASIC AND DILUTED LOSS PER SHARE Weighted Average Number Of Shares Outstanding, Basic and Diluted WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - BASIC AND DILUTED Weighted average number of common shares used in basic earnings per share Weighted average number of common shares and potential dilutive common shares outstanding used in dilutive earnings per share Weighted average number of common shares used in basic earnings per share Statements of Other Comprehensive Loss [Abstract] Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax Equity Adjustment for Foreign Currency Translation (Currency Translation, Net of Taxes) Currency Translation, Net of Taxes Comprehensive Income (Loss), Net of Tax, Attributable to Parent (Other Comprehensive Loss) Other Comprehensive Loss Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] ADJUSTMENT TO RECONCILE NET LOSS TO NET CASH USED IN OPERATING ACTIVITIES: Adjustments to reconcile net (loss) to net cash provided (used) by operations: Depreciation, Depletion and Amortization, Nonproduction Depreciation and Amortization Non Cash Compensation Non-cash compensation Non cash compensation. Increase (Decrease) in Interest Payable, Net Accrued Interest on Notes Payable - Related Party Accretion Expense Accretion of discount on notes payable Increase (Decrease) in Operating Capital [Abstract] Changes in assets and liabilities: CHANGES IN ASSETS AND LIABILITIES: Increase (Decrease) in Accounts Receivable (Increase) decrease in Accounts Receivable Dandrit USA (Increase) Decrease in Other Receivables Increase Decrease In Prepaid Expense And Deposits (Increase)Decrease in Prepaid Expenses/Deposits The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services and deposits that bring economic benefits for future periods. (Increase) Decrease in Prepaid Expenses/Deposits Increase (Decrease) in Accounts Payable Increase (Decrease) in Accounts Payable Increase (decrease) in accounts payable Increase (Decrease) in Accounts Payable, Related Parties Increase (Decrease) in Accounts Payable - Related Party Increase (Decrease) in Accounts Payable - Related Party Increase (Decrease) in Accrued Liabilities Increase (decrease) in accrued expenses Increase (Decrease) in Accrued Expenses Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities Total Adjustments Net Cash Provided By Used In Operating Activities NET CASH USED IN OPERATING ACTIVITIES NET CASH USED IN OPERATING ACTIVITIES Net Cash Provided By Used In Investing Activities [Abstract] CASH FLOWS FROM INVESTING ACTIVITIES: Cash Flows from Investing Activities: Net Increase Decrease In Cash Held In Escrow Net (Increase) Decrease in Cash Held in Escrow Net (Increase) Decrease in Cash Held in Escrow Net increase decrease in cash held in Escrow. Net (Increase) Decrease in Cash Held in Escrow Net Cash Provided By Used In Investing Activities NET CASH USED BY INVESTING ACTIVITIES NET CASH USED BY INVESTING ACTIVITIES Net Cash Provided By Used In Financing Activities [Abstract] Cash Flows from Financing Activities: CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from Related Party Debt Proceeds from Notes Payable - Related Party Proceeds from Notes Payable Proceeds from Notes Payables Net Cash Provided By Used In Financing Activities NET CASH PROVIDED BY FINANCING ACTIVITIES NET CASH PROVIDED BY FINANCING ACTIVITIES NET CASH PROVIDED BY (USED BY) FINANCING ACTIVITIES Effect of Exchange Rate on Cash and Cash Equivalents (Gain) loss on Currency Translation Gain (Loss) on Currency Translation Cash and Cash Equivalents, Period Increase (Decrease) NET INCREASE IN CASH NET INCREASE (DECREASE) IN CASH Supplemental Cash Flow Information [Abstract] SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION Supplemental Disclosures of Cash Flow Information: Cash Paid During Periods For [Abstract] Cash paid during the year for Cash paid during the periods for: Cash Paid During Periods For. Interest Paid Interest Interest (expense) Income Taxes Paid, Net Income Taxes Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES Imputed Interest On Non-Interest Bearing Convertible Notes Payable Imputed interest on Non-interest bearing Convertible Notes Payable Imputed interest on Non interest bearing Convertible Notes Payable. Beneficial Conversion Feature Of Convertible Notes Payable Beneficial Conversion Feature of Convertible Notes Payable Beneficial Conversion Feature of Convertible Notes Payable. Compensation For Issuance Of Stock Options Compensation for the issuance of stock options to the Board Compensation for issuance of stock options. Summary of Significant Accounting Policies [Abstract] Significant Accounting Policies [Text Block] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Going Concern [Abstract] Going Concern [Text Block] GOING CONCERN The entire disclosure for going Concern. Property and Equipment [Abstract] Property and Equipment [Abstract] Property, Plant and Equipment Disclosure [Text Block] PROPERTY AND EQUIPMENT Definite-Life Intangible Assets [Abstract] Intangible Assets Disclosure [Text Block] DEFINITE-LIFE INTANGIBLE ASSETS Notes Payable - Related Party [Abstract] Notes Payable Due To Related Party Disclosure [Text Block] NOTES PAYABLE - RELATED PARTY The entire disclosure for notes payable due to related party. Convertible Notes Payable - Related Party [Abstract] Convertible Notes Payable - Related Party [Abstract] Convertible Notes Payable Related Party [Text Block] CONVERTIBLE NOTES PAYABLE - RELATED PARTY The entire disclosure for Convertible Notes Payable Related Party. CONVERTIBLE NOTES PAYABLE Leases [Abstract] Operating Leases of Lessor Disclosure [Text Block] LEASES Income Taxes [Abstract] Income Tax Disclosure [Abstract] Income Tax Disclosure [Text Block] Income Taxes INCOME TAXES Loss Per Share [Abstract] Earnings Per Share [Text Block] LOSS PER SHARE Stockholders' Equity [Abstract] Stockholders' Equity Note Disclosure [Text Block] STOCKHOLDERS' EQUITY Commitments and Contingencies [Abstract] Commitments and Contingencies Disclosure [Text Block] COMMITMENTS AND CONTINGENCIES Related Party Transactions [Abstract] Related Party Transactions Disclosure [Text Block] RELATED PARTY TRANSACTIONS Asset Purchase Agreement [Abstract] Asset Purchase Agreement [Text Block] ASSET PURCHASE AGREEMENT The entire disclosure of asset purchase agreement. Subsequent Events [Abstract] Subsequent Event [Abstract] Subsequent Events [Text Block] SUBSEQUENT EVENT Basis of Accounting, Policy [Policy Text Block] Business and Basis of Presentation Fiscal Period, Policy [Policy Text Block] Fiscal Year End Reverse Acquisition [Policy Text Block] Reverse Acquisition Disclosure of accounting policy for reverse acquisition. Consolidation, Policy [Policy Text Block] Consolidation Foreign Currency Transactions and Translations Policy [Policy Text Block] Functional Currency / Foreign currency translation Cash and Cash Equivalents, Policy [Policy Text Block] Cash and Cash Equivalents Property, Plant and Equipment, Policy [Policy Text Block] Property and Equipment Intangible Assets, Finite-Lived, Policy [Policy Text Block] Intangible Assets Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Impairment of Long-Lived Assets Revenue Recognition, Sales of Services [Policy Text Block] Revenue Recognition and Sales Value Added Tax [Policy Text Block] Value Added Tax Disclosure of accounting policy for Value Added Tax. Research and Development Expense, Policy [Policy Text Block] Research and Development Expenses Income Tax, Policy [Policy Text Block] Income Taxes Earnings Per Share, Policy [Policy Text Block] Loss Per Share Fair Value Measurement, Policy [Policy Text Block] Fair Value of Financial Instruments Use of Estimates, Policy [Policy Text Block] Accounting Estimates New Accounting Pronouncements, Policy [Policy Text Block] Recent Accounting Pronouncements Reclassification, Policy [Policy Text Block] Reclassification Property, Plant and Equipment [Table Text Block] Summary of property and equipment Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Schedule of finite-lived intangible assets, future amortization expense Schedule of Related Party Transactions [Table Text Block] Summary of notes payable to related parties Schedule of maturities of long term debt [Table Text Block] Schedule of future maturities of long-term debt Schedule of Long-term Debt Instruments [Table] Debt Instrument [Axis] Debt Instrument, Name [Domain] Convertible Notes Payable Related Parties [Member] Convertible notes payable related parties [Member] Convertible Notes payable related parties. Debt Instrument [Line Items] Convertible Debt [Table Text Block] Schedule of convertible notes payable Schedule of convertible notes payable to related party Schedule of Long-term Debt Instruments [Table Text Block] Schedule of future maturities of long term debt Schedule of Short-term Debt [Table] Short-term Debt, Type [Axis] Short-term Debt, Type [Domain] Convertible Notes Payable [Member] Convertible notes payable [Member] Short-term Debt [Line Items] Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Summary of deferred tax asset (liabilities) Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Summary of reconciliation of income tax expense at federal statutory rate Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Summary of components of income tax expense (benefit) from continuing operations Schedule of Weighted Average Number of Shares [Table Text Block] Schedule of weighted average number of shares of potential dilutive common stock Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Summary of weighted-average assumptions used to fair value calculation for options granted Schedule of Share-based Compensation, Activity [Table Text Block] Summary of stock option outstanding Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Summary of stock option activity Statement [Table] Statement [Table] Statement [Table] Equity Components [Axis] Statement, Equity Components [Axis] Statement, Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Equity Component [Domain] Common Stock [Member] Common Stock Common Stock [Member] Legal Entity [Axis] Entity [Domain] Parent Company [Member] Parent company [Member] Legal Entity of Counterparty, Type [Axis] Legal Entity Type of Counterparty [Domain] Stockholders [Member] Stockholders [Member] Stockholders person that is legally permitted to enter into a contract EX-101.PRE 9 ddrt-20160930_pre.xml XBRL PRESENTATION FILE XML 10 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Sep. 30, 2016	Nov. 14, 2016
Document and Entity Information [Abstract]
Entity Registrant Name	DanDrit Biotech USA, Inc.
Entity Central Index Key	0001527728
Amendment Flag	false
Current Fiscal Year End Date	--06-30
Document Type	10-Q
Document Period End Date	Sep. 30, 2016
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q1
Entity Filer Category	Smaller Reporting Company
Entity Common Stock Shares Outstanding		9,533,290

XML 11 R2.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets - USD ($)	Sep. 30, 2016	Jun. 30, 2016
CURRENT ASSETS:
Cash	$ 31,675	$ 23,368
Other Receivables	746,452	695,418
Prepaid Expenses	6,435	13,693
Total Current Assets	784,562	732,479
PROPERTY AND EQUIPMENT, Net accumulated Depreciation
OTHER ASSETS
Definite Life Intangible Assets	132,503	135,743
Deferred stock offering costs	25,000
Deposits	2,619	2,609
Total Other Assets	160,122	138,352
TOTAL ASSETS	944,684	870,831
CURRENT LIABILITIES:
Notes Payable - Related Party	103,474	102,882
Accounts Payable	979,029	1,087,758
Accounts Payable - Related Party	97,718	97,357
Accrued Expenses	229,838	220,232
Total Current Liabilities	1,410,059	1,508,229
Convertible Notes Payable, Current Portion (Net of discounts of $10,931 and $0, respectively)	229,669
Convertible Notes Payable - Related Party, (Net of discounts of $17,359 and $0, respectively)	102,941
Total Long Term Liabilities	332,610
Total Liabilities	1,742,669	1,508,229
STOCKHOLDER'S EQUITY(Deficit):
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding
Common stock, par value $0.0001, 100,000,000 shares authorized, 9,533,290, and 9,533,290 issued and outstanding at September 30, 2016 and June 30, 2016, respectively	953	953
Additional paid-in capital	25,756,232	25,098,050
Accumulated Deficit	(27,093,875)	(26,300,694)
Other comprehensive income, net	538,705	564,293
Total Stockholder's Equity (Deficit)	(797,985)	(637,398)
TOTAL LIABILITIES AND STOCKHOLDER'S EQUITY	$ 944,684	$ 870,831

XML 12 R3.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets (Parenthetical) - USD ($)	Sep. 30, 2016	Jun. 30, 2016
Balance Sheet [Abstract]
Convertible Notes Payable Current Portion Net of discounts	$ 10,931	$ 0
Convertible Notes Payable - Related Party Net of discounts	$ 17,359	$ 0
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common Stock, Shares, Issued	9,533,290	9,533,290
Common stock, shares outstanding	9,533,290	9,533,290

XML 13 R4.htm IDEA: XBRL DOCUMENT

Consolidated Statement of Operations - USD ($)	3 Months Ended
Consolidated Statement of Operations - USD ($)	Sep. 30, 2016	Sep. 30, 2015
Statement of Operations [Abstract]
Revenues
Cost of Goods Sold
Gross profit (Loss)
Operating Expenses
General and Administrative Expenses	204,951	204,851
Non-cash compensation expenses	626,487
Research and Development Expenses	17,104	101,759
Depreciation and Amortization	3,749	3,937
Consulting Expenses		30,848
Total Operating Expense	852,291	341,395
(LOSS) FROM OPERATIONS	(852,291)	(341,395)
Other Income (Expense)
Interest (expense)	(1,017)
Interest (expense) - Related Party	(3,464)	(592)
Gain (Loss) on Currency Transactions	23,084	(32,228)
Interest and Other Income
Total Other Income (Expense)	18,603	(32,820)
(Loss) Before Income Taxes	(833,688)	(374,215)
Income Tax Expense (Benefit)	(40,507)	(23,913)
NET (LOSS)	$ (793,181)	$ (350,302)
BASIC AND DILUTED LOSS PER SHARE	$ (0.08)	$ (0.04)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - BASIC AND DILUTED	9,533,290	9,533,290

XML 14 R5.htm IDEA: XBRL DOCUMENT

Statements of Other Comprehensive Loss - USD ($)	3 Months Ended
Statements of Other Comprehensive Loss - USD ($)	Sep. 30, 2016	Sep. 30, 2015
Statements of Other Comprehensive Loss [Abstract]
Net Loss	$ (793,181)	$ (350,302)
Currency Translation, Net of Taxes	(25,588)	(9,816)
Other Comprehensive Loss	$ (818,769)	$ (360,118)

XML 15 R6.htm IDEA: XBRL DOCUMENT

Consolidated Statement of Cash Flows - USD ($)	3 Months Ended
Consolidated Statement of Cash Flows - USD ($)	Sep. 30, 2016	Sep. 30, 2015
Statement of Cash Flows [Abstract]
Net (Loss)	$ (793,181)	$ (350,302)
ADJUSTMENT TO RECONCILE NET LOSS TO NET CASH USED IN OPERATING ACTIVITIES:
Depreciation and Amortization	3,749	3,937
Non-cash compensation	626,487
Accrued Interest on Notes Payable - Related Party	592	592
Accretion of discount on notes payable	3,404
CHANGES IN ASSETS AND LIABILITIES:
(Increase) Decrease in Other Receivables	(51,034)	(28,134)
(Increase) Decrease in Prepaid Expenses/Deposits	7,248	(59,800)
Increase (Decrease) in Accounts Payable	(133,728)	4,761
Increase (Decrease) in Accounts Payable - Related Party	361	9,667
Increase (Decrease) in Accrued Expenses	9,606	3,243
Total Adjustments	466,685	(65,734)
NET CASH USED IN OPERATING ACTIVITIES	(326,496)	(416,036)
CASH FLOWS FROM INVESTING ACTIVITIES:
Net (Increase) Decrease in Cash Held in Escrow		1,052,989
NET CASH USED BY INVESTING ACTIVITIES		1,052,989
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from Notes Payable - Related Party	138,070
Proceeds from Notes Payables	222,830
NET CASH PROVIDED BY (USED BY) FINANCING ACTIVITIES	360,900
Gain (Loss) on Currency Translation	(26,097)	(9,978)
NET INCREASE (DECREASE) IN CASH	8,307	626,975
CASH, BEGINNING OF PERIOD	23,368	421,145
CASH, END OF PERIOD	31,675	1,048,120
Cash paid during the periods for:
Interest
Income Taxes
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES
Imputed interest on Non-interest bearing Convertible Notes Payable	14,402
Beneficial Conversion Feature of Convertible Notes Payable	17,293
Compensation for the issuance of stock options to the Board	$ 626,487

XML 16 R7.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

3 Months Ended

Sep. 30, 2016

Summary of Significant Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 1 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Fiscal Year End - In June 2015, DanDrit’s board of directors approved a change to DanDrit’s fiscal year end from December 31 to June 30.

Our research and development expenses may fluctuate substantially from quarter to quarter depending on the clinical studies and the timing of samples supporting the clinical studies.

●

Level 1. Observable inputs such as quoted prices in active markets for identical assets or liabilities;

●

Level 2. Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and

●

Level 3. Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

Other recent accounting pronouncements issued by the FASB did not or are not believed by management to have a material impact on the Company's present or future financial statements.

XML 17 R8.htm IDEA: XBRL DOCUMENT

Going Concern

3 Months Ended

Sep. 30, 2016

Going Concern [Abstract]

GOING CONCERN

NOTE 2 — GOING CONCERN

XML 18 R9.htm IDEA: XBRL DOCUMENT

Property and Equipment

3 Months Ended

Sep. 30, 2016

Property and Equipment [Abstract]

PROPERTY AND EQUIPMENT

NOTE 3 — PROPERTY AND EQUIPMENT

Property and equipment consisted of the following at September 30, 2016 and June 30, 2016:

	Useful Life	September 30, 2016			June 30, 2016
Lab equipment and instruments	4-6	$	164,565		$	163,959
Computer equipment	4-6		56,363			56,155
			220,928			220,114
Less Accumulated Depreciation			(220,928	)		(220,114	)
Net Property and Equipment		$	-		$	-

Depreciation expense amounted to $0 and $0 for the three month period ended September 30, 2016 and 2015, respectively.

XML 19 R10.htm IDEA: XBRL DOCUMENT

Definite-Life Intangible Assets

3 Months Ended

Sep. 30, 2016

Definite-Life Intangible Assets [Abstract]

DEFINITE-LIFE INTANGIBLE ASSETS

NOTE 4 — DEFINITE-LIFE INTANGIBLE ASSETS

Year ending June 30,
2017	$	11,106
2018		14,849
2019		14,849
2020		14,890
2021		14,849
Thereafter		61,960
	$	132,503

XML 20 R11.htm IDEA: XBRL DOCUMENT

Notes Payable - Related Party

3 Months Ended

Sep. 30, 2016

Notes Payable - Related Party [Abstract]

NOTES PAYABLE - RELATED PARTY

NOTE 5 — NOTES PAYABLE – RELATED PARTY

Notes payable to related parties consists of the following as of September 30, 2016 and June 30, 2016:

	September 30, 2016			June 30, 2016
Non-Interest Bearing Loan Payable Sunrise Financial Group Inc.	$	38,235		$	38,235
Note Payable ML Group		17,478			17,414
6% Promissory Note payable to NLBDIT 2010 Enterprises, LLC		47,825			47,233
Total Notes Payable – Related Party		103,538			102,882
Less Current Maturities		(103,538	)		(102,882	)
Note Payables – Related Party Long Term	$	-		$	-

The following represents the future maturities of long-term debt as of September 30, 2016:

Year ending June 30,
2017			103,538
2018			-
2019			-
2020			-
2021			-
Thereafter			-
			103,538

XML 21 R12.htm IDEA: XBRL DOCUMENT

Convertible Notes Payable - Related Party

3 Months Ended

Sep. 30, 2016

Convertible Notes Payable - Related Party [Abstract]

CONVERTIBLE NOTES PAYABLE - RELATED PARTY

NOTE 6 — CONVERTIBLE NOTES PAYABLE – RELATED PARTY

Convertible Notes payable to related parties consists of the following as of September 30, 2016 and June 30, 2016:

	September 30, 2016			June 30, 2016
Non-Interest Bearing Notes Payable Paseco ApS	$	120,300		$	-
Less Discount		(17,359	)		-
Total Convertible Notes Payable – Related Party		102,941		$	-
Less Current Maturities		-			-
Net Convertible Note Payables – Related Party Long Term	$	102,941			-

The following represents the future maturities of long-term debt as of September 30, 2016:

Year ending June 30,
2017			-
2018			120,300
2019			-
2020			-
2021			-
Thereafter			-
			120,300

XML 22 R13.htm IDEA: XBRL DOCUMENT

Convertible Notes Payable

3 Months Ended

Sep. 30, 2016

Notes Payable - Related Party [Abstract]

CONVERTIBLE NOTES PAYABLE

NOTE 7 — CONVERTIBLE NOTES PAYABLE

Convertible Notes payable to consists of the following as of September 30, 2016 and June 30, 2016:

	September 30, 2016			June 30, 2016
Non-Interest Bearing Notes Payable Equine Invest Aps	$	240,600		$	-
Less Discounts		(10,931	)		-
Total Convertible Notes Payable		229,669
Less Current Maturities		-			-
Net Convertible Note Payables – Long Term	$	229,669		$	-

The following represents the future maturities of long-term debt as of September 30, 2016:

Year ending June 30,
2017			-
2018			240,600
2019			-
2020			-
2021			-
Thereafter			-
			240,600

On August 24, 2016, the Company entered into a non interest bearing convertible notes $90,225. The note matures December 31, 2017. The note is convertible into common shares at $2.00 per share. As the Company’s stock was trading at $2.05 on July 1, 2016, the Company bifurcated the intrinsic value of the beneficial conversion feature and recorded a discount of $2,256. As the note is non-interest bearing the Company imputed the interest at 3% and further recorded a discount of $3,577. The interest will be amortized to expense using the effective interest method through the December 31, 2017 maturity. For the three months ended September 30, 2016, recorded interest expense of $425 for the amortization of the discount.

On September 21, 2016 the Company entered into a non interest bearing convertible notes for $150,375. The note matures December 31, 2017. The note is convertible into common shares at $2.00 per share. As the note is non-interest bearing the Company imputed the interest at 3% and further recorded a discount of $5,630. The interest will be amortized to expense using the effective interest method through the December 31, 2017 maturity. For the three months ended September 30, 2016, recorded interest expense of $107 for the amortization of the discount.

XML 23 R14.htm IDEA: XBRL DOCUMENT

Leases

3 Months Ended

Sep. 30, 2016

Leases [Abstract]

LEASES

NOTE 8 — LEASES

Lease expense charged to operations was $3,960 and $3,940 for the three ended September 30, 2016 and 2015, respectively.

XML 24 R15.htm IDEA: XBRL DOCUMENT

Income Taxes

3 Months Ended

Sep. 30, 2016

Income Taxes [Abstract]

INCOME TAXES

NOTE 9 — INCOME TAXES

The Company files U.S. and Danish income tax returns, and they are generally no longer subject to tax examinations for years prior to 2012 and 2008, respectively.

The temporary differences, tax credits and carry forwards gave rise to the following deferred tax asset (liabilities) at September 30, 2016 and June 30, 2016:

	September 30, 2016			June 30, 2016
Excess of Tax over book depreciation Fixed assets	$	7,660		$	7,660
Excess of Tax over book depreciation Patents		870			870
Net Operating Loss Carry forward		2,639,879			2,558,080
Valuation Allowance		(2,648,409	)		(2,566,610	)
Total Deferred Tax Asset (Liabilities)	$	-		$	-

A reconciliation of income tax expense at the federal statutory rate to income tax expense at the Company’s effective rate is as follows at September 30, 2016 and 2015:

	September 30, 2016			September 30, 2015
Computed Tax at Expected Statutory Rate	$	(283,454	)	$	(127,233	)
Non-US Income Taxed at Different Rates		14,465			41,760
Non-Deductible expenses		214,163			-
Valuation allowance		14,319			61,560
Income Tax Expense	$	(40,507	)	$	(23,913	)

The components of income tax expense (benefit) from continuing operations for the three months ended September, 2016 and 2015 consisted of the following:

	2016			2015
Current Tax Expense
Danish Income Tax	$	(40,507	)	$	(23,913	)
Total Current Tax Expense		(40,507	)		(23,913	)
Deferred Income Tax Expense (Benefit)
Excess of Tax over Book Depreciation Fixed Assets		-			-
Excess of Tax over Book Depreciation Patents		-			-
Net Operating Loss Carry forwards		(81,798	)		(52,647	)
Change in the Valuation allowance		81,798			52,647
Total Deferred Tax Expense	$	-		$	-

Deferred income tax expense / (benefit) results primarily from the reversal of temporary timing differences between tax and financial statement income.

XML 25 R16.htm IDEA: XBRL DOCUMENT

Loss Per Share

3 Months Ended

Sep. 30, 2016

Loss Per Share [Abstract]

LOSS PER SHARE

NOTE 10 — LOSS PER SHARE

	For the 3 Months Ended
	September 30,
	2016			2015
Net (Loss)		(793,181	)		(350,302	)
Weighted average number of common shares used in basic earnings per share		9,533,290			9,533,290
Effect of dilutive securities, stock options and warrants		-			-
Weighted average number of common shares and potential dilutive common shares outstanding used in dilutive earnings per share		9,533,290			9,533,290

At September 30, 2015, the Company had no common stock equivalents.

XML 26 R17.htm IDEA: XBRL DOCUMENT

Stockholders' Equity

3 Months Ended

Sep. 30, 2016

Stockholders' Equity [Abstract]

STOCKHOLDERS' EQUITY

NOTE 11 — STOCKHOLDERS’ EQUITY

Common Stock — The Company has 100,000,000 authorized shares of Common stock $0.0001. As of September 30, 2016 and June 30, 2016 there were 9,533,290 shares issued and outstanding.

Dividends — Holders of the Company’s common stock are entitled to receive ratably such dividends as our Board of Directors from time to time may declare out of funds legally available.

	DanDrit Biotech USA, Inc.
Expected term (in years)		3.29
Volatility		189.65	%
Risk free interest rate		0.87	%
Dividend yield		0	%

A summary of the status of the options outstanding at September 30, 2016 is presented below:

			Options Outstanding						Options Exercisable
	Exercise Prices		Number Outstanding		Weighted Average Remaining Contractual Life (years)		Weighted Average Exercise Price		Number Exercisable		Weighted Average Exercise Price
	$	2.00		900,000		3.25	$	2.00		900,000	$	2.00
Total				900,000		3.25	$	2.00		900,000	$	2.00

A summary of the status of the options at September 30, 2016, and changes during the period are presented below:

	September 30, 2016
	Shares		Weighted Average Exercise Price		Average Remaining Life		Weighted Average Intrinsic Value

Outstanding at beginning of period		0	$	-		-	$	-
Granted		900,000		2.00		3.25		675,000
Exercised		-		-		-		-
Forfeited		-		-		-		-
Expired		-		-		-		-
Outstanding at end of period		900,000	$	2.00		3.25	$	675,000
Vested and expected to vest		900,000	$	2.00		3.25	$	675,000
Exercisable end of period		900,000	$	2.00		3.25	$	675,000

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

XML 27 R18.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies	3 Months Ended
Commitments and Contingencies	Sep. 30, 2016
Commitments and Contingencies [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 12 — COMMITMENTS AND CONTINGENCIES *Shares held for non-consenting shareholders* – In connection with the Share Exchange agreement certain shareholders of Dandrit Denmark had not been identified or did not consent to the exchange of shares. In accordance with Section 70 of the Danish Companies Act and the Articles of Association of DanDrit Denmark, the Non-Consenting Shareholders that did not exchange the DanDrit Denmark equity interests owned by such Non-Consenting Shareholders for shares of the Company, will be entitled to receive up to 185,053 shares of common stock of the Company that each such Non-Consenting Shareholder would have been entitled to receive if such shareholder had consented to the Share Exchange. The 185,053 shares have been reflected as issued and outstanding in the accompanying financial statements. *Clinical Trial Agreements* – The Company’s subsidiary, DanDrit Biotech A/S signed a contract of collaboration with the University Hospital IRCCS “San Martino” - IST – National Institute for Cancer Research, known as the San Martino Hospital of Genoa. Dr. Alberto Sobrero, the Head of the Medical Oncology Unit at the San Martino Hospital, is principal investigator of the randomized multicenter study. The collaboration relates to a Phase III adjuvant study of DanDrit’s vaccine in patients with no evident disease (“NED”) stage IV colorectal cancer (“CRC”). The primary goal of the study is to evaluate the efficacy of DanDrit’sMelCancerVac® (“MCV”) in stage IV CRC patients rendered disease free after the completion of standard treatments in accordance with local practices. On April 28, 2015 the Company entered into a service agreement with Fondazione Giscad per la Ricerca sui Tumori to support Dandrit in a clinical trial to be conducted in Italy. *Patient Name Use Program Agreements* - On December 16, 2013, DanDrit Denmark entered into an agreement with a Dutch company (the “MCV Partner”) regarding a Patient Name Use Program (PNU) for the Company’s MCV. This program will allow DanDrit Denmark to sell MCV for a year of treatment (10 vaccines) to cancer patients through the MCV Partner. The MCV Partner offers a worldwide online platform providing access to non-registered medicines for patients with life threatening diseases. The MCV Partner is a turnkey solution and will be in charge of regulatory, recruitment, logistics, and pharmaco vigilance. The Company will pay the MCV Partner a royalty on a country to country basis for 20 years on MCV sales sold under the agreement. Either party may terminate the agreement with 180 day written notice. On April 23, 2015, the Company entered into a collaboration agreement with Riyadh Pharma in Saudi Arabia to promote cooperation in the manufacturing and marketing of DanDrit's dendritic cell cancer vaccine. *Manufacturing Agreements -* On January 28, 2014, the Company entered into an agreement with Cellin Technologies for the manufacture of the MCV Cancer vaccine. On August 8, 2014, the Company entered into an agreement with Cellin Technologies for the manufacture of the Melanoma Cell Lysate. *Food and Drug Administration (FDA) -* The FDA has extensive regulatory authority over biopharmaceutical products (drugs and biological products), manufacturing protocols and procedures and the facilities in which they will be manufactured. Any new bio product intended for use in humans is subject to rigorous testing requirements imposed by the FDA with respect to product efficacy and safety, possible toxicity and side effects. FDA approval for the use of new bio products (which can never be assured) requires several rounds of extensive preclinical testing and clinical investigations conducted by the sponsoring pharmaceutical company prior to sale and use of the product. At each stage, the approvals granted by the FDA include the manufacturing process utilized to produce the product. Accordingly, the Company’s cell systems used for the production of therapeutic or bio therapeutic products are subject to significant regulation by the FDA under the Federal Food, Drug and Cosmetic Act, as amended. *Product liability -* The contract production services for therapeutic products offered exposes an inherent risk of liability as bio therapeutic substances manufactured, at the request and to the specifications of customers, could foreseeably cause adverse effects. The Company seeks to obtain agreements from contract production customers indemnifying and defending the Company from any potential liability arising from such risk. There can be no assurance, however, that the Company will be successful in obtaining such agreements in the future or that such indemnification agreements will adequately protect the Company against potential claims relating to such contract production services. The Company may also be exposed to potential product liability claims by users of its products. A successful partial or completely uninsured claim against the Company could have a material adverse effect on the Company’s operations. *Employment Agreements* - The Company and its Subsidiary have an employment agreement with an officer of the Company. *Contingencies* - The Company is from time to time involved in routine legal and administrative proceedings and claims of various types. While any proceedings or claim contains an element of uncertainty, management does not expect a material impact on our results of operations or financial position.

XML 28 R19.htm IDEA: XBRL DOCUMENT

Related Party Transactions

3 Months Ended

Sep. 30, 2016

RELATED PARTY TRANSACTIONS

NOTE 13 — RELATED PARTY TRANSACTIONS

At September 30, 2016 and 2015, the Company had various notes payable with shareholders of the Company (See Note 5 and 6).

In July, 2015 the Company paid DKK50.000 ($7,448) to Paseco ApS, an entity owned by a shareholder of the Company, for consultancy services provided in July 2015.

XML 29 R20.htm IDEA: XBRL DOCUMENT

Asset Purchase Agreement

3 Months Ended

Sep. 30, 2016

Asset Purchase Agreement [Abstract]

ASSET PURCHASE AGREEMENT

NOTE 14 — ASSET PURCHASE AGREEMENT

XML 30 R21.htm IDEA: XBRL DOCUMENT

Subsequent Event

3 Months Ended

Sep. 30, 2016

Subsequent Events [Abstract]

SUBSEQUENT EVENT

NOTE 15 — SUBSEQUENT EVENTS

The Company’s management reviewed material events through November 14, 2016.

XML 31 R22.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies)

3 Months Ended

Sep. 30, 2016

Summary of Significant Accounting Policies [Abstract]

Business and Basis of Presentation

Fiscal Year End

Fiscal Year End - In June 2015, DanDrit’s board of directors approved a change to DanDrit’s fiscal year end from December 31 to June 30.

Reverse Acquisition

Consolidation

Functional Currency / Foreign currency translation

Cash and Cash Equivalents

Property and Equipment

Intangible Assets

Impairment of Long-Lived Assets

Revenue Recognition and Sales

Value Added Tax

Research and Development Expenses

Income Taxes

Loss Per Share

Fair Value of Financial Instruments

●

Level 1. Observable inputs such as quoted prices in active markets for identical assets or liabilities;

●

Level 2. Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and

●

Level 3. Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

Accounting Estimates

Recent Accounting Pronouncements

Other recent accounting pronouncements issued by the FASB did not or are not believed by management to have a material impact on the Company's present or future financial statements.

Reclassification

XML 32 R23.htm IDEA: XBRL DOCUMENT

Property and Equipment (Tables)

3 Months Ended

Sep. 30, 2016

Property and Equipment [Abstract]

Summary of property and equipment

	Useful Life	September 30, 2016			June 30, 2016
Lab equipment and instruments	4-6	$	164,565		$	163,959
Computer equipment	4-6		56,363			56,155
			220,928			220,114
Less Accumulated Depreciation			(220,928	)		(220,114	)
Net Property and Equipment		$	-		$	-

XML 33 R24.htm IDEA: XBRL DOCUMENT

Definite-Life Intangible Assets (Tables)

3 Months Ended

Sep. 30, 2016

Definite-Life Intangible Assets [Abstract]

Schedule of finite-lived intangible assets, future amortization expense

Year ending June 30,
2017	$	11,106
2018		14,849
2019		14,849
2020		14,890
2021		14,849
Thereafter		61,960
	$	132,503

XML 34 R25.htm IDEA: XBRL DOCUMENT

Notes Payable - Related Party (Tables)

3 Months Ended

Sep. 30, 2016

Notes Payable - Related Party [Abstract]

Summary of notes payable to related parties

	September 30, 2016			June 30, 2016
Non-Interest Bearing Loan Payable Sunrise Financial Group Inc.	$	38,235		$	38,235
Note Payable ML Group		17,478			17,414
6% Promissory Note payable to NLBDIT 2010 Enterprises, LLC		47,825			47,233
Total Notes Payable – Related Party		103,538			102,882
Less Current Maturities		(103,538	)		(102,882	)
Note Payables – Related Party Long Term	$	-		$	-

Schedule of future maturities of long-term debt

Year ending June 30,
2017			103,538
2018			-
2019			-
2020			-
2021			-
Thereafter			-
			103,538

XML 35 R26.htm IDEA: XBRL DOCUMENT

Convertible Notes Payable - Related Party (Tables) - Convertible notes payable related parties [Member]

3 Months Ended

Sep. 30, 2016

Debt Instrument [Line Items]

Schedule of convertible notes payable to related party

	September 30, 2016			June 30, 2016
Non-Interest Bearing Notes Payable Paseco ApS	$	120,300		$	-
Less Discount		(17,359	)		-
Total Convertible Notes Payable – Related Party		102,941		$	-
Less Current Maturities		-			-
Net Convertible Note Payables – Related Party Long Term	$	102,941			-

Schedule of future maturities of long term debt

Year ending June 30,
2017			-
2018			120,300
2019			-
2020			-
2021			-
Thereafter			-
			120,300

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6479336&loc=d3e64711-112823

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=64930739&loc=d3e28878-108400

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21538-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28541-108399

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28551-108399

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21521-112644

+ Details

XML 36 R27.htm IDEA: XBRL DOCUMENT

Convertible Notes Payable (Tables) - Convertible Notes Payable [Member]

3 Months Ended

Sep. 30, 2016

Short-term Debt [Line Items]

Schedule of convertible notes payable

	September 30, 2016			June 30, 2016
Non-Interest Bearing Notes Payable Equine Invest Aps	$	240,600		$	-
Less Discounts		(10,931	)		-
Total Convertible Notes Payable		229,669
Less Current Maturities		-			-
Net Convertible Note Payables – Long Term	$	229,669		$	-

Schedule of future maturities of long term debt

Year ending June 30,
2017			-
2018			240,600
2019			-
2020			-
2021			-
Thereafter			-
			240,600

- Definition

+ References

+ Details

XML 37 R28.htm IDEA: XBRL DOCUMENT

Income Taxes (Tables)

3 Months Ended

Sep. 30, 2016

Income Taxes [Abstract]

Summary of deferred tax asset (liabilities)

	September 30, 2016			June 30, 2016
Excess of Tax over book depreciation Fixed assets	$	7,660		$	7,660
Excess of Tax over book depreciation Patents		870			870
Net Operating Loss Carry forward		2,639,879			2,558,080
Valuation Allowance		(2,648,409	)		(2,566,610	)
Total Deferred Tax Asset (Liabilities)	$	-		$	-

Summary of reconciliation of income tax expense at federal statutory rate

	September 30, 2016			September 30, 2015
Computed Tax at Expected Statutory Rate	$	(283,454	)	$	(127,233	)
Non-US Income Taxed at Different Rates		14,465			41,760
Non-Deductible expenses		214,163			-
Valuation allowance		14,319			61,560
Income Tax Expense	$	(40,507	)	$	(23,913	)

Summary of components of income tax expense (benefit) from continuing operations

	2016			2015
Current Tax Expense
Danish Income Tax	$	(40,507	)	$	(23,913	)
Total Current Tax Expense		(40,507	)		(23,913	)
Deferred Income Tax Expense (Benefit)
Excess of Tax over Book Depreciation Fixed Assets		-			-
Excess of Tax over Book Depreciation Patents		-			-
Net Operating Loss Carry forwards		(81,798	)		(52,647	)
Change in the Valuation allowance		81,798			52,647
Total Deferred Tax Expense	$	-		$	-

XML 38 R29.htm IDEA: XBRL DOCUMENT

Loss Per Share (Tables)

3 Months Ended

Sep. 30, 2016

Loss Per Share [Abstract]

Schedule of weighted average number of shares of potential dilutive common stock

	For the 3 Months Ended
	September 30,
	2016			2015
Net (Loss)		(793,181	)		(350,302	)
Weighted average number of common shares used in basic earnings per share		9,533,290			9,533,290
Effect of dilutive securities, stock options and warrants		-			-
Weighted average number of common shares and potential dilutive common shares outstanding used in dilutive earnings per share		9,533,290			9,533,290

XML 39 R30.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Tables)

3 Months Ended

Sep. 30, 2016

Stockholders' Equity [Abstract]

Summary of weighted-average assumptions used to fair value calculation for options granted

	DanDrit Biotech USA, Inc.
Expected term (in years)		3.29
Volatility		189.65	%
Risk free interest rate		0.87	%
Dividend yield		0	%

Summary of stock option outstanding

			Options Outstanding						Options Exercisable
	Exercise Prices		Number Outstanding		Weighted Average Remaining Contractual Life (years)		Weighted Average Exercise Price		Number Exercisable		Weighted Average Exercise Price
	$	2.00		900,000		3.25	$	2.00		900,000	$	2.00
Total				900,000		3.25	$	2.00		900,000	$	2.00

Summary of stock option activity

	September 30, 2016
	Shares		Weighted Average Exercise Price		Average Remaining Life		Weighted Average Intrinsic Value

Outstanding at beginning of period		0	$	-		-	$	-
Granted		900,000		2.00		3.25		675,000
Exercised		-		-		-		-
Forfeited		-		-		-		-
Expired		-		-		-		-
Outstanding at end of period		900,000	$	2.00		3.25	$	675,000
Vested and expected to vest		900,000	$	2.00		3.25	$	675,000
Exercisable end of period		900,000	$	2.00		3.25	$	675,000

XML 40 R31.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Details) - USD ($)		3 Months Ended
	Feb. 12, 2014	Sep. 30, 2016	Sep. 30, 2015	Jun. 30, 2016	Jun. 28, 2016	Jun. 30, 2015
Summary of Significant Accounting Policies (Textual)
Common stock, par value		$ 0.0001		$ 0.0001
Cash held in escrow balance		$ 31,675	$ 1,048,120	$ 23,368	$ 23,368	$ 421,145
Property, plant and equipment, depreciation methods		Straight line basis over the estimated useful life of twenty years.
Property plant and equipment estimated useful lives		Depreciation is computed for financial statement purposes on a straight-line basis over the estimated useful lives of the assets which range from four to nine years
Common stock reserved for issuance		185,053
Value added tax, percentage		25.00%
Value added tax paid to Danish and EU vendors		25.00%
Research and development expense		$ 17,104	$ 101,759
Share exchange agreement, shares issued to parent company	6,000,000
Common Stock [Member]
Summary of Significant Accounting Policies (Textual)
Common stock, par value	$ 0.0001
Shares of parent common stock outstanding	8,040,000
Common stock reserved for issuance	185,053
Shares prior to share exchange agreement	5,000,000
Share exchange agreement, acquisition percentage	100.00%
Share exchange agreement, shares held by consenting shareholders of company	1.498842
Share exchange agreement, shares issued to parent company	6,000,000
Share exchange agreement, number of shares cancelled	4,400,000
Common shares issued for legal and consulting services	1,440,000

XML 41 R32.htm IDEA: XBRL DOCUMENT

Going Concern (Details)	3 Months Ended
Going Concern (Details)	Sep. 30, 2016 USD ($)
Going Concern (Textual)
Private placement offering	$ 15,000,000

XML 42 R33.htm IDEA: XBRL DOCUMENT

Property and Equipment (Details) - USD ($)	3 Months Ended
Property and Equipment (Details) - USD ($)	Sep. 30, 2016	Jun. 30, 2016
Property, Plant and Equipment [Line Items]
Gross Property and Equipment	$ 220,928	$ 220,114
Less Accumulated Depreciation	(220,928)	(220,114)
Net Property and Equipment
Lab equipment and instruments [Member]
Property, Plant and Equipment [Line Items]
Gross Property and Equipment	$ 164,565	163,959
Lab equipment and instruments [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Useful Life	4 years
Lab equipment and instruments [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Useful Life	6 years
Computer equipment [Member]
Property, Plant and Equipment [Line Items]
Gross Property and Equipment	$ 56,363	$ 56,155
Computer equipment [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Useful Life	4 years
Computer equipment [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Useful Life	6 years

XML 43 R34.htm IDEA: XBRL DOCUMENT

Property and Equipment (Details Textual) - USD ($)	3 Months Ended
Property and Equipment (Details Textual) - USD ($)	Sep. 30, 2016	Sep. 30, 2015
Property and Equipment (Textual)
Depreciation expense	$ 0	$ 0

XML 44 R35.htm IDEA: XBRL DOCUMENT

Definite-Life Intangible Assets (Details) - USD ($)	Sep. 30, 2016	Jun. 30, 2016
Definite-Life Intangible Assets [Abstract]
2017	$ 11,106
2018	14,849
2019	14,849
2020	14,890
2021	14,849
Thereafter	61,960
Finite-Lived Intangible Assets, Net	$ 132,503	$ 135,743

XML 45 R36.htm IDEA: XBRL DOCUMENT

Definite-Life Intangible Assets (Details Textual) - USD ($)	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Jun. 30, 2016
Definite-Life Intangible Assets (Textual)
Definite-life intangible assets	$ 132,503		$ 135,743
Amortization expense	$ 3,749	$ 3,937

XML 46 R37.htm IDEA: XBRL DOCUMENT

Notes Payable - Related Party (Details) - USD ($)	Sep. 30, 2016	Jun. 30, 2016
Related Party Transaction [Line Items]
Total Notes Payable - Related Party	$ 103,538	$ 102,882
Less Current Maturities	(103,538)	(102,882)
Note Payables - Related Party Long Term
Non-Interest Bearing Loan Payable Sunrise Financial Group Inc. [Member]
Related Party Transaction [Line Items]
Total Notes Payable - Related Party	38,235	38,235
Note Payable ML Group [Member]
Related Party Transaction [Line Items]
Total Notes Payable - Related Party	17,478	17,414
6% Promissory Note payable to NLBDIT 2010 Enterprises, LLC [Member]
Related Party Transaction [Line Items]
Total Notes Payable - Related Party	$ 47,825	$ 47,233

XML 47 R38.htm IDEA: XBRL DOCUMENT

Notes Payable - Related Party (Details 1) - Notes Payable Related Parties [Member]	Jun. 30, 2016 USD ($)
Debt Instrument [Line Items]
2017	$ 103,538
2018
2019
2020
2021
Thereafter
Total	$ 103,538

XML 48 R39.htm IDEA: XBRL DOCUMENT

Notes Payable - Related Party (Details Textual) - USD ($)	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Notes Payable - Related Party (Textual)
Notes payable acquired in reverse acquisition	$ 38,235
Outstanding balance for professional fees paid by a shareholder and amounts advanced to parent	38,235
Accrued Interest on Notes Payable - Related Party	592	$ 592
6% Promissory Note payable to NLBDIT 2010 Enterprises, LLC [Member]
Notes Payable - Related Party (Textual)
Outstanding balance on note including accrued interest	$ 47,825

XML 49 R40.htm IDEA: XBRL DOCUMENT

Convertible Notes Payable - Related Party (Details) - USD ($)	Sep. 30, 2016	Jun. 30, 2016
Convertible Notes Payable - Related Party [Abstract]
Non-Interest Bearing Notes Payable Paseco ApS	$ 120,300
Less Discount	(17,359)	0
Total Convertible Notes Payable - Related Party	102,941
Less Current Maturities
Net Convertible Note Payables - Related Party Long Term	$ 102,941

XML 50 R41.htm IDEA: XBRL DOCUMENT

Convertible Notes Payable - Related Party (Details 1) - Convertible notes payable related parties [Member]	Sep. 30, 2016 USD ($)
Debt Instrument [Line Items]
2017	$ 120,300
2018
2019
2020
2021
Thereafter
Total	$ 120,300

XML 51 R42.htm IDEA: XBRL DOCUMENT

Convertible Notes Payable - Related Party (Details Textual) - USD ($)			3 Months Ended
	Jul. 19, 2016	Jun. 30, 2016	Sep. 30, 2016
Debt Instrument [Line Items]
Amortization of discount			$ 2,527
Convertible notes payable related parties [Member]
Debt Instrument [Line Items]
Convertible Notes Payable	$ 60,150	$ 60,150
Interest rate	3.00%	3.00%
Common stock price per share	$ 2.00	$ 2.00
Maturity date	Dec. 31, 2017	Dec. 31, 2017
Trading price		$ 2.50
Discount rate	$ 2,555	$ 2,639
Beneficial conversion feature discount		$ 15,038
Amortization of discount			$ 346

XML 52 R43.htm IDEA: XBRL DOCUMENT

Convertible Notes Payable (Details) - USD ($)	Sep. 30, 2016	Jun. 30, 2016
Notes Payable - Related Party [Abstract]
Non-Interest Bearing Notes Payable Equine Invest Aps	$ 240,600
Less Discounts	(10,931)	0
Total Convertible Notes Payable	229,669
Less Current Maturities
Net Convertible Note Payables - Long Term	$ 229,669

XML 53 R44.htm IDEA: XBRL DOCUMENT

Convertible Notes Payable (Details 1) - Convertible notes payable [Member]	Sep. 30, 2016 USD ($)
Short-term Debt [Line Items]
2017	$ 240,600
2018
2019
2020
2021
Thereafter
Total	$ 240,600

XML 54 R45.htm IDEA: XBRL DOCUMENT

Convertible Notes Payable (Details Textual) - USD ($)			3 Months Ended
Convertible Notes Payable (Details Textual) - USD ($)	Sep. 21, 2016	Aug. 24, 2016	Sep. 30, 2016
Short-term Debt [Line Items]
Interest expense			$ 425
Convertible Notes Payable [Member]
Short-term Debt [Line Items]
Interest rate	3.00%	3.00%
Maturity date	Dec. 31, 2017	Dec. 31, 2017
Convertible Notes Payable	$ 150,375	$ 90,225
Common stock price per share	$ 2.00	$ 2.00
Trading price		$ 2.05
Beneficial conversion feature discount		$ 2,256
Discount rate	$ 5,630	$ 3,577
Interest expense			$ 107

XML 55 R46.htm IDEA: XBRL DOCUMENT

Leases (Details)	1 Months Ended	3 Months Ended
Leases (Details)	Mar. 25, 2015 USD ($)	Sep. 30, 2016 USD ($)	Sep. 30, 2016 DKK	Sep. 30, 2015 USD ($)
Leases (Textual)
Rental payments for operating leases		$ 3,960		$ 3,940
Lab space [Member]
Leases (Textual)
Rental payments for operating leases		$ 945	DKK 6,300
Virtual office [Member]
Leases (Textual)
Rental payments for operating leases	$ 375

XML 56 R47.htm IDEA: XBRL DOCUMENT

Income Taxes (Details) - USD ($)	Sep. 30, 2016	Jun. 30, 2016
Income Taxes [Abstract]
Excess of Tax over book depreciation Fixed assets	$ 7,660	$ 7,660
Excess of Tax over book depreciation Patents	870	870
Net Operating Loss Carry forward	2,639,879	2,558,080
Valuation Allowance	(2,648,409)	(2,566,610)
Total Deferred Tax Asset (Liabilities)

XML 57 R48.htm IDEA: XBRL DOCUMENT

Income Taxes (Details 1) - USD ($)	3 Months Ended
Income Taxes (Details 1) - USD ($)	Sep. 30, 2016	Sep. 30, 2015
Income Taxes [Abstract]
Computed Tax at Expected Statutory Rate	$ (283,454)	$ (127,233)
Non-US Income Taxed at Different Rates	14,465	41,760
Non-Deductible expenses	214,163
Valuation allowance	14,319	61,560
Income Tax Expense	$ (40,507)	$ (23,913)

XML 58 R49.htm IDEA: XBRL DOCUMENT

Income Taxes (Details 2) - USD ($)	3 Months Ended
Income Taxes (Details 2) - USD ($)	Sep. 30, 2016	Sep. 30, 2015
Current Tax Expense
Danish Income Tax	$ (40,507)	$ (23,913)
Total Current Tax Expense	(40,507)	(23,913)
Deferred Income Tax Expense (Benefit)
Excess of Tax over Book Depreciation Fixed Assets
Excess of Tax over Book Depreciation Patents
Net Operating Loss Carry forwards	(81,798)	(52,647)
Change in the Valuation allowance	81,798	52,647
Total Deferred Tax Expense

XML 59 R50.htm IDEA: XBRL DOCUMENT

Income Taxes (Details Textual)	3 Months Ended
Income Taxes (Details Textual)	Sep. 30, 2016 USD ($)
Income Taxes (Textual)
Net operating loss carry-forwards	$ 10,379,545
Danish Tax [Member]
Income Taxes (Textual)
Net operating loss carry-forwards	$ 1,048,174
Estimated effective tax rate, Danish tax purpose	22.00%
Estimated effective tax rate in amount	$ 2,283,500
United States tax [Member]
Income Taxes (Textual)
Net operating loss carry-forwards expiration period	Sep. 30, 2034
Estimated effective tax rate, Danish tax purpose	34.00%
Estimated effective tax rate in amount	$ 356,379

XML 60 R51.htm IDEA: XBRL DOCUMENT

Loss Per Share (Details) - USD ($)	3 Months Ended
Loss Per Share (Details) - USD ($)	Sep. 30, 2016	Sep. 30, 2015
Loss Per Share [Abstract]
Net (Loss)	$ (793,181)	$ (350,302)
Weighted average number of common shares used in basic earnings per share	9,533,290	9,533,290
Effect of dilutive securities, stock options and warrants
Weighted average number of common shares and potential dilutive common shares outstanding used in dilutive earnings per share	9,533,290	9,533,290
Convertible notes payable	$ 360,900
Convertible notes payable, Shares	180,450

XML 61 R52.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Details)	3 Months Ended
Stockholders' Equity (Details)	Sep. 30, 2016
Stockholders' Equity [Abstract]
Expected term (in years)	3 years 3 months 15 days
Volatility	189.65%
Risk free interest rate	0.87%
Dividend yield	0.00%

XML 62 R53.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Details 1) - Employee Stock Option [Member] - $ / shares	3 Months Ended
	Sep. 30, 2016	Jun. 28, 2016
Option Indexed to Issuer's Equity [Line Items]
Options Outstanding, Number Outstanding	900,000	0
Options Outstanding, Weighted Average Remaining Contractual Life (years)	3 years 3 months
Options Outstanding, Weighted Average Exercise Price	$ 2.00
Options Exercisable, Number Exercisable	900,000
Options Exercisable, Weighted Average Exercise Price	$ 2.00
Exercise Price Range [Member]
Option Indexed to Issuer's Equity [Line Items]
Exercise Prices	$ 2.00
Options Outstanding, Number Outstanding	900,000
Options Outstanding, Weighted Average Remaining Contractual Life (years)	3 years 3 months
Options Outstanding, Weighted Average Exercise Price	$ 2.00
Options Exercisable, Number Exercisable	900,000
Options Exercisable, Weighted Average Exercise Price	$ 2.00

XML 63 R54.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Details 2) - Stock Option [Member]	3 Months Ended
	Sep. 30, 2016 USD ($) $ / shares shares
Option Indexed to Issuer's Equity [Line Items]
Outstanding at beginning of period \| shares	0
Granted \| shares	900,000
Exercised \| shares
Forfeited \| shares
Expired \| shares
Outstanding at end of period \| shares	900,000
Vested and expected to vest \| shares	900,000
Exercisable end of period \| shares	900,000
Weighted Average Exercise Price, Outstanding at beginning of period \| $ / shares
Weighted Average Exercise Price, Granted \| $ / shares	2.00
Weighted Average Exercise Price, Exercised \| $ / shares
Weighted Average Exercise Price, Forfeited \| $ / shares
Weighted Average Exercise Price, Expired \| $ / shares
Weighted Average Exercise Price, Outstanding at end of period \| $ / shares	2.00
Weighted Average Exercise Price, Vested and expected to vest \| $ / shares	2.00
Weighted Average Exercise Price, Exercisable end of period \| $ / shares	$ 2.00
Average Remaining Life, Granted	3 years 3 months
Average Remaining Life, Outstanding at end of period	3 years 3 months
Average Remaining Life, Vested and expected to vest	3 years 3 months
Average Remaining Life, Exercisable end of period	3 years 3 months
Weighted Average Intrinsic Value, Outstanding at beginning of period \| $
Weighted Average Intrinsic Value, Granted \| $	675,000
Weighted Average Intrinsic Value, Outstanding at end of period \| $	675,000
Weighted Average Intrinsic Value, Vested and expected to vest \| $	675,000
Weighted Average Intrinsic Value, Exercisable end of period \| $	$ 675,000

XML 64 R55.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Details Textual) - USD ($)		1 Months Ended	3 Months Ended
Stockholders' Equity (Details Textual) - USD ($)	Feb. 12, 2014	Sep. 15, 2016	Sep. 30, 2016	Sep. 30, 2015	Jun. 30, 2016	Jun. 28, 2016
Stockholders' Equity (Textual)
Common stock, shares authorized			100,000,000		100,000,000
Common stock, shares issued			9,533,290		9,533,290
Common stock, shares outstanding			9,533,290		9,533,290
Common stock, par value			$ 0.0001		$ 0.0001
Common stock reserved for issuance			185,053
Share exchange agreement, shares issued to parent company	6,000,000
Non-cash compensation			$ 626,487
Employee Stock Option [Member]
Stockholders' Equity (Textual)
Offering of common stock, shares		300,000
Gross proceeds from share issuance		$ 16,500,000
Options granted and outstanding			900,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value			$ 675,000
Maturity date			Dec. 31, 2019
Strike price		$ 2.00
Common Stock [Member]
Stockholders' Equity (Textual)
Common stock, par value	$ 0.0001
Common stock reserved for issuance	185,053
Share exchange agreement, acquisition percentage	100.00%
Share exchange agreement number of share cancellation	4,400,000
Exchanged shares of parent's common stock	1.498842
Share exchange agreement, shares issued to parent company	6,000,000

XML 65 R56.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details) - shares	Dec. 16, 2013	Sep. 30, 2016
Commitments and Contingencies (Textual)
Common stock reserved for issuance		185,053
Termination of agreement	180 days
Payments for royalties period	20 years

XML 66 R57.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Details)			1 Months Ended			3 Months Ended
Related Party Transactions (Details)	Jul. 19, 2016 USD ($) $ / shares	Jun. 30, 2016 USD ($) $ / shares shares	Sep. 15, 2016 $ / shares shares	Jun. 30, 2015 USD ($)	Jun. 30, 2015 DKK	Sep. 30, 2016 USD ($) shares	Sep. 30, 2015 USD ($)	Jul. 02, 2016 USD ($)
Related Party Transactions (Textual)
Proceeds from Notes Payable - Related Party						$ 138,070
Legal service						0	8,193
Escrow account				$ 1,052,989
Payable to related parties
Purchase of commons shares \| shares		9,533,290				9,533,290
Interest expense						$ 425
Non-cash compensation						626,487
Amortization of discount						2,527
Accounts Payable, Related Parties, Current		$ 97,357				97,718
Convertible notes payable related parties [Member]
Related Party Transactions (Textual)
Shares price, Per share \| $ / shares	$ 2.00	$ 2.00
Beneficial conversion feature discount		$ 15,038
Trading price \| $ / shares		$ 2.50
Convertible Notes Payable	$ 60,150	$ 60,150
Discount rate	$ 2,555	$ 2,639
Amortization of discount						346
Interest rate	3.00%	3.00%
Common stock price per share \| $ / shares	$ 2.00	$ 2.00
Maturity date	Dec. 31, 2017	Dec. 31, 2017
Paseco Aps [Member]
Related Party Transactions (Textual)
Medical consultancy expense				$ 7,448	DKK 50.000
Jaro Holding Aps [Member]
Related Party Transactions (Textual)
Medical consultancy expense
Ape Invest As [Member]
Related Party Transactions (Textual)
Payable to related parties								$ 100,000
Financial service agreement, description						The agreement calls for monthly payment of $20,000 with a $100,000 retainer payment due November 1, 2016. The agreement can be terminated with 12 month notice.
Board of Directors Chairman [Member]
Related Party Transactions (Textual)
Purchase of commons shares \| shares			900,000
Shares price, Per share \| $ / shares			$ 2
Lease expiration date			Dec. 31, 2019

XML 67 R58.htm IDEA: XBRL DOCUMENT

Asset Purchase Agreement (Details)	1 Months Ended
Asset Purchase Agreement (Details)	Apr. 30, 2016
OncoSynergy, Inc. [Member]
Asset Purchase Agreement (Textual)
Asset purchase agreement, description	(i) a number of shares of Common Stock of the Company equal to the number of shares of Series A Common Stock and Common Stock outstanding of the OncoSynergy, Inc. immediately prior to the closing of the Transaction, and (ii) derivative securities (including any option, right, warrant, call, convertible security, right to subscribe, conversion right or other agreement or commitment immediately outstanding prior to the closing, if any), of like tenor, except as to timing of exercisability and maturity, exercisable or convertible into a like number of shares of Common Stock, and having rights, preferences, terms and conditions consistent in all other respects with such outstanding derivative security. Immediately following the closing it is estimated OncoSynergy, Inc. will hold between 33% and 40% of the capital stock of the Company on a fully diluted basis, assuming the exercise or conversion in full of all outstanding derivative securities of the Dandrit BioTech USA, Inc.

EXCEL 68 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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ݶ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how.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 70 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 72 FilingSummary.xml IDEA: XBRL DOCUMENT 3.5.0.2 html 59 257 1 false 22 0 false 5 false false R1.htm 001 - Document - Document and Entity Information Sheet http://www.0001527728.com/role/Documentandentityinformation Document and Entity Information Cover 1 false false R2.htm 002 - Statement - Consolidated Balance Sheets Sheet http://www.0001527728.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 003 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.0001527728.com/role/ConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 004 - Statement - Consolidated Statement of Operations Sheet http://www.0001527728.com/role/ConsolidatedStatementOfOperations Consolidated Statement of Operations Statements 4 false false R5.htm 005 - Statement - Statements of Other Comprehensive Loss Sheet http://www.0001527728.com/role/StatementsOfOtherComprehensiveLoss Statements of Other Comprehensive Loss Statements 5 false false R6.htm 006 - Statement - Consolidated Statement of Cash Flows Sheet http://www.0001527728.com/role/ConsolidatedStatementOfCashFlows Consolidated Statement of Cash Flows Statements 6 false false R7.htm 007 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.0001527728.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 7 false false R8.htm 008 - Disclosure - Going Concern Sheet http://www.0001527728.com/role/GoingConcern Going Concern Notes 8 false false R9.htm 009 - Disclosure - Property and Equipment Sheet http://www.0001527728.com/role/PropertyAndEquipment Property and Equipment Notes 9 false false R10.htm 010 - Disclosure - Definite-Life Intangible Assets Sheet http://www.0001527728.com/role/DefiniteLifeIntangibleAssets Definite-Life Intangible Assets Notes 10 false false R11.htm 011 - Disclosure - Notes Payable - Related Party Notes http://www.0001527728.com/role/NotesPayableRelatedParty Notes Payable - Related Party Notes 11 false false R12.htm 012 - Disclosure - Convertible Notes Payable - Related Party Notes http://www.0001527728.com/role/ConvertibleNotesPayableRelatedParty Convertible Notes Payable - Related Party Notes 12 false false R13.htm 013 - Disclosure - Convertible Notes Payable Notes http://www.0001527728.com/role/ConvertibleNotesPayable Convertible Notes Payable Notes 13 false false R14.htm 014 - Disclosure - Leases Sheet http://www.0001527728.com/role/Leases Leases Notes 14 false false R15.htm 015 - Disclosure - Income Taxes Sheet http://www.0001527728.com/role/IncomeTaxes Income Taxes Notes 15 false false R16.htm 016 - Disclosure - Loss Per Share Sheet http://www.0001527728.com/role/LossPerShare Loss Per Share Notes 16 false false R17.htm 017 - Disclosure - Stockholders' Equity Sheet http://www.0001527728.com/role/StockholdersEquity Stockholders' Equity Notes 17 false false R18.htm 018 - Disclosure - Commitments and Contingencies Sheet http://www.0001527728.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 18 false false R19.htm 019 - Disclosure - Related Party Transactions Sheet http://www.0001527728.com/role/Relatedpartytransactions Related Party Transactions Notes 19 false false R20.htm 020 - Disclosure - Asset Purchase Agreement Sheet http://www.0001527728.com/role/AssetPurchaseAgreement Asset Purchase Agreement Notes 20 false false R21.htm 021 - Disclosure - Subsequent Event Sheet http://www.0001527728.com/role/SubsequentEvent Subsequent Event Notes 21 false false R22.htm 022 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.0001527728.com/role/SummaryofSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.0001527728.com/role/SummaryOfSignificantAccountingPolicies 22 false false R23.htm 023 - Disclosure - Property and Equipment (Tables) Sheet http://www.0001527728.com/role/PropertyandEquipmentTables Property and Equipment (Tables) Tables http://www.0001527728.com/role/PropertyAndEquipment 23 false false R24.htm 024 - Disclosure - Definite-Life Intangible Assets (Tables) Sheet http://www.0001527728.com/role/Definitelifeintangibleassetstables Definite-Life Intangible Assets (Tables) Tables http://www.0001527728.com/role/DefiniteLifeIntangibleAssets 24 false false R25.htm 025 - Disclosure - Notes Payable - Related Party (Tables) Notes http://www.0001527728.com/role/Notespayablerelatedpartytables Notes Payable - Related Party (Tables) Tables http://www.0001527728.com/role/NotesPayableRelatedParty 25 false false R26.htm 026 - Disclosure - Convertible Notes Payable - Related Party (Tables) Notes http://www.0001527728.com/role/ConvertibleNotesPayableRelatedPartyTables Convertible Notes Payable - Related Party (Tables) Tables http://www.0001527728.com/role/ConvertibleNotesPayableRelatedParty 26 false false R27.htm 027 - Disclosure - Convertible Notes Payable (Tables) Notes http://www.0001527728.com/role/ConvertibleNotesPayableTables Convertible Notes Payable (Tables) Tables http://www.0001527728.com/role/ConvertibleNotesPayableRelatedParty 27 false false R28.htm 028 - Disclosure - Income Taxes (Tables) Sheet http://www.0001527728.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://www.0001527728.com/role/IncomeTaxes 28 false false R29.htm 029 - Disclosure - Loss Per Share (Tables) Sheet http://www.0001527728.com/role/LossPerShareTables Loss Per Share (Tables) Tables http://www.0001527728.com/role/LossPerShare 29 false false R30.htm 030 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.0001527728.com/role/StockholdersEquityTables Stockholders' Equity (Tables) Tables http://www.0001527728.com/role/StockholdersEquity 30 false false R31.htm 031 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://www.0001527728.com/role/SummaryofSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details http://www.0001527728.com/role/SummaryofSignificantAccountingPoliciesPolicies 31 false false R32.htm 032 - Disclosure - Going Concern (Details) Sheet http://www.0001527728.com/role/GoingConcernDetails Going Concern (Details) Details http://www.0001527728.com/role/GoingConcern 32 false false R33.htm 033 - Disclosure - Property and Equipment (Details) Sheet http://www.0001527728.com/role/PropertyandEquipmentDetails Property and Equipment (Details) Details http://www.0001527728.com/role/PropertyandEquipmentTables 33 false false R34.htm 034 - Disclosure - Property and Equipment (Details Textual) Sheet http://www.0001527728.com/role/PropertyAndEquipmentDetailsTextual Property and Equipment (Details Textual) Details http://www.0001527728.com/role/PropertyandEquipmentTables 34 false false R35.htm 035 - Disclosure - Definite-Life Intangible Assets (Details) Sheet http://www.0001527728.com/role/DefiniteLifeIntangibleAssetsDetails Definite-Life Intangible Assets (Details) Details http://www.0001527728.com/role/Definitelifeintangibleassetstables 35 false false R36.htm 036 - Disclosure - Definite-Life Intangible Assets (Details Textual) Sheet http://www.0001527728.com/role/DefiniteLifeIntangibleAssetsDetailsTextual Definite-Life Intangible Assets (Details Textual) Details http://www.0001527728.com/role/Definitelifeintangibleassetstables 36 false false R37.htm 037 - Disclosure - Notes Payable - Related Party (Details) Notes http://www.0001527728.com/role/Notespayablerelatedpartydetails Notes Payable - Related Party (Details) Details http://www.0001527728.com/role/Notespayablerelatedpartytables 37 false false R38.htm 038 - Disclosure - Notes Payable - Related Party (Details 1) Notes http://www.0001527728.com/role/Notespayablerelatedpartydetails1 Notes Payable - Related Party (Details 1) Details http://www.0001527728.com/role/Notespayablerelatedpartytables 38 false false R39.htm 039 - Disclosure - Notes Payable - Related Party (Details Textual) Notes http://www.0001527728.com/role/NotesPayableRelatedPartyDetailsTextual Notes Payable - Related Party (Details Textual) Details http://www.0001527728.com/role/Notespayablerelatedpartytables 39 false false R40.htm 040 - Disclosure - Convertible Notes Payable - Related Party (Details) Notes http://www.0001527728.com/role/ConvertibleNotesPayableRelatedPartyDetails Convertible Notes Payable - Related Party (Details) Details http://www.0001527728.com/role/ConvertibleNotesPayableRelatedPartyTables 40 false false R41.htm 041 - Disclosure - Convertible Notes Payable - Related Party (Details 1) Notes http://www.0001527728.com/role/ConvertibleNotesPayableRelatedPartyDetails1 Convertible Notes Payable - Related Party (Details 1) Details http://www.0001527728.com/role/ConvertibleNotesPayableRelatedPartyTables 41 false false R42.htm 042 - Disclosure - Convertible Notes Payable - Related Party (Details Textual) Notes http://www.0001527728.com/role/ConvertibleNotesPayableRelatedPartyDetailsTextual Convertible Notes Payable - Related Party (Details Textual) Details http://www.0001527728.com/role/ConvertibleNotesPayableRelatedPartyTables 42 false false R43.htm 043 - Disclosure - Convertible Notes Payable (Details) Notes http://www.0001527728.com/role/ConvertibleNotesPayableDetails Convertible Notes Payable (Details) Details http://www.0001527728.com/role/ConvertibleNotesPayableRelatedPartyTables 43 false false R44.htm 044 - Disclosure - Convertible Notes Payable (Details 1) Notes http://www.0001527728.com/role/ConvertibleNotesPayableDetails1 Convertible Notes Payable (Details 1) Details http://www.0001527728.com/role/ConvertibleNotesPayableRelatedPartyTables 44 false false R45.htm 045 - Disclosure - Convertible Notes Payable (Details Textual) Notes http://www.0001527728.com/role/ConvertibleNotesPayableDetailsTextual Convertible Notes Payable (Details Textual) Details http://www.0001527728.com/role/ConvertibleNotesPayableRelatedPartyTables 45 false false R46.htm 046 - Disclosure - Leases (Details) Sheet http://www.0001527728.com/role/LeasesDetails Leases (Details) Details http://www.0001527728.com/role/Leases 46 false false R47.htm 047 - Disclosure - Income Taxes (Details) Sheet http://www.0001527728.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.0001527728.com/role/IncomeTaxesTables 47 false false R48.htm 048 - Disclosure - Income Taxes (Details 1) Sheet http://www.0001527728.com/role/Incometaxesdetails1 Income Taxes (Details 1) Details http://www.0001527728.com/role/IncomeTaxesTables 48 false false R49.htm 049 - Disclosure - Income Taxes (Details 2) Sheet http://www.0001527728.com/role/IncomeTaxesDetails2 Income Taxes (Details 2) Details http://www.0001527728.com/role/IncomeTaxesTables 49 false false R50.htm 050 - Disclosure - Income Taxes (Details Textual) Sheet http://www.0001527728.com/role/Incometaxesdetailstextual Income Taxes (Details Textual) Details http://www.0001527728.com/role/IncomeTaxesTables 50 false false R51.htm 051 - Disclosure - Loss Per Share (Details) Sheet http://www.0001527728.com/role/LossPerShareDetails Loss Per Share (Details) Details http://www.0001527728.com/role/LossPerShareTables 51 false false R52.htm 052 - Disclosure - Stockholders' Equity (Details) Sheet http://www.0001527728.com/role/StockholdersEquityDetails Stockholders' Equity (Details) Details http://www.0001527728.com/role/StockholdersEquityTables 52 false false R53.htm 053 - Disclosure - Stockholders' Equity (Details 1) Sheet http://www.0001527728.com/role/StockholdersEquityDetails1 Stockholders' Equity (Details 1) Details http://www.0001527728.com/role/StockholdersEquityTables 53 false false R54.htm 054 - Disclosure - Stockholders' Equity (Details 2) Sheet http://www.0001527728.com/role/StockholdersEquityDetails2 Stockholders' Equity (Details 2) Details http://www.0001527728.com/role/StockholdersEquityTables 54 false false R55.htm 055 - Disclosure - Stockholders' Equity (Details Textual) Sheet http://www.0001527728.com/role/StockholdersEquityDetailsTextual Stockholders' Equity (Details Textual) Details http://www.0001527728.com/role/StockholdersEquityTables 55 false false R56.htm 056 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.0001527728.com/role/CommitmentsandContingenciesDetails Commitments and Contingencies (Details) Details http://www.0001527728.com/role/CommitmentsAndContingencies 56 false false R57.htm 057 - Disclosure - Related Party Transactions (Details) Sheet http://www.0001527728.com/role/RelatedPartyTransactionsDetails Related Party Transactions (Details) Details http://www.0001527728.com/role/Relatedpartytransactions 57 false false R58.htm 058 - Disclosure - Asset Purchase Agreement (Details) Sheet http://www.0001527728.com/role/AssetPurchaseAgreementDetails Asset Purchase Agreement (Details) Details http://www.0001527728.com/role/AssetPurchaseAgreement 58 false false All Reports Book All Reports ddrt-20160930.xml ddrt-20160930.xsd ddrt-20160930_cal.xml ddrt-20160930_def.xml ddrt-20160930_lab.xml ddrt-20160930_pre.xml true true ZIP 74 0001213900-16-018520-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-16-018520-xbrl.zip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�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